
<html lang="en"     class="pb-page"  data-request-id="bddba18d-c4a5-4df3-878c-83a8b67ca257"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2014.57.issue-19;wgroup:string:ACHS website Group;article:article:10.1021/jm500552c;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering" /></meta><meta name="dc.Creator" content="Thomas H.  Pillow" /></meta><meta name="dc.Creator" content="Janet  Tien" /></meta><meta name="dc.Creator" content="Kathryn L.  Parsons-Reponte" /></meta><meta name="dc.Creator" content="Sunil  Bhakta" /></meta><meta name="dc.Creator" content="Hao  Li" /></meta><meta name="dc.Creator" content="Leanna R.  Staben" /></meta><meta name="dc.Creator" content="Guangmin  Li" /></meta><meta name="dc.Creator" content="Josefa  Chuh" /></meta><meta name="dc.Creator" content="Aimee  Fourie-O’Donohue" /></meta><meta name="dc.Creator" content="Martine  Darwish" /></meta><meta name="dc.Creator" content="Victor  Yip" /></meta><meta name="dc.Creator" content="Luna  Liu" /></meta><meta name="dc.Creator" content="Douglas D.  Leipold" /></meta><meta name="dc.Creator" content="Dian  Su" /></meta><meta name="dc.Creator" content="Elmer  Wu" /></meta><meta name="dc.Creator" content="Susan D.  Spencer" /></meta><meta name="dc.Creator" content="Ben-Quan  Shen" /></meta><meta name="dc.Creator" content="Keyang  Xu" /></meta><meta name="dc.Creator" content="Katherine R.  Kozak" /></meta><meta name="dc.Creator" content="Helga  Raab" /></meta><meta name="dc.Creator" content="Richard  Vandlen" /></meta><meta name="dc.Creator" content="Gail D.  Lewis Phillips" /></meta><meta name="dc.Creator" content="Richard H.  Scheller" /></meta><meta name="dc.Creator" content="Paul  Polakis" /></meta><meta name="dc.Creator" content="Mark X.  Sliwkowski" /></meta><meta name="dc.Creator" content="John A.  Flygare" /></meta><meta name="dc.Creator" content="Jagath R.  Junutula" /></meta><meta name="dc.Description" content="Antibody–drug conjugates (ADCs) have a significant impact toward the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lympho..." /></meta><meta name="Description" content="Antibody–drug conjugates (ADCs) have a significant impact toward the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lympho..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 18, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500552c" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500552c" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500552c" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500552c" /></link>
        
    
    

<title>Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500552c" /></meta><meta property="og:title" content="Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0010.jpeg" /></meta><meta property="og:description" content="Antibody–drug conjugates (ADCs) have a significant impact toward the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lymphoma and ado-trastuzumab emtansine (trastuzumab-MCC-DM1) for metastatic HER2+ breast cancer. DM1 is an analog of the natural product maytansine, a microtubule inhibitor that by itself has limited clinical activity and high systemic toxicity. However, by conjugation of DM1 to trastuzumab, the safety was improved and clinical activity was demonstrated. Here, we report that through chemical modification of the linker–drug and antibody engineering, the therapeutic activity of trastuzumab maytansinoid ADCs can be further improved. These improvements include eliminating DM1 release in the plasma and increasing the drug load by engineering four cysteine residues into the antibody. The chemical synthesis of highly stable linker–drugs and the modification of cysteine residues of engineered site-specific antibodies resulted in a homogeneous ADC with increased therapeutic activity compared to the clinically approved ADC, trastuzumab-MCC-DM1." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500552c"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500552c">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500552c&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500552c&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500552c&amp;href=/doi/10.1021/jm500552c" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 7890-7899</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501298k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/jm501177w" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+H.++Pillow">Thomas H. Pillow</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Janet++Tien">Janet Tien</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathryn+L.++Parsons-Reponte">Kathryn L. Parsons-Reponte</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sunil++Bhakta">Sunil Bhakta</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Li">Hao Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leanna+R.++Staben">Leanna R. Staben</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guangmin++Li">Guangmin Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Josefa++Chuh">Josefa Chuh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aimee++Fourie-O%E2%80%99Donohue">Aimee Fourie-O’Donohue</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martine++Darwish">Martine Darwish</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor++Yip">Victor Yip</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luna++Liu">Luna Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+D.++Leipold">Douglas D. Leipold</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dian++Su">Dian Su</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elmer++Wu">Elmer Wu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+D.++Spencer">Susan D. Spencer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ben-Quan++Shen">Ben-Quan Shen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keyang++Xu">Keyang Xu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+R.++Kozak">Katherine R. Kozak</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helga++Raab">Helga Raab</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Vandlen">Richard Vandlen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gail+D.++Lewis+Phillips">Gail D. Lewis Phillips</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+H.++Scheller">Richard H. Scheller</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Polakis">Paul Polakis</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+X.++Sliwkowski">Mark X. Sliwkowski</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+A.++Flygare">John A. Flygare</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jagath+R.++Junutula">Jagath R. Junutula</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="corresp-info"><strong>*</strong>T.H.P.: phone, 650-225-1652; e-mail, <a href="/cdn-cgi/l/email-protection#a6d2cec9cbc7d5ced6e6c1c3c8c388c5c9cb"><span class="__cf_email__" data-cfemail="dda9b5b2b0bcaeb5ad9dbab8b3b8f3beb2b0">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>J.R.J.: phone, 650-703-2498; e-mail, <a href="/cdn-cgi/l/email-protection#9df7fcfafce9f5f7efddfaf0fcf4f1b3fef2f0"><span class="__cf_email__" data-cfemail="83e9e2e4e2f7ebe9f1c3e4eee2eaefade0ecee">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500552c&amp;href=/doi/10.1021%2Fjm500552c" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 7890–7899</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 5, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 December 2013</li><li><span class="item_label"><b>Published</b> online</span>18 September 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 October 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500552c" title="DOI URL">https://doi.org/10.1021/jm500552c</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7890%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DThomas%2BH.%2BPillow%252C%2BJanet%2BTien%252C%2BKathryn%2BL.%2BParsons-Reponte%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D19%26contentID%3Djm500552c%26title%3DSite-Specific%2BTrastuzumab%2BMaytansinoid%2BAntibody%25E2%2580%2593Drug%2BConjugates%2Bwith%2BImproved%2BTherapeutic%2BActivity%2Bthrough%2BLinker%2Band%2BAntibody%2BEngineering%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7899%26publicationDate%3DOctober%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500552c"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4344</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">65</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500552c" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;H. Pillow&quot;},{&quot;first_name&quot;:&quot;Janet&quot;,&quot;last_name&quot;:&quot;Tien&quot;},{&quot;first_name&quot;:&quot;Kathryn&quot;,&quot;last_name&quot;:&quot;L. Parsons-Reponte&quot;},{&quot;first_name&quot;:&quot;Sunil&quot;,&quot;last_name&quot;:&quot;Bhakta&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Leanna&quot;,&quot;last_name&quot;:&quot;R. Staben&quot;},{&quot;first_name&quot;:&quot;Guangmin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Josefa&quot;,&quot;last_name&quot;:&quot;Chuh&quot;},{&quot;first_name&quot;:&quot;Aimee&quot;,&quot;last_name&quot;:&quot;Fourie-O’Donohue&quot;},{&quot;first_name&quot;:&quot;Martine&quot;,&quot;last_name&quot;:&quot;Darwish&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;Yip&quot;},{&quot;first_name&quot;:&quot;Luna&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;D. Leipold&quot;},{&quot;first_name&quot;:&quot;Dian&quot;,&quot;last_name&quot;:&quot;Su&quot;},{&quot;first_name&quot;:&quot;Elmer&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;D. Spencer&quot;},{&quot;first_name&quot;:&quot;Ben-Quan&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Keyang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;R. Kozak&quot;},{&quot;first_name&quot;:&quot;Helga&quot;,&quot;last_name&quot;:&quot;Raab&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Vandlen&quot;},{&quot;first_name&quot;:&quot;Gail&quot;,&quot;last_name&quot;:&quot;D. Lewis Phillips&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;H. Scheller&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Polakis&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;X. Sliwkowski&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;A. Flygare&quot;},{&quot;first_name&quot;:&quot;Jagath&quot;,&quot;last_name&quot;:&quot;R. Junutula&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;7890-7899&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500552c&quot;},&quot;abstract&quot;:&quot;Antibody–drug conjugates (ADCs) have a significant impact toward the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lymphoma and ado-trastuzumab emtansine (trastuzumab-MCC-DM1) for metastatic HER2+ breast cancer. DM1 is an analog of the natural product maytansine, a microtubule inhibitor that by itself has limited clinical activity and high systemic toxicity. However, by conjugation of DM1 to trastuzumab, the safety was improved and clinical activity was demonstrated. Here, we report that through chemical modification of the linker–drug and antibody engineering, the therapeutic activity of trastuzumab maytansinoid ADCs can be further improved. These improvements include eliminating DM1 release in the plasma and increasing the drug load by engineering four cysteine residues into the antibody. The chemical synthesis of highly stable linker–drugs and the modification of cysteine residues of engineered site-specific antibodies resulted in &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500552c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500552c" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500552c&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500552c" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500552c&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500552c" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500552c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500552c&amp;href=/doi/10.1021/jm500552c" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500552c" /></input><a href="/doi/pdf/10.1021/jm500552c" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500552c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500552c%26sid%3Dliteratum%253Aachs%26pmid%3D25191794%26genre%3Darticle%26aulast%3DPillow%26date%3D2014%26atitle%3DSite-Specific%2BTrastuzumab%2BMaytansinoid%2BAntibody%25E2%2580%2593Drug%2BConjugates%2Bwith%2BImproved%2BTherapeutic%2BActivity%2Bthrough%2BLinker%2Band%2BAntibody%2BEngineering%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D19%26spage%3D7890%26epage%3D7899%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jmcmar.2014.57.issue-19/20141009/jmcmar.2014.57.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Antibody–drug conjugates (ADCs) have a significant impact toward the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lymphoma and ado-trastuzumab emtansine (trastuzumab-MCC-DM1) for metastatic HER2+ breast cancer. DM1 is an analog of the natural product maytansine, a microtubule inhibitor that by itself has limited clinical activity and high systemic toxicity. However, by conjugation of DM1 to trastuzumab, the safety was improved and clinical activity was demonstrated. Here, we report that through chemical modification of the linker–drug and antibody engineering, the therapeutic activity of trastuzumab maytansinoid ADCs can be further improved. These improvements include eliminating DM1 release in the plasma and increasing the drug load by engineering four cysteine residues into the antibody. The chemical synthesis of highly stable linker–drugs and the modification of cysteine residues of engineered site-specific antibodies resulted in a homogeneous ADC with increased therapeutic activity compared to the clinically approved ADC, trastuzumab-MCC-DM1.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Natural products have had a profound impact on the treatment of cancer. Their ability to eradicate cancer cells through a variety of mechanisms has resulted in many successful drugs.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Yet the capacity to select for cancer cells in the presence of normal cells has been and will continue to be a significant challenge. This limited selectivity is the cause of many side effects associated with cancer chemotherapy as well as the inability to eliminate the tumor at tolerated doses in many cases. Conversely, monoclonal antibodies are able to exquisitely differentiate between cancer cells and normal cells by binding to tumor-associated antigens that are nonexistent or present only at low levels on normal cells. While several monoclonal antibodies have been approved for the treatment of cancer,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> many others lack therapeutic activity. Connecting a cytotoxic natural product to a monoclonal antibody can potentially synergize the strengths of both while mitigating the potential liabilities. The resulting conjugates, known as antibody–drug conjugates (ADCs),<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11">(4-11)</a> have been validated clinically,<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> and ado-trastuzumab emtansine (also known as Tmab-MCC-DM1 or T-DM1), the first ADC for the treatment of solid tumors, has recently been granted approval by the FDA.</div><div class="NLM_p">Tmab-MCC-DM1 consists of a maytansinoid natural product microtubule inhibitor linked to trastuzumab, a HER-2 targeting antibody.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The conjugate is formed by attachment of the linker and drug to the reactive lysines on the surface of the antibody. Since trastuzumab contains 90 lysines,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> the resulting conjugate is a heterogeneous mixture comprising varying drug load (0–8 drugs per antibody) conjugated at a number of reactive lysines.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> To reduce heterogeneity, THIOMAB technology was developed, where cysteine residues were engineered into the antibody at specific sites. The resulting site-specific ADCs allow uniform drug loads of two drugs per antibody, with the site of conjugation specified by the placement of the engineered cysteine.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Connecting DM1 to an engineered thio-trastuzumab gave a site-specific ADC (ThioTmab-MPEO-DM1) with an improved preclinical therapeutic index over Tmab-MCC-DM1.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">One of the key components to an ADC is the linker connecting the cytotoxic drug to the antibody.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref19'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref19">(4-11, 19)</a> Tmab-MCC-DM1 utilizes a noncleavable linker that enabled the conjugate to retain efficacy while improving safety over conjugates with disulfide cleavable linkers due to improved plasma stability.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Tmab-MCC-DM1 and thioTmab-MPEO-DM1 both utilize a maleimide to connect the drug to the linker and in the case of thioTmab-MPEO-DM1, another maleimide to also connect the linker to the antibody. Maleimides are incorporated into the linker primarily for ease of synthesis of the linker–drug and to facilitate conjugation of linker–drug to the antibody. Yet the product of the reaction between a maleimide and a thiol is a thioether succinimide, a potentially unstable functional group. The thioether succinimide, connecting antibody to linker and linker to drug, can revert through a retro-Michael reaction to the starting material thiol and maleimide, whereupon the maleimide can be trapped by other reactive thiols. The reversibility of this connection between antibody and linker has been demonstrated with several ADCs and has been shown to result in a decrease in efficacy of the corresponding drug conjugate.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> Here we investigate the impact of the lability of the functional group connecting the maytansinoid drug and the linker in trastuzumab–drug conjugates. We show that through semisynthesis from the natural product analog maytansinol, a maytansine linker–drug lacking this reversible functional group can be prepared. The resulting drug conjugates have improved efficacies over both the conventional ADC (Tmab-MCC-DM1) and the recently reported site-specific ADC (thioTmab-MPEO-DM1). In addition, we show that increasing the drug to antibody ratio (DAR) from 2 to 4 by engineering two additional cysteines into the previously reported trastuzumab THIOMAB improves the therapeutic activity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Rationale</h3><div class="NLM_p">Tmab-MCC-DM1, despite having a noncleavable linker between antibody and drug, showed an appreciable level of deconjugation (plasma: total antibody vs plasma: ADC) and overall instability (buffer: ADC vs plasma: ADC) of ADC in plasma as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A. Another observation indicating deconjugation of Tmab-MCC-DM1 was the detection of increasing unconjugated (or free) DM1 levels over the incubation time with an in vitro plasma stability study, as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B. Significantly higher concentrations of unconjugated DM1 were measured in mouse plasma than in buffer. Deconjugation is further supported by the difference in PK between the total antibody and Tmab-MCC-DM1 ADC, which has been observed both preclinically<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> and clinically,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> and by LC–MS analysis of Tmab-MCC-DM1 in human plasma.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> We have reported previously that conjugation of DM1 to an engineered thio-HC-A114C-trastuzumab via a BMPEO (bismaleimidopolyethylene oxide) linker gave a site-specific ADC (ThioTmab-MPEO-DM1).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition to having a potentially labile bond between linker and drug, thioTmab-MPEO-DM1 also has a labile bond between antibody and linker resulting in deconjugation as described previously (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>C).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Since a THIOMAB conjugate between LC-V205C-trastuzumab and MPEO-DM1 did not show significant levels of deconjugation between linker–drug and antibody,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> this THIOMAB antibody was chosen for the subsequent studies aimed at improving the stability of the site-specific ADC.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) In vitro plasma stability analysis of Tmab-MCC-DM1 showed an appreciable level of deconjugation and overall instability of the ADC in mouse plasma as compared to the buffer control up to 96 h. Concentrations of total and conjugated antibodies were determined using ELISA and the average of three replicates plotted. (B) Formation of unconjugated (or free) DM1, a product of deconjugation of Tmab-MCC-DM1, was seen increasing with time up to 168 h and in mouse plasma vs buffer control measured by LC–MS/MS for the in vitro plasma stability study. (C) Reversibility of the connection between a thiol-containing antibody or drug and a maleimide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of Maytansinoid Linker–Drugs</h3><div class="NLM_p">To enable the lysine-conjugated linker–drug in Tmab-MCC-DM1 to be conjugated to a cysteine-containing THIOMAB, a new bifunctional linker was previously selected (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This linker, designated BMPEO, utilizes one maleimide to connect to the thiol of the maytansinoid drug DM1, to generate the linker–drug MPEO-DM1. The second maleimide reacts with the cysteine of the antibody. The thioether succinimide connection formed between the maleimide and the sulfur atom of the drug (labeled in red) is reversible. To investigate the impact of the reversibility of this connection between drug and linker, the maleimide and sulfur atom were removed. These linker–drugs were prepared employing a semisynthesis strategy starting with maytansinol (<b>6</b>) (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), a maytansine analog easily obtained from the reduction of the C3-ansamitocin esters produced by microbial fermentation.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Maytansinol (<b>6</b>) reacts with the <i>N</i>-carboxyanhydride of <i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-alanine (<b>7</b>) in the presence of zinc triflate to provide amine <b>3</b> without epimerization of the alanine side chain. This amine was then coupled with carboxylic acids (<b>5</b>, <b>9</b>) to generate stable maytansinoid linker–drugs. In one example (<b>10</b>, MPA-May), the MPEO unit was kept and connected by an amide to adipic acid (A). This keeps the same number of atoms between the antibody and the maytansinoid core (May) while removing the reversible connection between linker and drug. Additionally, in a second compound (<b>11</b>, MC-May), the PEO group was removed entirely and the antibody was connected directly to the maytansioid core through a maleimidocaproyl (MC) spacer, a common conjugation spacer for ADCs.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of new maytansinoid linker–drugs and their connection to an antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for Stable Maytansinoid Linker–Drugs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro Binding and the Effect on Cell Proliferation of 2-DAR Site-Specific ADCs</h3><div class="NLM_p">To ensure that conjugation of new linker–drugs did not impact the ability of the antibody to bind to its target antigen, an in vitro binding assay was performed using SK-BR-3 cells (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). FACS analysis showed that the two new stably linked maytansinoid ADCs, thioTmab-MPA-May and thioTmab-MC-May, were indistinguishable from Tmab-MCC-DM1 and the unconjugated antibody (Tmab). The effect of the new linker–drugs on potency was explored in a cell proliferation assay (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B). ThioTmab-MPA-May and thioTmab-MC-May inhibited growth of SK-BR-3 cells in a 5-day assay with an IC<sub>50</sub> of 10.9 and 11.8 ng/mL, respectively. Tmab-MCC-DM1 was twice as potent (IC<sub>50</sub> = 5.0 ng/mL), which can be explained by the fact that it had twice the drug load (DAR of 3.5 vs 1.8).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. 2-DAR site-specific Tmab ADCs with stable linker–drugs (ThioTmab-MPA-May and ThioTmab-MC-May) showed (A) similar HER2 binding to and (B) reduced in vitro cell killing compared to Tmab-MCC-DM1 (3.5 DAR) in the HER2-amplified SK-BR-3 breast cancer cell line, with the cell proliferation activity correlating with drug load.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro Plasma Stability of the Engineered Trastuzumab Site-Specific ADCs</h3><div class="NLM_p">To investigate whether the chemical modifications to the linker have resulted in ADCs with improved stability, an in vitro plasma stability study was performed in mouse serum for the period of 0–96 h (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). ELISA was used to monitor both the total antibody and ADC over time as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Unlike Tmab-MCC-DM1 (shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A), less deconjugation and improved stability was observed with thioTmab-MPA-May and thioTmab-MC-May ADCs, where the labile bond between linker and drug has been removed Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A,B). Similar results were observed upon conducting plasma stability studies in human plasma measured by an independent LC–MS assay (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C,D). In addition, another in vitro stability study was performed in mouse plasma vs buffer control up to 168 h with thioTmab-LC-MPEO-DM1 and thioTmab-MPA-May, and unconjugated (or free) DM1 was measured using LC–MS/MS (shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The unconjugated DM1 level appeared to initially increase with time and then plateau indicating drug deconjugation. The DM1 concentration in buffer control also rose more slowly with time but ended up at a similar concentration by 168 h. Concentrations of unconjugated DM1 were significantly lower in thioTmab-MPEO-DM1 than that in Tmab-MCC-DM1. In comparison, no detectable unconjugated DM1 (lower limit of quantitation of 2.0 nM) was observed for thioTmab-MPA-May.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vitro stability of (A) thioTmab-MPA-May and (B) thioTmab-MC-May in mouse plasma and in (C, D) human plasma. In vitro plasma stability analysis of (A) thioTmab-MPA-May and (B) thioTmab-MC-May ADCs showed low levels of deconjugation and overall stability of the ADC in mouse plasma as compared to the buffer control. Concentrations of total and conjugated antibodies were determined using ELISA, and the average of three replicates was plotted. Similar in vitro plasma stability studies were conducted for thioTmab-MPA-May (C) and thioTmab-MC-May (D) in human plasma, and the samples were analyzed using an LC–MS method.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Concentrations of unconjugated (or free) DM1 released upon incubation of thioTmab-LC-MPEO-DM1 and thioTmab-MPA-May in mouse plasma and PBS buffer (control) up to 168 h and measured by LC–MS/MS. Please note that no detectable DM1 was observed in plasma or buffer control for thioTmab-MPA-May.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> In Vivo Efficacy of Engineered Trastuzumab 2-DAR Site-Specific ADCs</h3><div class="NLM_p">The impact of linker–drug stability on efficacy was studied in a HER2+ Fo5 transplant tumor model. A single dose of ADC was given at day 0, and tumor growth was measured over time, as compared with a vehicle control. At 10 mg/kg and 2-DAR, thioTmab-MPA-May showed improved efficacy over thioTmab-LC-MPEO-DM1 (10mg/kg, 284 μg drug/m<sup>2</sup>), where thioTmab-MPA-May (10 mg/kg, 300 μg drug/m<sup>2</sup>) resulted in a greater %TGI at 93% compared with 79% of the MPEO-DM1 linker drug. This increase in antitumor activity is also reflected in the time to tumor progression (TTP 2×) where tumors in the thioTmab-MPA-May group took a median time of 18 days to progress compared with the shorter time of 8 days in the thioTmab-LC-MPEO-DM1 group. This result is consistent with the improved stability between the linker and drug with MPA-May (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A). When thioTmab-MPA-May and Tmab-MCC-DM1 are compared at the same dose, both antibody drug conjugates had similar efficacy despite the higher DM1 drug load with Tmab-MCC-DM1 (10 mg/kg, 578 μg drug/m<sup>2</sup>) as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A (93% vs 92% TGI, and 18 vs 16 days TTP 2×, respectively) and in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B (103% vs 103% TGI, and 17 vs 15 days TTP 2×, respectively). This similarity in efficacy between thioTmab-MPA-May and Tmab-MCC-DM1 at the same antibody dose can be attributed to a combination of differences in stability and drug loading. Tmab-MCC-DM1 has less stability between linker and drug but a higher drug load than thioTmab-MPA-May. To obtain a better understanding of the efficacy improvement associated with the new stable MPA-May linker–drug, we set out to increase the drug load of the site-specific ADC so that it is similar to the DAR of Tmab-MCC-DM1.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo efficacy of 2-DAR site-specific Tmab ADCs vs Tmab-MCC-DM1 in a HER2+ Fo5 mammary tumor transplant mouse model. The MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the number 2/3 mammary fat pads of nu/nu mice in sections that measured approximately 2 mm × 2 mm. The tumor-bearing animals were randomized to a mean tumor volume range of 126–152 mm<sup>3</sup> (A) and 149–162 mm<sup>3</sup> (B) of 10 mice/group and then dosed iv once (day 0) with vehicle, thio gD-MPA-May or thio gD-MC-May controls, thioTmab-LC-MPEO-DM1(10 mg/kg, 284 μg drug/m<sup>2</sup>), thioTmab-MPA-May (10 mg/kg, 300 μg drug/m<sup>2</sup>), or Tmab-MCC-DM1 (10 mg/kg, 578 μg drug/m<sup>2</sup>). Fitted tumor volumes are plotted over time (days post dose). (A) At the same antibody dose, thioTmab-MPA-May showed improved efficacy over thioTmab-LC-MPEO-DM1. (A, B) thioTmab-MPA-May and Tmab-MCC-DM1 had similar efficacy at 10 mg/kg despite the former having a lower drug load.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro Binding and the Effect on Cell Proliferation of 4-DAR Site-Specific ADCs</h3><div class="NLM_p last">Despite improving the stability of the linker–drug, a direct comparison cannot be made between the improved THIOMAB conjugate (ThioTmab-MPA-May) and Tmab-MCC-DM1 because of differences in drug loading. To address this, a thioTmab containing engineered cysteines in both the heavy (HC-A114C, Kabat numbering) and light chain (LC-V205C) was prepared and conjugated with the new stable maytansinoid linkers (thioTmab-MPA-May, thioTmab-MC-May) to give a DAR of 4. LC–MS quantification analysis determined that the DAR of conjugated Tmab is 3.9. A FACS analysis with SK-BR-3 cells indicated that the 4-DAR site-specific ADCs showed binding similar to Tmab-MCC-DM1 and unconjugated Tmab (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A). In an in vitro cell proliferation assay, the 4-DAR ADCs were twice as potent as the 2-DAR site-specific ADCs and equipotent with Tmab-MCC-DM1 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B and Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>B).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vivo Efficacy of Engineered Trastuzumab 4-DAR Site-Specific ADCs</h3><div class="NLM_p">We next analyzed the in vivo efficacy of 4-DAR ADCs in a Fo5 transplant model as described above. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, the 2-DAR thioTmab-MPA-May was as efficacious as Tmab-MCC-DM1 at 10 mg/kg. The 4-DAR was tested at 5 and 10 mg/kg. As expected, 5 mg/kg of the 4-DAR ADCs (5 mg/kg, 326 μg drug/m<sup>2</sup>) resulted in less efficacy than Tmab-MCC-DM1 (10 mg/kg, 578 μg drug/m<sup>2</sup>), likely due to halving the drug dose. The slight difference in activity between thioTmab-MC-May and -MPA-May is likely due to tumor growth variability. However, gratifyingly, the 4-DAR ADC thioTmab-MC-May and thioTmab-MPA-May (10 mg/kg, 652 μg drug/m<sup>2</sup>) demonstrated improved efficacy over Tmab-MCC-DM1, with tumor stasis being observed with a single dose of 10 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>C). This improved activity is most clearly observed in the time to tumor progression where Tmab-MCC-DM1-treated tumors took a median time of 16 days to progress while the MPA-May and MC-May-treated tumors took about twice as long (32.5 and 28.5 days, respectively).</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. 4-DAR site specific Tmab ADCs with stable linker–drugs (thioTmab-MPA-May and thioTmab-MC-May) showed (A) similar HER2 binding to and (B) equivalent in vitro cell killing compared to Tmab-MCC-DM1 (3.5 DAR) in the HER2-amplified SK-BR-3 breast cancer cell line. (C) In vivo efficacy in a HER2+ Fo5 mammary tumor transplant mouse model. The MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the number 2/3 mammary fat pads of nu/nu mice in sections that measured approximately 2 mm × 2 mm. The tumor-bearing animals were randomized to a mean tumor volume range of 149–162 mm<sup>3</sup> of 10 mice/group and then dosed iv once (day 0) with vehicle or thio gD-MC-May controls, thioTmab-MC-May, thioTmab-MPA-May, or Tmab-MCC-DM1 at the doses indicated. Fitted tumor volumes are plotted over time (days post dose). 4-DAR site-specific ADCs at 5 mg/kg (326 μg drug/m<sup>2</sup>) resulted in less efficacy than Tmab-MCC-DM1 at 10 mg/kg (578 μg drug/m<sup>2</sup>). However, as expected, 10 mg/kg (652 μg drug/m<sup>2</sup>) of site-specific 4-DAR ADCs demonstrated superior efficacy over Tmab-MCC-DM1 at the same antibody dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tmab-MCC-DM1 or T-DM1 was recently approved by the FDA for the treatment of HER2-positive metastatic breast cancer. It is the first ADC approved for the treatment of solid tumors and therefore sets the stage for the next generation of ADCs. The phase III clinical data demonstrate that Tmab-MCC-DM1 has a very favorable safety profile combined with a significant improvement in progression-free and overall survival over capecitabine plus lapatinib in patients with HER2-positive MBC previously treated with trastuzumab and a taxane.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, Tmab-MCC-DM1 has a relatively narrow therapeutic window with a DLT observed at 4.8 mg/kg compared to the clinically efficacious dose of 3.6 mg/kg. Therefore, a second generation ADC with an improved therapeutic index might be desirable. Hence an attempt was made to design site-specific maytansinoid conjugates with improved relative linker stability and therapeutic activity.</div><div class="NLM_p">Our approach toward addressing this challenge was to improve efficacy through modulating the linker and increasing the drug load. Through rational design, we aimed to create a linker with a high level of stability. Previous studies have shown that maleimide exchange has an impact on the pharmacokinetics of an ADC. This exchange results in loss of drug from the antibody and a corresponding reduction in efficacy of the ADC.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> While the maleimide in Tmab-MCC-DM1 was installed to facilitate the connection of the linker and drug, we envisioned a different synthetic connection between the linker and drug, allowing the assembly of a more stable ADC.</div><div class="NLM_p">To improve stability, two linker–drugs (MPA-May, MC-May) were synthesized that lacked a reversible thioether succinimide connection between the drug and linker and these were conjugated at the LC-V205C site of trastuzumab to minimize the maleimide exchange.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This change in the linker–drug had no impact on the ability of the resulting conjugates to bind to their target, and the conjugates had in vitro potency half that of Tmab-MCC-DM1, correlating with half the drug load. The new conjugates had increased in vitro stability in plasma relative to Tmab-MCC-DM1 over time, which can be caused by both a reduction in the deconjugation and an increased stability of the engineered ADC by eliminating higher drug-loaded species. It is interesting to note that the stability of the antibody itself may be compromised in plasma at 37 °C for the Tmab-MCC-DM1 ADC, perhaps because of aggregation. In contrast, antibodies of engineered ADCs were stable in plasma. A direct evidence of enhanced stability was that no released drug, i.e., DM1, was detected in thioTmab-MPA-May vs up to approximately 180 nM DM1 was released in Tmab-MCC-DM1 incubated in mouse plasma for 168 h. This translated to improved efficacy, with the stabilized conjugates matching the efficacy of Tmab-MCC-DM1 with half the amount of drug while showing improved efficacy over the previously reported site-specific THIOMAB ADC (ThioTmab-MPEO-DM1) with the same drug load. To improve efficacy even further, four cysteine residues were engineered into the trastuzumab antibody. The resulting 4-DAR site-specific ADCs (ThioTmab-MPA-May, ThioTmab-MC-May) matched the in vitro potency of Tmab-MCC-DM1 while showing superior efficacy.</div><div class="NLM_p">It was important that the change in linker–drug not have an impact on the mechanism of action of the drug or the drug’s metabolism. While an ester at C3 on the maytansine core is required for activity, the nature of that ester is not important.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Since the only changes to the linker–drug were in modifications of the C3 ester, the stabilized linker–drugs did not impact the potency of the maytansinoid payload as evidenced by their potent inhibition of cell proliferation. It has also been demonstrated that while changes to the linker of maytansinoid ADCs can result in different pharmacokinetics, they do not impact the processing of the conjugates to their respective catabolites.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> As evidenced by the increased plasma stability and efficacy of the stabilized linker–drugs, the linker changes are likely to improve the pharmacokinetic properties.</div><div class="NLM_p last">On the basis of historical data, there seems to be a good correlation between drug load and safety.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Site-specific ADCs with a DAR of 2 showed a 2-fold improvement in safety over Tmab-MCC-DM1<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Therefore, it is reasonable to expect that doubling the drug load may make the 4-DAR site-specific ADC more toxic than the 2-DAR site-specific ADC. However, more importantly, doubling the drug load did increase the efficacy of the site-specific ADC. It is believed that increasing the efficacy is likely an impactful way of improving clinical activity for trastuzumab maytansinoid ADCs, given the unpredictable thrombocytopenia that was not seen in preclinical safety studies but is a dose-limiting factor in humans. The newly engineered trastuzumab site-specific ADCs with improved therapeutic activity can therefore serve as a potential next-generation ADC for HER2+ breast cancer patients.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All solvents and reagents were used as obtained. <sup>1</sup>H NMR spectra were recorded with a Bruker Avance DPX400 spectrometer or a Varian Inova 400 NMR spectrometer and referenced to tetramethylsilane. Chemical shifts are expressed as δ units using tetramethylsilane as the internal standard (in NMR description, s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak). All coupling constants (<i>J</i>) are reported in hertz. Mass spectra were measured with a Finnigan SSQ710C spectrometer using an ESI source coupled to a Waters 600MS HPLC system operating in reverse mode with an X-bridge phenyl column of dimensions 150 mm by 2.6 mm, with 5 μm sized particles. For all compounds evaluated biologically, a purity of >95% was confirmed by HPLC.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>tert</i>-Butyl 2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethylcarbamate (<b>2</b>)</h3><div class="NLM_p last">To a solution of diamine <b>1</b> (5.00 g, 0.0260 mol) in THF (525 mL) was added 4-dimethylaminopyridine (320 mg, 0.0026 mol). To this was added a solution of di-<i>tert</i>-butyl dicarbonate (5.68 g, 0.0260 mol) in THF (100 mL) over a period of 1 h, using an addition funnel, all at room temperature. The mixture initially became cloudy but then cleared. The mixture was stirred an additional 2 h and then concentrated and purified by ISCO (0–20% MeOH/DCM) to provide mono-Boc diamine <b>2</b> as a light yellow oil (2.70 g, 36%). MS [M + H]<sup>+</sup> 293.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.79 (s, 1H), 3.69–3.57 (m, 8H), 3.56–3.47 (m, 4H), 3.32–3.23 (m, 2H), 2.84 (t, <i>J</i> = 5.1 Hz, 2H), 1.44 (s, 9H).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Boc-aminopolyethelene Glycol Adipic Acid (<b>3</b>)</h3><div class="NLM_p last">To a flask containing amine <b>2</b> (1.219 g, 4.169 mmol) and hexanedioic acid (adipic acid, 3.046 g, 20.84 mmol) in tetrahydrofuran (100 mL) was added <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (1.23 g, 5.98 mmol). The mixture was stirred at room temperature and became cloudy. After 2 h, the solution was cooled to 0 °C and the byproduct <i>N</i>,<i>N</i>′-dicyclohexylurea was removed by filtration. The mixture was concentrated onto silica gel and purified via ISCO (40 g column, 0–10% MeOH/DCM). Concentration provided amide <b>3</b> as a clear oil (1.28 g, 73%). MS [M + H]<sup>+</sup> 421.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.55 (s, 1H), 6.65 (s, 1H), 5.27 (s, 1H), 3.67–3.62 (m, 8H), 3.60–3.52 (m, 4H), 3.48–3.41 (m, 2H), 3.35–3.23 (m, 2H), 2.35 (t, <i>J</i> = 6.3 Hz, 3H), 2.25 (t, <i>J</i> = 6.5 Hz, 2H), 1.44 (s, 9H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Maleimidopolyethylene Glycol Adipic Acid (MPA, <b>5</b>)</h3><div class="NLM_p last">To a vial containing Boc-protected amine <b>3</b> (682.3 mg, 1.623 mmol) was added 4 mL of 4 M hydrogen chloride in 1,4-dioxane. The mixture was stirred for 30 min and then concentrated. A saturated aqueous solution of sodium bicarbonate (5.1 mL) was added. The solution was cooled to 0 °C and stirred for 10 min, and then <i>N</i>-methoxycarbonylmaleimide (<b>4</b>) (251.7 mg, 1.622 mmol) was added. The mixture was stirred for 20 min more at 0 °C and then warmed to room temperature. The solution was diluted with DMF, quenched with 5 drops of formic acid, filtered, and purified by RP-HPLC to provide maleimide <b>5</b> as a clear oil (297 mg, 46%). MS [M + H]<sup>+</sup> 401.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.66 (s, 1H), 6.56 (t, <i>J</i> = 4.8 Hz, 1H), 3.73 (t, <i>J</i> = 5.6 Hz, 2H), 3.66–3.60 (m, 9H), 3.56 (t, <i>J</i> = 5.0 Hz, 2H), 3.47–3.41 (m, 2H), 2.35 (t, <i>J</i> = 6.7 Hz, 2H), 2.24 (t, <i>J</i> = 6.9 Hz, 2H), 1.77–1.58 (m, 4H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 3-(<i>S</i>-(<i>N</i>-Methylalaninyl)maytansinol (<b>8</b>)</h3><div class="NLM_p last">To a solution of maytansinol (<b>6</b>) (50.0 mg, 0.0885 mmol) in DMF (1.12 mL, 14.5 mmol) and THF (380 μL, 4.6 mmol) were added <i>N</i>,<i>N</i>-diisopropylethylamine (62 μL, 0.35 mmol), zinc triflate (129 mg, 0.354 mmol), and the <i>N</i>-carboxyanhydride of <i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-alanine (<b>7</b>) (80.0 mg, 0.619 mmol). The mixture was stirred for 24 h, and ethyl acetate (2 mL) was added. Then over 5 min, 2 mL of a saturated 1:1 sodium bicarbonate (aq)/sodium chloride (aq) solution was added. The solution was stirred for 30 min, and the salts were filtered and rinsed with ethyl acetate. The two phases were separated, and the aqueous phase was extracted with 3 × 2 mL of ethyl acetate. The combined organic phases were concentrated to 0.25 mL. Then 2 mL of ethyl acetate was added, and the solution was again reduced to 0.25 mL. This dilution and concentration were done once more. Finally, ethyl acetate was added to give around 2 mL of solution, and salts that had precipitated were filtered through a 0.45 μm syringe filter to give ester <b>8</b>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Maleimidopolyethylene Glycol Amidoadipic Acid Maytansinoid (MPA-May, <b>10</b>)</h3><div class="NLM_p last">To a solution of amine <b>8</b> was added acid <b>5</b> (65.5 mg, 0.164 mmol), <i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (31.4 mg, 0.164 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (7.71 μL, 0.0442 mmol). The mixture was stirred for 2 h, and the mixture was filtered and purified on RP-HPLC to provide MPA-May <b>(10)</b> as a clear oil (48.8 mg, 53%). MS [M + H]<sup>+</sup> 1032.7. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.83 (s, 1H), 6.71 (s, 2H), 6.70–6.64 (m, 2H), 6.47–6.37 (m, 2H), 6.27 (t, <i>J</i> = 4.8 Hz, 1H), 5.67 (dd, <i>J</i> = 15.3, 9.1 Hz, 1H), 5.35 (q, <i>J</i> = 6.7 Hz, 1H), 4.78 (dd, <i>J</i> = 12.0, 2.8 Hz, 1H), 4.29 (t, <i>J</i> = 10.8 Hz, 1H), 3.98 (s, 3H), 3.72 (t, <i>J</i> = 5.7 Hz, 2H), 3.67–3.56 (m, 12H), 3.54–3.48 (m, 3H), 3.44–3.38 (m, 2H), 3.36 (s, 3H), 3.19 (s, 3H), 3.11 (d, <i>J</i> = 12.7 Hz, 1H), 3.01 (d, <i>J</i> = 9.6 Hz, 1H), 2.84 (s, 3H), 2.60 (dd, <i>J</i> = 14.1, 12.4 Hz, 1H), 2.48–2.38 (m, 1H), 2.30–2.13 (m, 4H), 1.75–1.58 (m, 8H), 1.52–1.40 (m, 1H), 1.29 (t, <i>J</i> = 6.0 Hz, 6H), 1.22 (d, <i>J</i> = 12.9 Hz, 1H), 0.80 (s, 3H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Maleimidocaproyl Maytansinoid (MC-May, <b>11</b>)</h3><div class="NLM_p last">To the solution of amine <b>8</b> were added <b>9</b> (34.6 mg, 0.164 mmol), <i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (31.4 mg, 0.164 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (7.71 μL, 0.0442 mmol). The mixture was stirred for 2 h, and the mixture was filtered and purified on RP-HPLC to provide MC-May (<b>11</b>) as a clear oil (30.7 mg, 41%). MS [M + H]<sup>+</sup> 843.5. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.11 (s, 1H), 6.76 (s, 2H), 6.72–6.65 (m, 2H), 6.60 (dd, <i>J</i> = 14.7, 11.4 Hz, 1H), 5.69 (dd, <i>J</i> = 14.9, 9.1 Hz, 1H), 5.49 (q, <i>J</i> = 6.7 Hz, 1H), 4.65 (dd, <i>J</i> = 11.9, 2.1 Hz, 1H), 4.19 (td, <i>J</i> = 10.3, 4.1 Hz, 1H), 3.97 (s, 3H), 3.62–3.55 (m, 2H), 3.41–3.34 (m, 5H), 3.23 (d, <i>J</i> = 12.7 Hz, 1H), 3.20 (s, 3H), 2.94 (d, <i>J</i> = 9.6 Hz, 1H), 2.84 (s, 3H), 2.72–2.62 (m, 1H), 2.56–2.45 (m, 1H), 2.33–2.23 (m, 1H), 2.14 (dd, <i>J</i> = 14.1, 1.8 Hz, 1H), 1.68 (s, 3H), 1.65–1.42 (m, 7H), 1.29 (d, <i>J</i> = 6.8 Hz, 3H), 1.28–1.25 (m, 2H), 1.23 (d, <i>J</i> = 6.3 Hz, 3H), 0.84 (s, 3H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Antibody–Drug Conjugates</h3><div class="NLM_p last">Tmab-MCC-DM1 and thioTmab-LC-MPEO-DM1 were prepared as described earlier.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> Construction and production of the THIOMAB variants of trastuzumab (HC-A114C and LC-V205C, Kabat numbering) were previously reported.<a onclick="showRef(event, 'ref17 ref18 ref21'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref21">(17, 18, 21)</a> The drug to antibody ratios (DARs) of the ADCs were determined by liquid chromatography/mass spectrometry (LC/MS) analysis as previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The LC-V205C THIOMAB resulted in 2-DAR ADCs upon conjugation with thiol reactive maleimide linker drugs. To construct a 4-DAR engineered ADC, we have used HC-A114C and LC-V205C constructs co-transfected to generate a THIOMAB with four engineered cysteines. Site-specific 4-DAR ADCs were produced using the same method as described earlier for 2-DAR site specific ADCs.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The resulting thioTMab-MPA-May and thioTMab-MC-May site-specific ADCs had DAR of 3.9 with less than 3% aggregation as characterized by LC–MS and size exclusion chromatography analysis, respectively.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Flow Cytometric Analysis and Cell Viability Assays</h3><div class="NLM_p last">The SK-BR-3 cell line used in this study, a cell line with high human epidermal growth factor receptor 2 (HER2) expression with ∼2 million copies per cell, was obtained from the American Type Culture Collection, and cells were cultured in Ham’s F-12: high glucose (50:50) supplemented with 10% heat-inactivated fetal bovine serum and 2 mmol/L <span class="smallcaps smallerCapital">l</span>-glutamine (all from Invitrogen Corp.). SK-BR-3 cells (100,000 cells per sample) were incubated on ice with trastuzumab, Tmab-MCC-DM1, thioTmab-MPA-May, or thioTmab-MC-May at various concentrations in the range of 0–1600 ng/mL in fluorescence-activated cell sorting (FACS) buffer (PBS buffer containing 1% bovine serum albumin) for 1 h. Cells were washed with FACS buffer and incubated with phycoerythrin-labeled goat anti-human Fc secondary antibody (1:3000 dilution) on ice for 1 h. All samples were washed using FACS buffer and fixed with 2% paraformaldehyde followed by FACS analysis using a BD FACS Calibur system (BD Biosciences). Cell viability assays in the presence of Tmab-MCC-DM1, thioTmab-MPA-May, and thioTmab-MC-May (0–10 μg/mL) were carried out in SK-BR-3 cells in a 96-well format as previously described.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> In Vitro Plasma Stability Studies</h3><div class="NLM_p last">Plasma (lithium heparin) samples (mouse and human) were purchased from Bioreclamation. Plasma was thawed, spun at 157<i>g</i> (Eppendorf centrifuge 5810R) for 5 min followed by filtration through a 0.22 μm filter (Pall Corp.) into sterile polypropylene tubes and kept on ice. PBS buffer was filtered and kept on ice. Conjugate stock solutions were added to selected plasma samples at a final concentration of 100 μg/mL. PBS with 0.5% BSA was used as a control. Aliquots of 100 μL from each mixture were transferred into sialylated microcentrifuge tubes and incubated at 37 °C in a CO<sub>2</sub> incubator to maintain plasma pH levels close to the physiological pH of 7.2 throughout the incubation period. To terminate the reaction, samples were transferred to a −80 °C freezer at predetermined time points (0, 24, and 96 h). Additional time points (6, 48, and 168 h) were collected for the measurement of unconjugated drug (DM1). The 0 h collection was placed on dry ice within the first minute following the addition of the conjugate. Samples were stored in a −80 °C freezer until further analysis.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> ELISA Analysis</h3><div class="NLM_p last">Plasma samples from the stability study were analyzed by ELISA for total antibody (conjugated plus unconjugated antibody) and conjugate (conjugated antibody) concentrations. For the total antibody ELISA-based assay, microtiter plates (384 wells) (Nunc, Rochester, NY, USA) were coated with human Her2 extracellular domain (Genentech, Inc.) at 0.4 μg/mL in coat buffer (0.05 M carbonate/bicarbonate buffer, pH 9.6). After an overnight incubation at 4 °C, assay plates were washed and treated with blocking buffer (PBS buffer, pH 7.4, containing 0.05% Tween 20, 0.05% Proclin 300) for 1–2 h before a 2 h incubation with DM1-conjugated standards and samples diluted in sample diluent (PBS buffer, pH 7.4, containing 0.5% BSA, 10 ppm Proclin, 0.05% Tween 20, 0.25% CHAPS, 5 mM EDTA, and 0.35 M NaCl). Assay plates were first washed 6 times with wash buffer (PBS buffer, pH 7.4, containing 0.05% Tween 20) and then incubated for 1 h with AffiniPure F(ab′)2 fragment goat anti-human Fc, Fcγ fragment specific HRP conjugated (GxhFc-HRP) (Jackson Immuno-Research Laboratory) diluted to 40 ng/mL. After washing (6 times), the detection step was done using tetramethylbenzidine (TMB) substrate (Moss, Pasadena, MD, USA). Absorbance was measured at 450 nm against a reference wavelength of 620 nm. The limit of quantitation (LOQ) was 3 ng/mL. For the DM1-conjugated antibody ELISA-based assay, microtiter plates (384-well) (Nunc) were coated with 0.5 μg/mL anti-DM1 antibody (clone 2G9.5.7, produced at Genentech, South San Francisco, CA) in coat buffer. After an overnight incubation at 4 °C, assay plates were washed and treated with block buffer for 1–2 h before 2 h incubation with DM1-conjugate standards and samples diluted in sample diluent. Assay plates were washed 6 times with wash buffer and incubated for 1 h with goat anti-human IgG conjugated to HRP (GxhIgG-HRP) diluted to 25 ng/mL in assay buffer. After washing (6 times), the detection step was carried out using TMB substrate. Absorbance was measured at 450 nm against a reference wavelength of 620 nm. The limit of quantitation (LOQ) was 7 ng/mL.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Quantification of Unconjugated (or Free) DM1 by LC–MS/MS</h3><div class="NLM_p last">Calibration standards ranging from 2.00 to 500 nM DM1 (SICOR Pharmaceuticals Inc., Irvine, CA) were prepared in mouse plasma or PBS buffer. An aliquot of 30 μL of in vitro incubation samples, standards, or matrix blank was reduced with 1.25 μL of 26 mM tris(2-carboxyethyl)phosphine (TCEP) (neutral pH) (Thermo Scientific, Rockford, IL) by incubation at 37 °C for 15 min. Samples were treated by protein precipitation with 120 μL of internal standard (7.5 nM maytansine from Immunogen, Inc., Waltham, MA, in 80% acetonitrile). Derivatization was conducted by addition of 6.32 μL of 25 mM <i>N</i>-ethylmaleimide (NEM) (Sigma-Aldrich, Saint Louis, MO) to 80 μL of supernatant and incubation at 37 °C for 45 min. NEM-derivatized samples were subjected to separation using a reverse phase analytical column (Phenomenex Synergi MAX-RP 80A, C12, 4 μm, 50 mm × 2.00 mm) (Torrance, CA) heated to 50 °C run on a Shimadzu SCL-10A VP system (Columbia, MD). Separation was performed at a flow rate of 0.5 mL/min with a linear gradient using mobile phase A (5 mM ammonium acetate with 0.1% formic acid) and mobile phase B (5 mM ammonium acetate in 95% acetonitrile with 0.1% formic acid). Mass spectra were recorded on a 4000 QTRAP system (AB Sciex, Redwood City, CA) in the multiple reaction monitoring (MRM) mode. Transition <i>m</i>/<i>z</i> 845.7/485.3 was monitored for DM1-NEM, <i>m</i>/<i>z</i> 738.5/547.3 for DM1, and <i>m</i>/<i>z</i> 692.6/547.2 for maytansine. Data analysis was done with Analyst 1.6 software from AB Sciex. The lower limit of quantitation (LLOQ) of DM1-NEM is 2.0 nM.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Affinity Capture LC–MS</h3><div class="NLM_p last">Details of the affinity capture LC–MS procedure were described previously.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Briefly, an aliquot (typically 50 μL) of plasma or serum was added to a 96-well plate containing the HBS-EP buffer followed by addition of streptavidin paramagnetic beads coupled with the biotinylated HER2 extracellular domain (ECD) and incubated at room temperature for 2 h. The ADC analytes captured by the beads were isolated, washed, and subsequently deglycosylated by PNGase F overnight at 37 °C. The beads were extensively washed to remove nonspecifically bound proteins. The ADC was eluted by 30% acetonitrile in water with 1% formic acid and injected onto an LC–MS instrument for analysis. The ADC was analyzed by a Q-STAR XL quadrupole time-of-flight mass spectrometer (AB Sciex) equipped with a turbo ionspray source and coupled with a reversed phase PLRP-S capillary column (Varian, 0.3 mm × 50 mm, 5 μm, 4000 Å). The chromatographic separation was conducted under a gradient condition at a flow rate of 15 μL/min. Mobile phase A was water with 0.1% formic acid, and mobile phase B was acetonitrile with 0.1% formic acid. Positive time-of-flight (TOF) MS scan was acquired.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> In Vivo Efficacy Studies</h3><div class="NLM_p">The Fo5 mouse mammary tumor model was employed to evaluate the in vivo efficacy of Tmab-MCC-DM1, thioTmab-LC-MPEO-DM1, thioTmab-MPA-May, and thioTmab-MC-May (single-dose iv injections) as described previously.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The Fo5 model is a transgenic mouse model in which the human HER2 gene is overexpressed in mammary epithelium under transcriptional regulation of the murine mammary tumor virus promoter (MMTV-HER2). The HER2 overexpression causes spontaneous development of a mammary tumor. The mammary tumor of one of these founder animals [founder 5 (Fo5)] has been propagated in subsequent generations of FVB mice by serial transplantation of tumor fragments (∼2 mm × 2 mm in size). All treatment groups consisted of 10 animals per group, and tumor size was monitored twice weekly using caliper measurement. The tumor volume (mm<sup>3</sup>) was calculated using the following formula: length × width<sup>2</sup> × 0.5. The log 2 (tumor volume) growth traces were fitted to each treatment group with restricted cubic splines for the fixed time effect in each group.</div><div class="NLM_p last">To analyze the repeated measurement of tumor volumes from the same animals over time, a mixed-modeling approach was used. Fitting was done as previously described<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> via a linear mixed effects model, using the R package “nlme”, version 3.1-108<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> in R, version 2.15.2 (R Development Core Team 2012; R Foundation for Statistical Computing; Vienna, Austria). Tumor growth inhibition (TGI) as a percentage of control was calculated as the percentage of the area under the fitted tumor volume–time curve (AUC) per day reduction compared to control based on the fitted curves for only those days where the control group still has animals present, using the following formula: %TGI = 100 × [1 – (AUC<sub>dose</sub> per day ÷ AUC<sub>vehicle</sub> per day)]. A TGI value of 100% indicates tumor stasis. A TGI value of >1% but <100% indicates tumor growth delay, and a TGI value of >100% indicates tumor regression. Time to tumor progression of 2× (TTP 2×) is defined as the median time (in days) for a group’s tumors to progress to twice the median tumor volume of the vehicle group at time 0. Plotting was performed using Prism 5 (GraphPad software, San Diego, CA). All studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm500552c" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas H. Pillow</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#02766a6d6f63716a724265676c672c616d6f"><span class="__cf_email__" data-cfemail="57233f383a36243f2717303239327934383a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jagath R. Junutula</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a6ccc7c1c7d2ceccd4e6c1cbc7cfca88c5c9cb"><span class="__cf_email__" data-cfemail="741e151315001c1e06341319151d185a171b19">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janet Tien</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathryn L. Parsons-Reponte</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sunil Bhakta</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Li</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leanna R. Staben</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guangmin Li</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josefa Chuh</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aimee Fourie-O’Donohue</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martine Darwish</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor Yip</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luna Liu</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas D. Leipold</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dian Su</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elmer Wu</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan D. Spencer</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ben-Quan Shen</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keyang Xu</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine R. Kozak</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helga Raab</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Vandlen</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gail D. Lewis Phillips</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard H. Scheller</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Polakis</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark X. Sliwkowski</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John A. Flygare</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>T.H.P. and J.T. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are (or were) full time employees of Genentech, Inc. at the time this work was conducted.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1019e1139-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54473" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54473" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank our Genentech colleagues from the Early Stage Cell Culture and Protein Chemistry Departments for their help with large-scale production of trastuzumab and its THIOMAB variants. We also thank the core facilities: oligonucleotide synthesis, DNA sequencing, and DNA purification.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i29" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i29"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i30" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i30"> Abbreviations Used</h2><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">MCC</td><td class="NLM_def"><p class="first last">4-[<i>N</i>-maleimidomethyl]cyclohexane-1-carboxylate</p></td></tr><tr><td class="NLM_term">DM1</td><td class="NLM_def"><p class="first last">an analog of the natural product maytansine</p></td></tr><tr><td class="NLM_term">Tmab</td><td class="NLM_def"><p class="first last">trastuzumab</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Mann, J.</span><span> </span><span class="NLM_article-title">Natural Products in Cancer Chemotherapy: Past, Present and Future</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnrc723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=12635177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVehtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=143-148&author=J.+Mann&title=Natural+Products+in+Cancer+Chemotherapy%3A+Past%2C+Present+and+Future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products in cancer chemotherapy: past, present and future</span></div><div class="casAuthors">Mann, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-148</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products have been the mainstay of cancer chemotherapy for the past 30 yr.  However, the quickening pace of (aberrant) gene identification, and the new technologies of combinatorial chem. and high-throughput screening, should provide access to a wide range of new, totally synthetic drugs.  Will these new approaches sound the death knell for therapies based on natural products.  In reality, natural products are likely to provide many of the lead structures, and these will be used as templates for the construction of novel compds. with enhanced biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXHpZOuqpKvLVg90H21EOLACvtfcHk0lhh2ROjRyOBlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVehtL8%253D&md5=e58dae200970644fcc8f43883fdcb428</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc723%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DJ.%26atitle%3DNatural%2520Products%2520in%2520Cancer%2520Chemotherapy%253A%2520Past%252C%2520Present%2520and%2520Future%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D143%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Cragg, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, D. J.</span><span> </span><span class="NLM_article-title">Impact of Natural Products on Developing New Anti-Cancer Agents</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3012</span><span class="NLM_x">–</span> <span class="NLM_lpage">3043</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr900019j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=3012-3043&author=G.+M.+Craggauthor=P.+G.+Grothausauthor=D.+J.+Newman&title=Impact+of+Natural+Products+on+Developing+New+Anti-Cancer+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Natural Products on Developing New Anti-Cancer Agents</span></div><div class="casAuthors">Cragg, Gordon M.; Grothaus, Paul G.; Newman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3012-3043</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Throughout the ages, Nature has catered to the basic needs of humans, not the least of which is the provision of medicines for the treatment of a wide spectrum of diseases.  Plants, in particular, have played a dominant role in the development of sophisticated traditional medicine systems.  The continuing and essential role played by plant-based systems in the healthcare of many different cultures has been extensively documented, and the World Health Organization (WHO) has estd. that approx. 65 % of the world's population rely mainly on plant-derived traditional medicines for their primary health care.  Plant products, however, also play an important role in the health care systems of the remaining population, mainly residing in developed countries.  In a survey of plant-derived pure compds. used as drugs in countries hosting WHO-Traditional Medicine Centers, 80 % of 122 such compds. identified were found to be used for the same or related ethnomedical purposes and were derived from only 94 plant species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMIOcfoMKc7Vg90H21EOLACvtfcHk0lhh2ROjRyOBlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCns7Y%253D&md5=4d74768e702c8978c15c4802864b6deb</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fcr900019j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900019j%26sid%3Dliteratum%253Aachs%26aulast%3DCragg%26aufirst%3DG.%2BM.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26atitle%3DImpact%2520of%2520Natural%2520Products%2520on%2520Developing%2520New%2520Anti-Cancer%2520Agents%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D3012%26epage%3D3043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Scott, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Old, L. J.</span><span> </span><span class="NLM_article-title">Antibody Therapy of Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnrc3236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22437872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=278-287&author=A.+M.+Scottauthor=J.+D.+Wolchokauthor=L.+J.+Old&title=Antibody+Therapy+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody therapy of cancer</span></div><div class="casAuthors">Scott, Andrew M.; Wolchok, Jedd D.; Old, Lloyd J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-287</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years.  Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumors, and immunomodulatory antibodies have also recently achieved remarkable clin. success.  The development of therapeutic antibodies requires a deep understanding of cancer serol., protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells.  This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclin. studies to human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-oFh7ngWZT7Vg90H21EOLACvtfcHk0lgM0KxK-szlJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegsbs%253D&md5=568d4e9d2385eeba9d0bd211b31492f9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3236%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DA.%2BM.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26atitle%3DAntibody%2520Therapy%2520of%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D278%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Flygare, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aristoff, P.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates for the Treatment of Cancer</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1111%2Fcbdd.12085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=23253133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=113-121&author=J.+A.+Flygareauthor=T.+H.+Pillowauthor=P.+Aristoff&title=Antibody-Drug+Conjugates+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for the treatment of cancer</span></div><div class="casAuthors">Flygare, John A.; Pillow, Thomas H.; Aristoff, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-121</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  With over 20 antibody-drug conjugates in clin. trials as well as a recently FDA-approved drug, it is clear that this is becoming an important and viable approach for selectively delivering highly cytotoxic agents to tumor cells while sparing normal tissue.  This review discusses the crit. aspects for this approach with an emphasis on the properties of the linker between the antibody and the cytotoxic payload that are required for an effective antibody-drug conjugate.  Different linkers are illustrated with attention focused on (i) the specifics of attachment to the antibody, (ii) the polarity of the linker, (iii) the trigger on the linker that initiates cleavage from the drug, and (iv) the self-immolative spacer that liberates the active payload.  Future directions in the field are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVlj709scT7Vg90H21EOLACvtfcHk0lgM0KxK-szlJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D&md5=236ee3d312781e0b2ad27ad1f6c9365d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12085%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DAristoff%26aufirst%3DP.%26atitle%3DAntibody-Drug%2520Conjugates%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Adair, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, K. A.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates—A Perfect Synergy</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1191</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1517%2F14712598.2012.693473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22650648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Wls73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1191-1206&author=J.+R.+Adairauthor=P.+W.+Howardauthor=J.+A.+Hartleyauthor=D.+G.+Williamsauthor=K.+A.+Chester&title=Antibody-Drug+Conjugates%E2%80%94A+Perfect+Synergy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates - a perfect synergy</span></div><div class="casAuthors">Adair, John R.; Howard, Philip W.; Hartley, John A.; Williams, David G.; Chester, Kerry A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1191-1206</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: There is a great unmet need for effective new treatments in cancer, which continues to be a major cause of death.  Antibody-drug conjugates (ADCs) are emerging, after a long gestation, as a class of biopharmaceuticals with the potential to address this need by directing highly potent cytotoxic drugs to their point of action.  There is increasing interest in ADCs by major pharmaceutical companies and a growing pipeline of candidates for clin. use.  This review summarises progress with development of this new class of drugs.Areas covered: The authors describe sep. the antibody and drug elements of ADCs and then examine the technol. and consequences of linkage.  The work is presented in the light of recent developments in the design, using clin. examples where possible.Expert opinion: Since their emergence as independent drugs, antibodies and chemotherapy are being brought together in effective synergy.  The conjunction is timely: many of the tech. challenges in prepg. antibodies have been addressed; potent new drugs are available and linker technol. is advancing apace.  ADCs however are not just a sum of their individual parts.  The current challenge is in understanding the holistic nature of this exciting class of drugs that promise a new avenue for cancer treatment.  Target selection, the interaction of ADC with tumor and off-tumor targets and the internalisation of ADCs, are crit. to the effective maturation of ADC technol.  Ongoing recent developments in attachment sites and linker chem. can provide fine-tuning of drug loading, elements of ADC PK and off-target ADC toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY30NZYFPh-rVg90H21EOLACvtfcHk0lgM0KxK-szlJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Wls73P&md5=e3604ba9b52c917335b4c5568e54057c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F14712598.2012.693473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2012.693473%26sid%3Dliteratum%253Aachs%26aulast%3DAdair%26aufirst%3DJ.%2BR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DChester%26aufirst%3DK.%2BA.%26atitle%3DAntibody-Drug%2520Conjugates%25E2%2580%2594A%2520Perfect%2520Synergy%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2012%26volume%3D12%26spage%3D1191%26epage%3D1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Teicher, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Antibody Conjugate Therapeutics: Challenges and Potential</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6389</span><span class="NLM_x">–</span> <span class="NLM_lpage">6397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1078-0432.CCR-11-1417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22003066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6389-6397&author=B.+A.+Teicherauthor=R.+V.+J.+Chari&title=Antibody+Conjugate+Therapeutics%3A+Challenges+and+Potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Conjugate Therapeutics: Challenges and Potential</span></div><div class="casAuthors">Teicher, Beverly A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6389-6397</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells.  The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.  The history of antibody conjugates is marked by hurdles that have been identified and overcome.  Early conjugates used mouse antibodies; cytotoxic agents that were immunogenic (proteins), too toxic, or not sufficiently potent; and linkers that were not sufficiently stable in circulation.  Investigators have explored 4 main avenues using antibodies to target cytotoxic agents to malignant cells: antibody-protein toxin (or antibody fragment-protein toxin fusion) conjugates, antibody-chelated radionuclide conjugates, antibody-small-mol. drug conjugates, and antibody-enzyme conjugates administered along with small-mol. prodrugs that require metab. by the conjugated enzyme to release the activated species.  Only antibody-radionuclide conjugates and antibody-drug conjugates have reached the regulatory approval stage, and nearly 20 antibody conjugates are currently in clin. trials.  The time may have come for this technol. to become a major contributor to improving treatment for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhe-7pzpGkZbVg90H21EOLACvtfcHk0liUHlXa90c7-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzK&md5=860b08fb5e2dfda813cb411cf124e664</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1417%26sid%3Dliteratum%253Aachs%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DAntibody%2520Conjugate%2520Therapeutics%253A%2520Challenges%2520and%2520Potential%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6389%26epage%3D6397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Sapra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, H.-P.</span><span> </span><span class="NLM_article-title">Investigational Antibody Drug Conjugates for Solid Tumors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1131</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1131-1149&author=P.+Sapraauthor=A.+T.+Hooperauthor=C.+J.+O%E2%80%99Donnellauthor=H.-P.+Gerber&title=Investigational+Antibody+Drug+Conjugates+for+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSapra%26aufirst%3DP.%26aulast%3DHooper%26aufirst%3DA.%2BT.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DGerber%26aufirst%3DH.-P.%26atitle%3DInvestigational%2520Antibody%2520Drug%2520Conjugates%2520for%2520Solid%2520Tumors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1131%26epage%3D1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Polson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span> </span><span class="NLM_article-title">Investigational Antibody-Drug Conjugates for Hematological Malignancies</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=75-85&author=A.+G.+Polsonauthor=W.+Y.+Hoauthor=V.+Ramakrishnan&title=Investigational+Antibody-Drug+Conjugates+for+Hematological+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DHo%26aufirst%3DW.%2BY.%26aulast%3DRamakrishnan%26aufirst%3DV.%26atitle%3DInvestigational%2520Antibody-Drug%2520Conjugates%2520for%2520Hematological%2520Malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D75%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Antibody–Drug Conjugates: Targeted Drug Delivery for Cancer</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1016%2Fj.cbpa.2010.06.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=20643572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=529-537&author=S.+C.+Alleyauthor=N.+M.+Okeleyauthor=P.+D.+Senter&title=Antibody%E2%80%93Drug+Conjugates%3A+Targeted+Drug+Delivery+for+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: Targeted drug delivery for cancer</span></div><div class="casAuthors">Alley, Stephen C.; Okeley, Nicole M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technol., and the stoichiometry and placement of conjugated drugs.  The underlying reason for this was obtained in pre-clin. biodistribution and pharmacokinetics studies showing that targeted delivery leads to high intratumoral free drug concns., while non-target tissues are largely spared from chemotherapeutic exposure.  Recent developments in the field have led to an increase in the no. of ADCs being tested clin., with 3 in late stage clin. trials: Brentuximab vedotin (also referred to as SGN-35) for Hodgkin lymphoma; Trastuzumab-DM1 for breast cancer; and Inotuzumab ozogamicin for non-Hodgkin lymphoma.  This review highlights the recent pre-clin. and clin. advances that have been made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-9ugy8pi8C7Vg90H21EOLACvtfcHk0liUHlXa90c7-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D&md5=ace266066ea07d49d0e0b4338b48eeb3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.170%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugates%253A%2520Targeted%2520Drug%2520Delivery%2520for%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D529%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Potent Antibody Drug Conjugates for Cancer Therapy</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1016%2Fj.cbpa.2009.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=19414278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=235-244&author=P.+D.+Senter&title=Potent+Antibody+Drug+Conjugates+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in the past few years in the area of antibody drug conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors.  Early work in this field incorporated clin. approved drugs and mouse monoclonal antibodies (mAbs), which had modest activities, and were generally immunogenic.  The results of these studies prompted investigation that led to the identity of several key parameters that influenced activity and tolerability.  These included the antigen target, the use of non-immunogenic mAb carriers, the incorporation of highly potent drugs and novel conditionally stable linker technologies, and the specific methods used to attach drugs to mAbs.  As a result of these investigations, new agents with pronounced clin. activities have been developed.  These include SGN-35, an ADC directed against the CD30-pos. malignancies such as Hodgkin's disease and anaplastic large cell lymphoma, and trastuzumab-DM1 which has shown activity in metastatic breast carcinoma.  This review details many of the technol. advancements, and provides examples of promising ADCs that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomJSUUPIrcbVg90H21EOLACvtfcHk0liUHlXa90c7-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D&md5=3cf72b412351bae075fab1159c49d8c5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DPotent%2520Antibody%2520Drug%2520Conjugates%2520for%2520Cancer%2520Therapy%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700108g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=98-107&author=R.+V.+J.+Chari&title=Targeted+Cancer+Therapy%3A+Conferring+Specificity+to+Cytotoxic+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs</span></div><div class="casAuthors">Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Most anticancer drugs in clin. use today display poor tumor specificity, resulting in high systemic toxicity.  Monoclonal antibodies that recognize specific markers on the surface of tumor cells offer an alternative therapy that is tumor-specific and, thus, less toxic.  Although highly selective, very few monoclonal antibodies are therapeutically useful because they only display modest cell-killing activity.  The tumor selectivity of monoclonal antibodies can be exploited for the targeted delivery of highly cytotoxic drugs that are otherwise too toxic to be used on their own.  This Account provides a brief history of the development of antibody-drug conjugates, followed by a review of recent advances, wherein highly cytotoxic drugs have been linked to tumor-reactive antibodies.  Linkers have been designed such that these monoclonal antibody-drug conjugates are stable in circulation and are virtually nontoxic until they bind to the tumor cell through the antibody component.  Upon binding to the tumor cell and internalization, lysosomal processing releases the potent cytotoxic agents inside the cell.  These conjugates display high target-specific cytotoxicity in vitro and antitumor activity that is superior to that of the antibodies alone or the std. anticancer drugs in human tumor xenograft models.  Several conjugates from this new class of tumor-targeted anticancer agents are currently undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHel9bmmcerVg90H21EOLACvtfcHk0lh8CkFlxUBo7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D&md5=83bb7694ba47151534d9fd5c626edfc2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Far700108g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700108g%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DTargeted%2520Cancer%2520Therapy%253A%2520Conferring%2520Specificity%2520to%2520Cytotoxic%2520Drugs%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D98%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bross, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1490</span><span class="NLM_x">–</span> <span class="NLM_lpage">1496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=11410481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1490-1496&author=P.+F.+Brossauthor=J.+Beitzauthor=G.+Chenauthor=X.+H.+Chenauthor=E.+Duffyauthor=L.+Kiefferauthor=S.+Royauthor=R.+Sridharaauthor=A.+Rahmanauthor=G.+Williamsauthor=R.+Pazdur&title=Approval+Summary%3A+Gemtuzumab+Ozogamicin+in+Relapsed+Acute+Myeloid+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia</span></div><div class="casAuthors">Bross, Peter F.; Beitz, Julie; Chen, Gang; Chen, Xiao Hong; Duffy, Eric; Kieffer, Lydia; Roy, Sandip; Sridhara, Rajeshwari; Rahman, Atiqur; Williams, Grant; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1490-1496</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review with refs.  Gemtuzumab ozogamicin (Mylotarg; Wyeth Labs., Philadelphia, PA) consists of a semisynthetic deriv. of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).  In this study, we review the preclin. and clin. profiles of this immuno-conjugate and the regulatory review that led to marketing approval by the United States Food and Drug Administration.  From the literature and manufacturer's data, we review the activity, tolerability, and pharmacokinetics of gemtuzumab ozogamicin in preclin. and Phase I studies and its activity, efficacy, and side effects in three Phase 2 trials of 142 patients with relapsed AML.  In Phase I studies, the major toxicity was myelosuppression, esp. neutropenia and thrombocytopenia, resulting from the expression of CD33 on myeloid progenitor cells.  The Phase 2 dose was 9 mg/m2 infused i.v. over 4 h, repeated on day 14.  A minority of patients experienced acute infusion-related symptoms, usually transient and occasionally requiring hospitalization.  The complete response (CR) rate with full recovery of hematopoiesis was 16%.  A subset of patients [CRs with incomplete platelet recovery (CRps)] was identified with blast clearance and neutrophil recovery but incomplete platelet recovery.  The duration of responses of CRps appeared to be similar to those of the CRs, although the nos. were small.  The question of the equivalence of these response groups was a central issue in the review of this new drug application (NDA).  After considerable discussion, the Oncol. Drugs Advisory Committee recommended allowing inclusion of CRps resulting in an overall response rate in the Phase 2 studies of 30%.  In the subgroup of patients over 60 yr of age, the overall response rate was 26%.  Response duration was difficult to establish because of the high prevalence of postremission therapies.  Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes.  One patient died of liver failure in the Phase 2 trials.  Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by the United States Food and Drug Administration under the Accelerated Approval regulations.  Gemtuzumab ozogamicin is indicated for the treatment of patients with CD33 pos. AML in first relapse who are 60 yr of age or older and who are not considered candidates for cytotoxic chemotherapy.  The approved dose was 9 mg/m2 i.v. over 4 h and repeated in 14 days.  Completion of the ongoing studies of gemtuzumab ozogamicin in relapsed AML and initiation of randomized clin. trials comparing the effects of gemtuzumab ozogamicin in combination with conventional induction chemotherapy to conventional chemotherapy alone on survival are mandated to confirm clin. benefit under the accelerated approval Subpart H regulations.  Postmarketing reports of fatal anaphylaxis, adult respiratory distress syndrome (ARDS), and hepatotoxicity, esp. venoocclusive disease (VOD) in patients treated with gemtuzumab ozogamicin, with and without assocd. hematopoietic stem cell transplantation (HSCT), have required labeling revisions and the initiation of a registration surveillance program.  Tumor lysis and ARDS have been reported in patients with leukocytes above 30,000/mL treated with gemtuzumab ozogamicin; therefore, the redn. of leukocyte counts to below 30,000/mL is recommended prior to treatment.  Patients should be carefully monitored for acute hypersensitivity, hypoxia, and delayed hepatotoxicity following treatment with gemtuzumab ozogamicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxE3VNYYST67Vg90H21EOLACvtfcHk0lh8CkFlxUBo7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D&md5=8a85e32e3113034e98f05dfbd119110b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DBeitz%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DDuffy%26aufirst%3DE.%26aulast%3DKieffer%26aufirst%3DL.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520Summary%253A%2520Gemtuzumab%2520Ozogamicin%2520in%2520Relapsed%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D1490%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Katz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, A.</span><span> </span><span class="NLM_article-title">Brentuximab Vedotin (SGN-35)</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6428</span><span class="NLM_x">–</span> <span class="NLM_lpage">6436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1078-0432.CCR-11-0488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22003070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSksr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6428-6436&author=J.+Katzauthor=J.+E.+Janikauthor=A.+Younes&title=Brentuximab+Vedotin+%28SGN-35%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Brentuximab Vedotin (SGN-35)</span></div><div class="casAuthors">Katz, Jessica; Janik, John E.; Younes, Anas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6428-6436</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma.  SGN-35 consists of the cAC10 chimerized IgG1 monoclonal antibody SGN30, modified by the addn. of a valine-citrulline dipeptide linker to permit attachment of the potent inhibitor of microtubule polymn. monomethylauristatin E (MMAE).  In phase II trials, SGN-35 produced response rates of 75% in patients with Hodgkin lymphoma (n = 102) and 87% in patients with anaplastic large cell lymphoma (n = 30).  Responses to SGN-35 might be related not only to the cytotoxic effect due to release of MMAE within the malignant cell but also to other effects.  First, SGN-35 may signal malignant cells through CD30 ligation to deliver an apoptotic or proliferative response.  The former would amplify the cytotoxicity of MMAE.  A proliferative signal delivered in the context of MMAE intoxication could enhance cell death.  Second, the efficacy of SGN-35, particularly in Hodgkin lymphoma, might be attributed to its effect on the tumor microenvironment.  Diffusion of free MMAE from the targeted tumor cells could result in a bystander effect that kills the normal supporting cells in close proximity to the malignant cells.  The elimination of T regulatory cells that inhibit cytotoxic effector cells and elimination of cells that provide growth factor support for Hodgkin/Reed-Sternberg cells could further enhance the cytotoxic activity of SGN-35.  Here we review the biol. of SGN-35 and the clin. effects of SGN-35 administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr3UOlpwo1_LVg90H21EOLACvtfcHk0lh8CkFlxUBo7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSksr3M&md5=69707687c7cde6b47d7297c7524cc7fa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0488%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DJanik%26aufirst%3DJ.%2BE.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DBrentuximab%2520Vedotin%2520%2528SGN-35%2529%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6428%26epage%3D6436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welslau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diéras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">EMILIA Study Group.</span><span> </span><span class="NLM_article-title">Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1056%2FNEJMoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.-Y.+Ohauthor=V.+Di%C3%A9rasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwellauthor=EMILIA+Study+Group.&title=Trastuzumab+Emtansine+for+HER2-Positive+Advanced+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0lgR9EuoX7d-ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26aulast%3D%26atitle%3DTrastuzumab%2520Emtansine%2520for%2520HER2-Positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blättler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Bl%C3%A4ttlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-Positive+Breast+Cancer+with+Trastuzumab-DM1%2C+an+Antibody-Cytotoxic+Drug+Conjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lgR9EuoX7d-ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-Positive%2520Breast%2520Cancer%2520with%2520Trastuzumab-DM1%252C%2520an%2520Antibody-Cytotoxic%2520Drug%2520Conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wakankar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span> </span><span class="NLM_article-title">Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes Due to Modification and Conjugation Processes</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1588</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc900434c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1588-1595&author=A.+A.+Wakankarauthor=M.+B.+Feeneyauthor=J.+Riveraauthor=Y.+Chenauthor=M.+Kimauthor=V.+K.+Sharmaauthor=Y.+J.+Wang&title=Physicochemical+Stability+of+the+Antibody-Drug+Conjugate+Trastuzumab-DM1%3A+Changes+Due+to+Modification+and+Conjugation+Processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes</span></div><div class="casAuthors">Wakankar, Aditya A.; Feeney, Maria B.; Rivera, Javier; Chen, Yan; Kim, Michael; Sharma, Vikas K.; Wang, Y. John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1588-1595</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the manuf. of the antibody-drug conjugate Trastuzumab-DM1 (T-DM1), the lysine residues on the antibody trastuzumab (Tmab) are modified to form the intermediate Tmab-MCC (T-MCC) and then conjugated with the drug DM1.  Our goal is to understand the effects of modification and conjugation steps on the physicochem. stability of the antibody.  The structural stability of Tmab relative to its modified and conjugated forms was assessed, employing thermally induced stress conditions to formulations contg. Tmab, T-MCC, and T-DM1.  DSC, SEC, CE-SDS, and LC-MS were used to study the stability of Tmab, T-MCC, and T-DM1 to thermal stress.  The DSC thermograms show a decrease in melting temp. for the CH2 transition, in the order Tmab > T-MCC > T-DM1.  As per SEC anal., a significant increase in level of aggregation was detected in T-MCC (∼32%) and T-DM1 (∼5%) after 14 days at 40°.  Tmab did not show significant aggregate formation.  CE-SDS and LC-MS data demonstrate that the aggregation in the case of T-MCC is largely covalent and involves mechanisms other than formation of intermol. disulfide crosslinks.  The aggregation obsd. for T-MCC was significantly inhibited upon addn. of amino acids with nucleophilic side chains contg. thiol (Cys) and hydroxyl moieties (Ser, Tyr).  The covalent aggregation obsd. for T-MCC and the ability of nucleophilic amino acids, particularly Cys, to inhibit it indicate that the maleimide moiety in the MCC linker may react to form intermol. covalent crosslinks between T-MCC mols., possibly through a Michael addn. mechanism.  In addn., DSC results demonstrate that the conjugation of the drug moiety DM1 to Tmab results in destabilization of the CH2 domain of the antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoTooyTYRrPLVg90H21EOLACvtfcHk0lgR9EuoX7d-ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D&md5=6c67fb904a35f97adfeb62ec69b7d4be</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fbc900434c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc900434c%26sid%3Dliteratum%253Aachs%26aulast%3DWakankar%26aufirst%3DA.%2BA.%26aulast%3DFeeney%26aufirst%3DM.%2BB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DPhysicochemical%2520Stability%2520of%2520the%2520Antibody-Drug%2520Conjugate%2520Trastuzumab-DM1%253A%2520Changes%2520Due%2520to%2520Modification%2520and%2520Conjugation%2520Processes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D1588%26epage%3D1595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraragi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4769</span><span class="NLM_x">–</span> <span class="NLM_lpage">4778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1078-0432.CCR-10-0987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=20805300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4769-4778&author=J.+R.+Junutulaauthor=K.+M.+Flagellaauthor=R.+A.+Grahamauthor=K.+L.+Parsonsauthor=E.+Haauthor=H.+Raabauthor=S.+Bhaktaauthor=T.+Nguyenauthor=D.+L.+Duggerauthor=G.+Liauthor=E.+Maiauthor=G.+D.+Lewis+Phillipsauthor=H.+Hiraragiauthor=R.+N.+Fujiauthor=J.+Tibbittsauthor=R.+Vandlenauthor=S.+D.+Spencerauthor=R.+H.+Schellerauthor=P.+Polakisauthor=M.+X.+Sliwkowski&title=Engineered+Thio-Trastuzumab-DM1+Conjugate+with+an+Improved+Therapeutic+Index+to+Target+Human+Epidermal+Growth+Factor+Receptor+2-Positive+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer</span></div><div class="casAuthors">Junutula, Jagath R.; Flagella, Kelly M.; Graham, Richard A.; Parsons, Kathryn L.; Ha, Edward; Raab, Helga; Bhakta, Sunil; Nguyen, Trung; Dugger, Debra L.; Li, Guangmin; Mai, Elaine; Lewis Phillips, Gail D.; Hiraragi, Hajime; Fuji, Reina N.; Tibbitts, Jay; Vandlen, Richard; Spencer, Susan D.; Scheller, Richard H.; Polakis, Paul; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4769-4778</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) combine the ideal properties of both antibodies and cytotoxic drugs by targeting potent drugs to the antigen-expressing tumor cells, thereby enhancing their antitumor activity.  Successful ADC development for a given target antigen depends on optimization of antibody selection, linker stability, cytotoxic drug potency, and mode of linker-drug conjugation to the antibody.  Here, we systematically examd. the in vitro potency as well as in vivo preclin. efficacy and safety profiles of a heterogeneous prepn. of conventional trastuzumab-mcc-DM1 (TMAb-mcc-DM1) ADC with that of a homogeneous engineered thio-trastuzumab-mpeo-DM1 (thioTMAb-mpeo-DM1) conjugate.  To generate thioTMAb-mpeo-DM1, one drug maytansinoid 1 (DM1) mol. was conjugated to an engineered cysteine residue at Ala114 (Kabat numbering) on each trastuzumab-heavy chain, resulting in two DM1 mols. per antibody.  ThioTMAb-mpeo-DM1 retained similar in vitro anti-cell proliferation activity and human epidermal growth factor receptor 2 (HER2) binding properties to that of the conventional ADC.  Furthermore, it showed improved efficacy over the conventional ADC at DM1-equiv doses (μg/m2) and retained efficacy at equiv. antibody doses (mg/kg).  An improved safety profile of >2-fold was obsd. in a short-term target-independent rat safety study.  In cynomolgus monkey safety studies, thioTMAb-mpeo-DM1 was tolerated at higher antibody doses (up to 48 mg/kg or 6000 μg DM1/m2) compared with the conventional ADC that had dose-limiting toxicity at 30 mg/kg (6000 μg DM1/m2).  The engineered thioTMAb-mpeo-DM1 with broadened therapeutic index represents a promising antibody drug conjugate for future clin. development of HER2-pos. targeted breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowkqzAMGHmA7Vg90H21EOLACvtfcHk0lhqb8mKT1UcpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK&md5=888bda7f06d1ed864111b607dae5f969</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0987%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DGraham%26aufirst%3DR.%2BA.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DHiraragi%26aufirst%3DH.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DEngineered%2520Thio-Trastuzumab-DM1%2520Conjugate%2520with%2520an%2520Improved%2520Therapeutic%2520Index%2520to%2520Target%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor%25202-Positive%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4769%26epage%3D4778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venook, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee Wong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallet, W.</span><span> </span><span class="NLM_article-title">Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&author=J.+R.+Junutulaauthor=H.+Raabauthor=S.+Clarkauthor=S.+Bhaktaauthor=D.+D.+Leipoldauthor=S.+Weirauthor=Y.+Chenauthor=M.+Simpsonauthor=S.+P.+Tsaiauthor=M.+S.+Dennisauthor=Y.+Luauthor=Y.+G.+Mengauthor=C.+Ngauthor=J.+Yangauthor=C.+C.+Leeauthor=E.+Duenasauthor=J.+Gorrellauthor=V.+Kattaauthor=A.+Kimauthor=K.+McDormanauthor=K.+Flagellaauthor=R.+Venookauthor=S.+Rossauthor=S.+D.+Spencerauthor=W.+Lee+Wongauthor=H.+B.+Lowmanauthor=R.+Vandlenauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=W.+Mallet&title=Site-Specific+Conjugation+of+a+Cytotoxic+Drug+to+an+Antibody+Improves+the+Therapeutic+Index"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0lhqb8mKT1UcpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DWeir%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSimpson%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DY.%2BG.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DDuenas%26aufirst%3DE.%26aulast%3DGorrell%26aufirst%3DJ.%26aulast%3DKatta%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DVenook%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DLee%2BWong%26aufirst%3DW.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DMallet%26aufirst%3DW.%26atitle%3DSite-Specific%2520Conjugation%2520of%2520a%2520Cytotoxic%2520Drug%2520to%2520an%2520Antibody%2520Improves%2520the%2520Therapeutic%2520Index%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ducry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stump, B.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc9002019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=5-13&author=L.+Ducryauthor=B.+Stump&title=Antibody-Drug+Conjugates%3A+Linking+Cytotoxic+Payloads+to+Monoclonal+Antibodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span></div><div class="casAuthors">Ducry, Laurent; Stump, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-13</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic mols., thereby taking advantage of the best characteristics of both components.  Along with the development of the mAbs and cytotoxins, the design of chem. linkers to covalently bind these building blocks is making rapid progress but remains challenging.  Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlMw1v5iWdG7Vg90H21EOLACvtfcHk0lhqb8mKT1UcpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I&md5=bf79ac611e08674604d6b8cc29636abb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbc9002019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9002019%26sid%3Dliteratum%253Aachs%26aulast%3DDucry%26aufirst%3DL.%26aulast%3DStump%26aufirst%3DB.%26atitle%3DAntibody-Drug%2520Conjugates%253A%2520Linking%2520Cytotoxic%2520Payloads%2520to%2520Monoclonal%2520Antibodies%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D5%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc7004329" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=759-765&author=S.+C.+Alleyauthor=D.+R.+Benjaminauthor=S.+C.+Jeffreyauthor=N.+M.+Okeleyauthor=D.+L.+Meyerauthor=R.+J.+Sandersonauthor=P.+D.+Senter&title=Contribution+of+Linker+Stability+to+the+Activities+of+Anticancer+Immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates</span></div><div class="casAuthors">Alley, Stephen C.; Benjamin, Dennis R.; Jeffrey, Scott C.; Okeley, Nicole M.; Meyer, Damon L.; Sanderson, Russell J.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">759-765</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are highly active at well tolerated doses.  For maximal intratumoral drug delivery, linkers are required that are highly stable in the systemic circulation, yet allow for efficient drug release at the target site.  In this respect, amide bond-based technologies constitute a technol. advancement, since the linker half-lives in circulation (t1/2 ∼ 7 days) are much longer than earlier generation linkers that break down within 1-2 days.  The amide linkers, some of which contain peptides, are appended to the mAb carriers through thioether/maleimide adducts.  Here, we describe that use of a bromoacetamidecaproyl (bac) in place of the maleimidocaproyl (mc) increases the plasma stability of resulting thioether ADCs.  One such ADC, 1F6-C4v2-bac-MMAF, which is directed against the CD70 antigen on lymphomas and renal cell carcinoma, was prepd. contg. a bac thioether spacer between the drug (MMAF) and the mAb carrier (1F6-C4v2).  There was no measurable systemic drug release from this ADC for 2 wk postadministration in mice.  In order to assess the impact of improving linker stability beyond mc contg. ADCs, a series of mc and bac-linked 1F6-MMAF conjugates were compared for tolerability, intratumoral drug delivery, and therapeutic efficacy in nude mice with renal cell carcinoma xenografts.  There were no statistically significant efficacy differences between sets of mc and bac contg. ADCs, although the bac linker technol. led to 25% higher intratumoral drug exposure over a 7 day period compared to the corresponding mc linker.  The mechanism of drug release from maleimide-adducts likely involves a retro-Michael reaction that takes place in plasma, based on in vitro studies demonstrating that some of the released drug-maleimide deriv. became covalently bound to cysteine-34 of serum albumin.  In summary, the data indicate that new linkers can be obtained with improved in vivo stability by replacing the maleimide with an acetamide, but the resulting ADCs had similar tolerability and activity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAEuKHrhYzvrVg90H21EOLACvtfcHk0lgX_eWJoYDr0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D&md5=62abdec871dda99c160a9b989c12f6f0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbc7004329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc7004329%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DContribution%2520of%2520Linker%2520Stability%2520to%2520the%2520Activities%2520of%2520Anticancer%2520Immunoconjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D759%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Shen, B.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Reponte, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hass, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solis, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span> </span><span class="NLM_article-title">Conjugation Site Modulates the in Vivo Stability and Therapeutic Activity of Antibody-Drug Conjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&author=B.-Q.+Shenauthor=K.+Xuauthor=L.+Liuauthor=H.+Raabauthor=S.+Bhaktaauthor=M.+Kenrickauthor=K.+L.+Parsons-Reponteauthor=J.+Tienauthor=S.-F.+Yuauthor=E.+Maiauthor=D.+Liauthor=J.+Tibbittsauthor=J.+Baudysauthor=O.+M.+Saadauthor=S.+J.+Scalesauthor=P.+J.+McDonaldauthor=P.+E.+Hassauthor=C.+Eigenbrotauthor=T.+Nguyenauthor=W.+A.+Solisauthor=R.+N.+Fujiauthor=K.+M.+Flagellaauthor=D.+Patelauthor=S.+D.+Spencerauthor=L.+A.+Khawliauthor=A.+Ebensauthor=W.+L.+Wongauthor=R.+Vandlenauthor=S.+Kaurauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=J.+R.+Junutula&title=Conjugation+Site+Modulates+the+in+Vivo+Stability+and+Therapeutic+Activity+of+Antibody-Drug+Conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0lgX_eWJoYDr0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DKenrick%26aufirst%3DM.%26aulast%3DParsons-Reponte%26aufirst%3DK.%2BL.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DMcDonald%26aufirst%3DP.%2BJ.%26aulast%3DHass%26aufirst%3DP.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSolis%26aufirst%3DW.%2BA.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DConjugation%2520Site%2520Modulates%2520the%2520in%2520Vivo%2520Stability%2520and%2520Therapeutic%2520Activity%2520of%2520Antibody-Drug%2520Conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provenzano, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span> </span><span class="NLM_article-title">The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1535-7163.MCT-11-0727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22408268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1133-1142&author=H.+K.+Ericksonauthor=G.+D.+Lewis+Phillipsauthor=D.+D.+Leipoldauthor=C.+A.+Provenzanoauthor=E.+Maiauthor=H.+A.+Johnsonauthor=B.+Gunterauthor=C.+A.+Audetteauthor=M.+Guptaauthor=J.+Pinkasauthor=J.+Tibbitts&title=The+Effect+of+Different+Linkers+on+Target+Cell+Catabolism+and+Pharmacokinetics%2FPharmacodynamics+of+Trastuzumab+Maytansinoid+Conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates</span></div><div class="casAuthors">Erickson, Hans K.; Lewis Phillips, Gail D.; Leipold, Douglas D.; Provenzano, Carmela A.; Mai, Elaine; Johnson, Holly A.; Gunter, Bert; Audette, Charlene A.; Gupta, Manish; Pinkas, Jan; Tibbitts, Jay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1133-1142</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of the anti-HER2 antibody trastuzumab linked via a nonreducible thioether linker to the maytansinoid antitubulin agent DM1.  T-DM1 has shown favorable safety and efficacy in patients with HER2-pos. metastatic breast cancer.  In previous animal studies, T-DM1 exhibited better pharmacokinetics (PK) and slightly more efficacy than several disulfide-linked versions.  The efficacy findings are unique, as other disulfide-linked antibody-drug conjugates (ADC) have shown greater efficacy than thioether-linked designs.  To explore this further, the in vitro and in vivo activity, PK, and target cell activation of T-DM1 and the disulfide-linked T-SPP-DM1 were examd.  Both ADCs showed high in vitro potency, with T-DM1 displaying greater potency in two of four breast cancer cell lines.  In vitro target cell processing of T-DM1 and T-SPP-DM1 produced lysine-N.vepsiln.-MCC-DM1, and lysine-N.vepsiln.-SPP-DM1 and DM1, resp.; in vivo studies confirmed these results.  The in vitro processing rates for the two conjugate to their resp. catabolites were similar.  In vivo, the potencies of the conjugates were similar, and T-SPP-DM1 had a faster plasma clearance than T-DM1.  Slower T-DM1 clearance translated to higher overall tumor concns. (conjugate plus catabolites), but unexpectedly, similar levels of tumor catabolite.  These results indicate that, although the ADC linker can have clear impact on the PK and the chem. nature of the catabolites formed, both linkers seem to offer the same payload delivery to the tumor.  Mol Cancer Ther; 11(5); 1133-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynXKVoEvq_7Vg90H21EOLACvtfcHk0liOo25CouQp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D&md5=e7485e8164a5bf3210f6c68f174df112</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0727%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DProvenzano%26aufirst%3DC.%2BA.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DH.%2BA.%26aulast%3DGunter%26aufirst%3DB.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26atitle%3DThe%2520Effect%2520of%2520Different%2520Linkers%2520on%2520Target%2520Cell%2520Catabolism%2520and%2520Pharmacokinetics%252FPharmacodynamics%2520of%2520Trastuzumab%2520Maytansinoid%2520Conjugates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1133%26epage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Poon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, T.</span><span> </span><span class="NLM_article-title">Preclinical Safety Profile of Trastuzumab Emtansine (T-DM1): Mechanism of Action of Its Cytotoxic Component Retained with Improved Tolerability</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1016%2Fj.taap.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=24035823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2013&pages=298-313&author=K.+A.+Poonauthor=K.+Flagellaauthor=J.+Beyerauthor=J.+Tibbittsauthor=S.+Kaurauthor=O.+Saadauthor=J.-H.+Yiauthor=S.+Girishauthor=N.+Dybdalauthor=T.+Reynolds&title=Preclinical+Safety+Profile+of+Trastuzumab+Emtansine+%28T-DM1%29%3A+Mechanism+of+Action+of+Its+Cytotoxic+Component+Retained+with+Improved+Tolerability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability</span></div><div class="casAuthors">Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  The therapeutic premise of ADCs is based on the hypothesis that targeted delivery of potent cytotoxic drugs to tumors will provide better tolerability and efficacy compared with non-targeted delivery, where poor tolerability can limit efficacious doses.  Here, we present results from preclin. studies characterizing the toxicity profile of T-DM1, including limited assessment of unconjugated DM1.  T-DM1 binds primate ErbB2 and human HER2 but not the rodent homolog c-neu.  Therefore, antigen-dependent and non-antigen-dependent toxicity was evaluated in monkeys and rats, resp., in both single- and repeat-dose studies; toxicity of DM1 was assessed in rats only.  T-DM1 was well tolerated at doses up to 40 mg/kg (~ 4400 μg DM1/m2) and 30 mg/kg (~ 6000 μg DM1/m2) in rats and monkeys, resp.  In contrast, DM1 was only tolerated up to 0.2 mg/kg (1600 μg DM1/m2).  This suggests that at least two-fold higher doses of the cytotoxic agent are tolerated in T-DM1, supporting the premise of ADCs to improve the therapeutic index.  In addn., T-DM1 and DM1 safety profiles were similar and consistent with the mechanism of action of DM1 (i.e., microtubule disruption).  Findings included hepatic, bone marrow/hematol. (primarily platelet), lymphoid organ, and neuronal toxicities, and increased nos. of cells of epithelial and phagocytic origin in metaphase arrest.  These adverse effects did not worsen with chronic dosing in monkeys and are consistent with those reported in T-DM1-treated patients to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp36u8JDO92mbVg90H21EOLACvtfcHk0liOo25CouQp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO&md5=f2ae6f6fc865d8ad027752e1301be3cc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DDybdal%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DT.%26atitle%3DPreclinical%2520Safety%2520Profile%2520of%2520Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520Mechanism%2520of%2520Action%2520of%2520Its%2520Cytotoxic%2520Component%2520Retained%2520with%2520Improved%2520Tolerability%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2013%26volume%3D273%26spage%3D298%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzker, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span> </span><span class="NLM_article-title">Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients with HER2-Positive Metastatic Breast Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2698</span><span class="NLM_x">–</span> <span class="NLM_lpage">2704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1200%2FJCO.2009.26.2071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=20421541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2698-2704&author=I.+E.+Kropauthor=M.+Beeramauthor=S.+Modiauthor=S.+F.+Jonesauthor=S.+N.+Holdenauthor=W.+Yuauthor=S.+Girishauthor=J.+Tibbittsauthor=J.-H.+Yiauthor=M.+X.+Sliwkowskiauthor=F.+Jacobsonauthor=S.+G.+Lutzkerauthor=H.+A.+Burris&title=Phase+I+Study+of+Trastuzumab-DM1%2C+an+HER2+Antibody-Drug+Conjugate%2C+Given+Every+3+Weeks+to+Patients+with+HER2-Positive+Metastatic+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Krop, Ian E.; Beeram, Muralidhar; Modi, Shanu; Jones, Suzanne F.; Holden, Scott N.; Yu, Wei; Girish, Sandhy; Tibbitts, Jay; Yi, Joo-Hee; Sliwkowski, Mark X.; Jacobson, Fred; Lutzker, Stuart G.; Burris, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2698-2704</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-pos. cells.  This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-pos. breast cancer.  Patients and Methods: Successive cohorts of patients who had progressed on trastuzumab-based therapy received escalating doses of T-DM1.  Outcomes were assessed by std. solid-tumor phase I methods.  Results: Twenty-four patients who had received a median of four prior chemotherapeutic agents for metastatic disease received T-DM1 at 0.3 mg/kg to 4.8 mg/kg on an every-3-wk schedule.  Transient thrombocytopenia was dose-limiting at 4.8 mg/kg; the max.-tolerated dose (MTD) was 3.6 mg/kg.  The half-life of T-DM1 at the MTD was 3.5 days, with peak DM1 levels < 10 ng/mL.  Clearance at doses < 1.2 mg/kg was faster than at higher doses.  Common drug-related adverse events (AEs) included grade ≤ 2 thrombocytopenia, elevated transaminases, fatigue, nausea, and anemia.  No grade > 1 nausea, vomiting, alopecia, or neuropathy events and no cardiac effects requiring dose modification were reported.  The clin. benefit rate (objective response plus stable disease at 6 mo) among 15 patients treated at the MTD was 73%, including five objective responses.  The confirmed response rate in patients with measurable disease at the MTD (n = 9) was 44%.  Conclusion: At the MTD of 3.6 mg/kg every 3 wk, T-DM1 was assocd. with mild, reversible toxicity and substantial clin. activity in a heavily pretreated population.  Phase II and III trials in patients with advanced HER2-pos. breast cancer are under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65WWeQ3_JV7Vg90H21EOLACvtfcHk0liOo25CouQp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D&md5=98ba29a289f4ac0ea38c37a9b6bd0c5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.2071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.2071%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DJacobson%26aufirst%3DF.%26aulast%3DLutzker%26aufirst%3DS.%2BG.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DPhase%2520I%2520Study%2520of%2520Trastuzumab-DM1%252C%2520an%2520HER2%2520Antibody-Drug%2520Conjugate%252C%2520Given%2520Every%25203%2520Weeks%2520to%2520Patients%2520with%2520HER2-Positive%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2698%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris Iii, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span> </span><span class="NLM_article-title">Clinical Pharmacology of Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate in Development for the Treatment of HER2-Positive Cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1007%2Fs00280-011-1817-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22271209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1229-1240&author=S.+Girishauthor=M.+Guptaauthor=B.+Wangauthor=D.+Luauthor=I.+E.+Kropauthor=C.+L.+Vogelauthor=H.+A.+Burris+Iiiauthor=P.+M.+LoRussoauthor=J.-H.+Yiauthor=O.+Saadauthor=B.+Tongauthor=Y.-W.+Chuauthor=S.+Holdenauthor=A.+Joshi&title=Clinical+Pharmacology+of+Trastuzumab+Emtansine+%28T-DM1%29%3A+An+Antibody-Drug+Conjugate+in+Development+for+the+Treatment+of+HER2-Positive+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer</span></div><div class="casAuthors">Girish, Sandhya; Gupta, Manish; Wang, Bei; Lu, Dan; Krop, Ian E.; Vogel, Charles L.; Burris, Howard A., III; LoRusso, Patricia M.; Yi, Joo-Hee; Saad, Ola; Tong, Barbara; Chu, Yu-Waye; Holden, Scott; Joshi, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1240</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab and DM1, a microtubule polymn. inhibitor, covalently bound via a stable thioether linker.  To characterize the pharmacokinetics (PK) of T-DM1 in patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer, data from four studies (TDM3569g, TDM4258g, TDM4374g, and TDM4688g) of single-agent T-DM1 administered at 3.6 mg/kg every 3 wk (q3w) were assessed in aggregate.  Methods: Multiple analytes-T-DM1, total trastuzumab (TT), DM1, and key metabolites-were quantified using enzyme-linked immunosorbent assays or liq. chromatog. tandem mass spectrometry.  PK parameters of T-DM1, TT, and DM1 exposure were calcd. using std. noncompartmental approaches and correlated to efficacy (objective response rate) and safety (platelet counts, hepatic transaminase concns.).  Immunogenicity was evaluated by measuring anti-therapeutic antibodies (ATA) to T-DM1 after repeated dosing using validated bridging antibody electrochemiluminescence or enzyme-linked immunosorbent assays.  Results: PK parameters for T-DM1, TT, and DM1 were consistent across studies at cycle 1 and steady state.  T-DM1 PK was not affected by residual trastuzumab from prior therapy or circulating extracellular domain of HER2.  No significant correlations were obsd. between T-DM1 exposure and efficacy, thrombocytopenia, or increased concns. of transaminases.  Across the studies, ATA formation was detected in 4.5% (13/286) of evaluable patients receiving T-DM1 q3w.  Conclusions The PK profile of single-agent T-DM1 (3.6 mg/kg q3w) is predictable, well characterized, and unaffected by circulating levels of HER2 extracellular domain or residual trastuzumab.  T-DM1 exposure does not correlate with clin. responses or key adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA6MaBSuH37Vg90H21EOLACvtfcHk0li75gCSoBWllQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D&md5=f4b2a4ef4aaa79a96adbb1810a0c44d9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1817-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1817-3%26sid%3Dliteratum%253Aachs%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DBurris%2BIii%26aufirst%3DH.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DTong%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.-W.%26aulast%3DHolden%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%26atitle%3DClinical%2520Pharmacology%2520of%2520Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520An%2520Antibody-Drug%2520Conjugate%2520in%2520Development%2520for%2520the%2520Treatment%2520of%2520HER2-Positive%2520Cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1229%26epage%3D1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dere, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendricks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span> </span><span class="NLM_article-title">Characterization of the Drug-to-Antibody Ratio Distribution for Antibody-Drug Conjugates in Plasma/Serum</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.4155%2Fbio.13.66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=23641696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFOks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1057-1071&author=K.+Xuauthor=L.+Liuauthor=R.+Dereauthor=E.+Maiauthor=R.+Ericksonauthor=A.+Hendricksauthor=K.+Linauthor=J.+R.+Junutulaauthor=S.+Kaur&title=Characterization+of+the+Drug-to-Antibody+Ratio+Distribution+for+Antibody-Drug+Conjugates+in+Plasma%2FSerum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum</span></div><div class="casAuthors">Xu, Keyang; Liu, Luna; Dere, Randall; Mai, Elaine; Erickson, Rebecca; Hendricks, Angela; Lin, Kedan; Junutula, Jagath R.; Kaur, Surinder</div><div class="citationInfo"><span class="NLM_cas:title">Bioanalysis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1057-1071</span>CODEN:
                <span class="NLM_cas:coden">BIOAB4</span>;
        ISSN:<span class="NLM_cas:issn">1757-6180</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Antibody-drug conjugates (ADCs) are a new class of cancer therapeutics that deliver potent cytotoxins specifically to tumors to minimize systemic toxicity.  However, undesirable release of covalently linked drugs in circulation can affect safety and efficacy.  The objective of this manuscript was to propose and assess the assays that allow for the characterization of the drug deconjugation in plasma/serum.  Results: ADCs of three main drug conjugation platforms, linked via lysine, site-specific engineered cysteine or reduced interchain disulfide cysteine residues, were analyzed using affinity capture for sample enrichment coupled with LC-MS or hydrophobic interaction chromatog.-UV for detection.  These novel approaches enabled measurement of the relative abundance of individual ADC species with different drug-to-antibody ratios, while maintaining their structural integrity.  Conclusion: The characterization data generated by affinity capture LC-MS or hydrophobic interaction chromatog.-UV provided crit. mechanistic insights into understanding the stability and bioactivity of ADCs in vivo, and also helped the development of appropriate quant. ELISAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5VhU6IzYMjbVg90H21EOLACvtfcHk0li75gCSoBWllQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFOks7g%253D&md5=ad6754407f7da2b0c0addf4e6b16bc88</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4155%2Fbio.13.66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.13.66%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDere%26aufirst%3DR.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DHendricks%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKaur%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520the%2520Drug-to-Antibody%2520Ratio%2520Distribution%2520for%2520Antibody-Drug%2520Conjugates%2520in%2520Plasma%252FSerum%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D1057%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanagh, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blättler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Bl%C3%A4ttlerauthor=R.+V.+J.+Chari&title=Semisynthetic+Maytansine+Analogues+for+the+Targeted+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0li75gCSoBWllQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DSemisynthetic%2520Maytansine%2520Analogues%2520for%2520the%2520Targeted%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Cassady, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floss, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leistner, E.</span><span> </span><span class="NLM_article-title">Recent Developments in the Maytansinoid Antitumor Agents</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1248%2Fcpb.52.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=14709862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVCitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=1-26&author=J.+M.+Cassadyauthor=K.+K.+Chanauthor=H.+G.+Flossauthor=E.+Leistner&title=Recent+Developments+in+the+Maytansinoid+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the maytansinoid antitumor agents</span></div><div class="casAuthors">Cassady, John M.; Chan, Kenneth K.; Floss, Heinz G.; Leistner, Eckhard</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-26</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  Maytansine and its congeners have been isolated from higher plants, mosses and from an Actinomycete, Actinosynnema pretiosum.  Many of these compds. are antitumor agents of extraordinary potency, yet phase II clin. trials with maytansine proved disappointing.  The chem. and biol. of maytansinoids has been reviewed repeatedly in the late 1970s and early 1980s; the present review covers new developments in this field during the last two decades.  These include the use of maytansinoids as "warheads" in tumor-specific antibodies, preliminary metab. studies, investigations of their biosynthesis at the biochem. and genetic level, and ecol. issues related to the occurrence of such typical microbial metabolites in higher plants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbS-UKXv38LVg90H21EOLACvtfcHk0li2f1j_6f_AiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVCitLw%253D&md5=6073feaee668e24d08e5e93a5b588c4f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1248%2Fcpb.52.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.52.1%26sid%3Dliteratum%253Aachs%26aulast%3DCassady%26aufirst%3DJ.%2BM.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DFloss%26aufirst%3DH.%2BG.%26aulast%3DLeistner%26aufirst%3DE.%26atitle%3DRecent%2520Developments%2520in%2520the%2520Maytansinoid%2520Antitumor%2520Agents%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span> </span><span class="NLM_article-title">Characterization of Intact Antibody-Drug Conjugates from Plasma/Serum in Vivo by Affinity Capture Capillary Liquid Chromatography–Mass Spectrometry</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2011&pages=56-66&author=K.+Xuauthor=L.+Liuauthor=O.+M.+Saadauthor=J.+Baudysauthor=L.+Williamsauthor=D.+Leipoldauthor=B.+Shenauthor=H.+Raabauthor=J.+R.+Junutulaauthor=A.+Kimauthor=S.+Kaur&title=Characterization+of+Intact+Antibody-Drug+Conjugates+from+Plasma%2FSerum+in+Vivo+by+Affinity+Capture+Capillary+Liquid+Chromatography%E2%80%93Mass+Spectrometry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DKaur%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520Intact%2520Antibody-Drug%2520Conjugates%2520from%2520Plasma%252FSerum%2520in%2520Vivo%2520by%2520Affinity%2520Capture%2520Capillary%2520Liquid%2520Chromatography%25E2%2580%2593Mass%2520Spectrometry%26jtitle%3DAnal.%2520Biochem.%26date%3D2011%26volume%3D412%26spage%3D56%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Dijkgraaf, G. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Januario, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Sauvage, F. J.</span><span> </span><span class="NLM_article-title">Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F0008-5472.CAN-10-2876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=21123452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=435-444&author=G.+J.+P.+Dijkgraafauthor=B.+Alickeauthor=L.+Weinmannauthor=T.+Januarioauthor=K.+Westauthor=Z.+Modrusanauthor=D.+Burdickauthor=R.+Goldsmithauthor=K.+Robargeauthor=D.+Sutherlinauthor=S.+J.+Scalesauthor=S.+E.+Gouldauthor=R.+L.+Yauchauthor=F.+J.+de+Sauvage&title=Small+Molecule+Inhibition+of+GDC-0449+Refractory+Smoothened+Mutants+and+Downstream+Mechanisms+of+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance</span></div><div class="casAuthors">Dijkgraaf, Gerrit J. P.; Alicke, Bruno; Weinmann, Lasse; Januario, Thomas; West, Kristina; Modrusan, Zora; Burdick, Dan; Goldsmith, Richard; Robarge, Kirk; Sutherlin, Dan; Scales, Suzie J.; Gould, Stephen E.; Yauch, Robert L.; de Sauvage, Frederic J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-444</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inappropriate Hedgehog (Hh) signaling has been directly linked to medulloblastoma (MB), a common malignant brain tumor in children.  GDC-0449 is an Hh pathway inhibitor (HPI) currently under clin. investigation as an anticancer agent.  Treatment of a MB patient with GDC-0449 initially regressed tumors, but this individual ultimately relapsed with a D473H resistance mutation in Smoothened (SMO), the mol. target of GDC-0449.  To explore the role of the mutated aspartic acid residue in SMO function, we substituted D473 with every amino acid and found that all functional mutants were resistant to GDC-0449, with pos. charged residues conferring potential oncogenic properties.  Alanine scan mutagenesis of SMO further identified E518 as a novel prospective mutation site for GDC-0449 resistance.  To overcome this form of acquired resistance, we screened a panel of chem. diverse HPIs and identified several antagonists with potent in vitro activity against these GDC-0449-resistant SMO mutants.  The bis-amide compd. 5 was of particular interest, as it was able to inhibit tumor growth mediated by drug resistant SMO in a murine allograft model of MB.  However, focal amplifications of the Hh pathway transcription factor Gli2 and the Hh target gene cyclin D1 (Ccnd1) were obsd. in two addnl. resistant models, indicating that resistance may also occur downstream of SMO.  Importantly, these HPI resistant MB allografts retained their sensitivity to PI3K inhibition, presenting addnl. opportunities for the treatment of such tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJl8oB7usSbVg90H21EOLACvtfcHk0li2f1j_6f_AiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFKmtA%253D%253D&md5=d0b110e7c8c22ba9bde5635503565b72</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2876%26sid%3Dliteratum%253Aachs%26aulast%3DDijkgraaf%26aufirst%3DG.%2BJ.%2BP.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DWeinmann%26aufirst%3DL.%26aulast%3DJanuario%26aufirst%3DT.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DSutherlin%26aufirst%3DD.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3Dde%2BSauvage%26aufirst%3DF.%2BJ.%26atitle%3DSmall%2520Molecule%2520Inhibition%2520of%2520GDC-0449%2520Refractory%2520Smoothened%2520Mutants%2520and%2520Downstream%2520Mechanisms%2520of%2520Drug%2520Resistance%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D435%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Pinheiro, P.; Bates, D.; DebRoy, S.; Sarkar, D.; R Development Core Team 2013.</span><span> </span><span class="NLM_article-title">Nlme: Linear and Nonlinear Mixed Effects Models</span>.  <span class="citation_source-book">R Package</span>, version <span class="NLM_edition">3.1-108</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pinheiro%2C+P.%3B+Bates%2C+D.%3B+DebRoy%2C+S.%3B+Sarkar%2C+D.%3B+R+Development+Core+Team+2013.+Nlme%3A+Linear+and+Nonlinear+Mixed+Effects+Models.+R+Package%2C+version+3.1-108."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPinheiro%26aufirst%3DP.%26atitle%3DNlme%253A%2520Linear%2520and%2520Nonlinear%2520Mixed%2520Effects%2520Models%26btitle%3DR%2520Package" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">R Development Core Team 2012</span><span class="NLM_x">. </span>R Package, version <span class="NLM_edition">3.1-110</span>; <span class="NLM_publisher-name">R Foundation for Statistical Computing</span>: <span class="NLM_publisher-loc">Vienna, Austria</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R+Development+Core+Team+2012&title=R+Package"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DR%2520Package%26pub%3DR%2520Foundation%2520for%2520Statistical%2520Computing%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 65 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shin Hye Ahn, Brett A. Vaughn, Willy A. Solis, Mark L. Lupher, Jr., Trevor J. Hallam, <span class="NLM_string-name hlFld-ContribAuthor">Eszter Boros</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific 89Zr- and 111In-Radiolabeling and In Vivo Evaluation of Glycan-free Antibodies by Azide–Alkyne Cycloaddition with a Non-natural Amino Acid. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (4)
                                     , 1177-1187. <a href="https://doi.org/10.1021/acs.bioconjchem.0c00100" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.0c00100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.0c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.0c00100%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSite-Specific%252B89Zr-%252Band%252B111In-Radiolabeling%252Band%252BIn%252BVivo%252BEvaluation%252Bof%252BGlycan-free%252BAntibodies%252Bby%252BAzide%2525E2%252580%252593Alkyne%252BCycloaddition%252Bwith%252Ba%252BNon-natural%252BAmino%252BAcid%26aulast%3DAhn%26aufirst%3DShin%2BHye%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20022020%26date%3D16032020%26date%3D05032020%26volume%3D31%26issue%3D4%26spage%3D1177%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chen Bai, Emily E. Reid, Alan Wilhelm, Manami Shizuka, Erin K. Maloney, Rassol Laleau, Lauren Harvey, Katie E. Archer, Dilrukshi Vitharana, Sharlene Adams, Yelena Kovtun, Michael L. Miller, Ravi Chari, Thomas A. Keating, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas C. Yoder</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (1)
                                     , 93-103. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00777" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00777%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSite-Specific%252BConjugation%252Bof%252Bthe%252BIndolinobenzodiazepine%252BDGN549%252Bto%252BAntibodies%252BAffords%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Bwith%252Ban%252BImproved%252BTherapeutic%252BIndex%252Bas%252BCompared%252Bwith%252BLysine%252BConjugation%26aulast%3DBai%26aufirst%3DChen%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15112019%26date%3D10122019%26date%3D20112019%26volume%3D31%26issue%3D1%26spage%3D93%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicholas C. Yoder, Chen Bai, Daniel Tavares, Wayne C. Widdison, Kathleen R. Whiteman, Alan Wilhelm, Sharon D. Wilhelm, Molly A. McShea, Erin K. Maloney, Olga Ab, Lintao Wang, Shan Jin, Hans K. Erickson, Thomas A. Keating, <span class="NLM_string-name hlFld-ContribAuthor">John M. Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (9)
                                     , 3926-3937. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00529" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00529%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DA%252BCase%252BStudy%252BComparing%252BHeterogeneous%252BLysine-%252Band%252BSite-Specific%252BCysteine-Conjugated%252BMaytansinoid%252BAntibody-Drug%252BConjugates%252B%252528ADCs%252529%252BIllustrates%252Bthe%252BBenefits%252Bof%252BLysine%252BConjugation%26aulast%3DYoder%26aufirst%3DNicholas%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15052019%26date%3D09072019%26date%3D03072019%26date%3D31072019%26date%3D09072019%26volume%3D16%26issue%3D9%26spage%3D3926%26epage%3D3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Byoung-Chul Lee, Cecile Chalouni, Sophia Doll, Sam C. Nalle, Martine Darwish, Siao Ping Tsai, Katherine R. Kozak, Geoffrey Del-Rosario, Shang-Fan Yu, Hans Erickson, <span class="NLM_string-name hlFld-ContribAuthor">Richard Vandlen</span>. </span><span class="cited-content_cbyCitation_article-title">FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2018,</strong> <em>29 </em>
                                    (7)
                                     , 2468-2477. <a href="https://doi.org/10.1021/acs.bioconjchem.8b00362" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.8b00362</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.8b00362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.8b00362%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DFRET%252BReagent%252BReveals%252Bthe%252BIntracellular%252BProcessing%252Bof%252BPeptide-Linked%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DLee%26aufirst%3DByoung-Chul%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D23052018%26date%3D13062018%26date%3D01062018%26volume%3D29%26issue%3D7%26spage%3D2468%26epage%3D2477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Hoa  Le</span>, <span class="hlFld-ContribAuthor ">Josefa dela  Cruz-Chuh</span>, <span class="hlFld-ContribAuthor ">Sudheer  Bobba</span>, <span class="hlFld-ContribAuthor ">Jun  Guo</span>, <span class="hlFld-ContribAuthor ">Leanna  Staben</span>, <span class="hlFld-ContribAuthor ">Chenghong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Ma</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Gail D.  Lewis Phillips</span>, <span class="hlFld-ContribAuthor ">Breanna S.  Vollmar</span>, <span class="hlFld-ContribAuthor ">Jack D.  Sadowsky</span>, <span class="hlFld-ContribAuthor ">Richard  Vandlen</span>, <span class="hlFld-ContribAuthor ">BinQing  Wei</span>, <span class="hlFld-ContribAuthor ">Dian  Su</span>, <span class="hlFld-ContribAuthor ">Peter  Fan</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Cornelis E. C. A.  Hop</span>, and <span class="hlFld-ContribAuthor ">Thomas H.  Pillow</span>  . </span><span class="cited-content_cbyCitation_article-title">Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody–Drug Conjugates with Phenol-Containing Payloads. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2018,</strong> <em>29 </em>
                                    (2)
                                     , 267-274. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00576" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00576%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DImmolation%252Bof%252Bp-Aminobenzyl%252BEther%252BLinker%252Band%252BPayload%252BPotency%252Band%252BStability%252BDetermine%252Bthe%252BCell-Killing%252BActivity%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Bwith%252BPhenol-Containing%252BPayloads%26aulast%3DZhang%26aufirst%3DDonglu%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2018%26date%3D26092017%26date%3D04012018%26date%3D07022018%26date%3D21022018%26date%3D25012018%26volume%3D29%26issue%3D2%26spage%3D267%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Breanna S.  Vollmar</span>, <span class="hlFld-ContribAuthor ">Binqing  Wei</span>, <span class="hlFld-ContribAuthor ">Rachana  Ohri</span>, <span class="hlFld-ContribAuthor ">Jianhui  Zhou</span>, <span class="hlFld-ContribAuthor ">Jintang  He</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Douglas  Leipold</span>, <span class="hlFld-ContribAuthor ">Ely  Cosino</span>, <span class="hlFld-ContribAuthor ">Sharon  Yee</span>, <span class="hlFld-ContribAuthor ">Aimee  Fourie-O’Donohue</span>, <span class="hlFld-ContribAuthor ">Guangmin  Li</span>, <span class="hlFld-ContribAuthor ">Gail L.  Phillips</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Amrita  Kamath</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>, <span class="hlFld-ContribAuthor ">Genee  Lee</span>, <span class="hlFld-ContribAuthor ">Greg A.  Lazar</span>, and <span class="hlFld-ContribAuthor ">Hans K.  Erickson</span>  . </span><span class="cited-content_cbyCitation_article-title">Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (10)
                                     , 2538-2548. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00365" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00365%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DAttachment%252BSite%252BCysteine%252BThiol%252BpKa%252BIs%252Ba%252BKey%252BDriver%252Bfor%252BSite-Dependent%252BStability%252Bof%252BTHIOMAB%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DVollmar%26aufirst%3DBreanna%2BS.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D26062017%26date%3D25082017%26date%3D22092017%26date%3D18102017%26date%3D08092017%26volume%3D28%26issue%3D10%26spage%3D2538%26epage%3D2548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romas A.  Kudirka</span>, <span class="hlFld-ContribAuthor ">Robyn M.  Barfield</span>, <span class="hlFld-ContribAuthor ">Jesse M.  McFarland</span>, <span class="hlFld-ContribAuthor ">Penelope M.  Drake</span>, <span class="hlFld-ContribAuthor ">Adam  Carlson</span>, <span class="hlFld-ContribAuthor ">Stefanie  Bañas</span>, <span class="hlFld-ContribAuthor ">Wes  Zmolek</span>, <span class="hlFld-ContribAuthor ">Albert W.  Garofalo</span>, and <span class="hlFld-ContribAuthor ">David  Rabuka</span>  . </span><span class="cited-content_cbyCitation_article-title">Site-Specific Tandem Knoevenagel Condensation–Michael Addition To Generate Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (11)
                                     , 994-998. <a href="https://doi.org/10.1021/acsmedchemlett.6b00253" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00253%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSite-Specific%252BTandem%252BKnoevenagel%252BCondensation%2525E2%252580%252593Michael%252BAddition%252BTo%252BGenerate%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DKudirka%26aufirst%3DRomas%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D28062016%26date%3D30082016%26date%3D01092016%26date%3D10112016%26date%3D30082016%26volume%3D7%26issue%3D11%26spage%3D994%26epage%3D998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cindy J.  Choy</span>, <span class="hlFld-ContribAuthor ">Corinne R.  Ley</span>, <span class="hlFld-ContribAuthor ">Austen L.  Davis</span>, <span class="hlFld-ContribAuthor ">Brian S.  Backer</span>, <span class="hlFld-ContribAuthor ">Jonathan J.  Geruntho</span>, <span class="hlFld-ContribAuthor ">Brian H.  Clowers</span>, and <span class="hlFld-ContribAuthor ">Clifford E.  Berkman</span>  . </span><span class="cited-content_cbyCitation_article-title">Second-Generation Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (9)
                                     , 2206-2213. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00422" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00422%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSecond-Generation%252BTunable%252BpH-Sensitive%252BPhosphoramidate-Based%252BLinkers%252Bfor%252BControlled%252BRelease%26aulast%3DChoy%26aufirst%3DCindy%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D27072016%26date%3D02092016%26date%3D21092016%26date%3D26082016%26volume%3D27%26issue%3D9%26spage%3D2206%26epage%3D2213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brendon E.  Cook</span>, <span class="hlFld-ContribAuthor ">Pierre  Adumeau</span>, <span class="hlFld-ContribAuthor ">Rosemery  Membreno</span>, <span class="hlFld-ContribAuthor ">Kathryn E.  Carnazza</span>, <span class="hlFld-ContribAuthor ">Christian  Brand</span>, <span class="hlFld-ContribAuthor ">Thomas  Reiner</span>, <span class="hlFld-ContribAuthor ">Brian J.  Agnew</span>, <span class="hlFld-ContribAuthor ">Jason S.  Lewis</span>, and <span class="hlFld-ContribAuthor ">Brian M.  Zeglis</span>  . </span><span class="cited-content_cbyCitation_article-title">Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (8)
                                     , 1789-1795. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00235" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00235%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DPretargeted%252BPET%252BImaging%252BUsing%252Ba%252BSite-Specifically%252BLabeled%252BImmunoconjugate%26aulast%3DCook%26aufirst%3DBrendon%2BE.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D10052016%26date%3D24062016%26date%3D14072016%26date%3D17082016%26date%3D29062016%26volume%3D27%26issue%3D8%26spage%3D1789%26epage%3D1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiren  Xu</span>, <span class="hlFld-ContribAuthor ">Guifeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Cuong  Tran</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Li</span>, <span class="hlFld-ContribAuthor ">Tyler H.  Heibeck</span>, <span class="hlFld-ContribAuthor ">Mary Rose  Masikat</span>, <span class="hlFld-ContribAuthor ">Qi  Cai</span>, <span class="hlFld-ContribAuthor ">Alexander R.  Steiner</span>, <span class="hlFld-ContribAuthor ">Aaron K.  Sato</span>, <span class="hlFld-ContribAuthor ">Trevor J.  Hallam</span>, and <span class="hlFld-ContribAuthor ">Gang  Yin</span>  . </span><span class="cited-content_cbyCitation_article-title">RP-HPLC DAR Characterization of Site-Specific Antibody Drug Conjugates Produced in a Cell-Free Expression System. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (6)
                                     , 1034-1043. <a href="https://doi.org/10.1021/acs.oprd.6b00072" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00072%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DRP-HPLC%252BDAR%252BCharacterization%252Bof%252BSite-Specific%252BAntibody%252BDrug%252BConjugates%252BProduced%252Bin%252Ba%252BCell-Free%252BExpression%252BSystem%26aulast%3DXu%26aufirst%3DYiren%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D04032016%26date%3D08062016%26date%3D17062016%26date%3D31052016%26volume%3D20%26issue%3D6%26spage%3D1034%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David Y.  Jackson</span>  . </span><span class="cited-content_cbyCitation_article-title">Processes for Constructing Homogeneous Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (5)
                                     , 852-866. <a href="https://doi.org/10.1021/acs.oprd.6b00067" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DProcesses%252Bfor%252BConstructing%252BHomogeneous%252BAntibody%252BDrug%252BConjugates%26aulast%3DJackson%26aufirst%3DDavid%2BY.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D04032016%26date%3D04052016%26date%3D20052016%26date%3D14042016%26volume%3D20%26issue%3D5%26spage%3D852%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cindy J.  Choy</span>, <span class="hlFld-ContribAuthor ">Jonathan J.  Geruntho</span>, <span class="hlFld-ContribAuthor ">Austen L.  Davis</span>, and <span class="hlFld-ContribAuthor ">Clifford E.  Berkman</span>  . </span><span class="cited-content_cbyCitation_article-title">Tunable pH-Sensitive Linker for Controlled Release. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (3)
                                     , 824-830. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00027" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTunable%252BpH-Sensitive%252BLinker%252Bfor%252BControlled%252BRelease%26aulast%3DChoy%26aufirst%3DCindy%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D14012016%26date%3D11022016%26date%3D02032016%26date%3D16032016%26date%3D17022016%26volume%3D27%26issue%3D3%26spage%3D824%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannes  Merten</span>, <span class="hlFld-ContribAuthor ">Fabian  Brandl</span>, <span class="hlFld-ContribAuthor ">Andreas  Plückthun</span>, and <span class="hlFld-ContribAuthor ">Uwe  Zangemeister-Wittke</span>  . </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2015,</strong> <em>26 </em>
                                    (11)
                                     , 2176-2185. <a href="https://doi.org/10.1021/acs.bioconjchem.5b00260" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.5b00260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.5b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.5b00260%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%252Bfor%252BTumor%252BTargeting%2525E2%252580%252594Novel%252BConjugation%252BChemistries%252Band%252Bthe%252BPromise%252Bof%252Bnon-IgG%252BBinding%252BProteins%26aulast%3DMerten%26aufirst%3DHannes%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D06052015%26date%3D14062015%26date%3D08072015%26date%3D18112015%26date%3D18062015%26volume%3D26%26issue%3D11%26spage%3D2176%26epage%3D2185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher R.  Behrens</span>, <span class="hlFld-ContribAuthor ">Edward H.  Ha</span>, <span class="hlFld-ContribAuthor ">Lawrence L.  Chinn</span>, <span class="hlFld-ContribAuthor ">Simeon  Bowers</span>, <span class="hlFld-ContribAuthor ">Gary  Probst</span>, <span class="hlFld-ContribAuthor ">Maureen  Fitch-Bruhns</span>, <span class="hlFld-ContribAuthor ">Jorge  Monteon</span>, <span class="hlFld-ContribAuthor ">Amanda  Valdiosera</span>, <span class="hlFld-ContribAuthor ">Abel  Bermudez</span>, <span class="hlFld-ContribAuthor ">Sindy  Liao-Chan</span>, <span class="hlFld-ContribAuthor ">Tiffany  Wong</span>, <span class="hlFld-ContribAuthor ">Jonathan  Melnick</span>, <span class="hlFld-ContribAuthor ">Jan-Willem  Theunissen</span>, <span class="hlFld-ContribAuthor ">Mark R.  Flory</span>, <span class="hlFld-ContribAuthor ">Derrick  Houser</span>, <span class="hlFld-ContribAuthor ">Kristy  Venstrom</span>, <span class="hlFld-ContribAuthor ">Zoia  Levashova</span>, <span class="hlFld-ContribAuthor ">Paul  Sauer</span>, <span class="hlFld-ContribAuthor ">Thi-Sau  Migone</span>, <span class="hlFld-ContribAuthor ">Edward H.  van der Horst</span>, <span class="hlFld-ContribAuthor ">Randall L.  Halcomb</span>, and <span class="hlFld-ContribAuthor ">David Y.  Jackson</span>  . </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (11)
                                     , 3986-3998. <a href="https://doi.org/10.1021/acs.molpharmaceut.5b00432" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.5b00432</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.5b00432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.5b00432%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADCs%252529%252BDerived%252Bfrom%252BInterchain%252BCysteine%252BCross-Linking%252BDemonstrate%252BImproved%252BHomogeneity%252Band%252BOther%252BPharmacological%252BProperties%252Bover%252BConventional%252BHeterogeneous%252BADCs%26aulast%3DBehrens%26aufirst%3DChristopher%2BR.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D01062015%26date%3D22092015%26date%3D18092015%26date%3D02102015%26date%3D02112015%26date%3D22092015%26volume%3D12%26issue%3D11%26spage%3D3986%26epage%3D3998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian M.  Zeglis</span>, <span class="hlFld-ContribAuthor ">Charles B.  Davis</span>, <span class="hlFld-ContribAuthor ">Dalya  Abdel-Atti</span>, <span class="hlFld-ContribAuthor ">Sean D.  Carlin</span>, <span class="hlFld-ContribAuthor ">Aimei  Chen</span>, <span class="hlFld-ContribAuthor ">Robert  Aggeler</span>, <span class="hlFld-ContribAuthor ">Brian J.  Agnew</span>, and <span class="hlFld-ContribAuthor ">Jason S.  Lewis</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2014,</strong> <em>25 </em>
                                    (12)
                                     , 2123-2128. <a href="https://doi.org/10.1021/bc500499h" title="DOI URL">https://doi.org/10.1021/bc500499h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bc500499h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbc500499h%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DChemoenzymatic%252BStrategy%252Bfor%252Bthe%252BSynthesis%252Bof%252BSite-Specifically%252BLabeled%252BImmunoconjugates%252Bfor%252BMultimodal%252BPET%252Band%252BOptical%252BImaging%26aulast%3DZeglis%26aufirst%3DBrian%2BM.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D31102014%26date%3D21112014%26date%3D26112014%26date%3D17122014%26date%3D24112014%26volume%3D25%26issue%3D12%26spage%3D2123%26epage%3D2128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlos  Garcia-Echeverria</span>  . </span><span class="cited-content_cbyCitation_article-title">Developing Second Generation Antibody–Drug Conjugates: The Quest for New Technologies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (19)
                                     , 7888-7889. <a href="https://doi.org/10.1021/jm501298k" title="DOI URL">https://doi.org/10.1021/jm501298k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501298k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501298k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDeveloping%252BSecond%252BGeneration%252BAntibody%2525E2%252580%252593Drug%252BConjugates%25253A%252BThe%252BQuest%252Bfor%252BNew%252BTechnologies%26aulast%3DGarcia-Echeverria%26aufirst%3DCarlos%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D25082014%26date%3D15092014%26date%3D09102014%26volume%3D57%26issue%3D19%26spage%3D7888%26epage%3D7889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Breanna S.  Vollmar</span>, <span class="hlFld-ContribAuthor ">Chris  Frantz</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Schutten</span>, <span class="hlFld-ContribAuthor ">Fiona  Zhong</span>, <span class="hlFld-ContribAuthor ">Geoffrey  del Rosario</span>, <span class="hlFld-ContribAuthor ">Mary Ann T.  Go</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Douglas D.  Leipold</span>, <span class="hlFld-ContribAuthor ">Amrita V.  Kamath</span>, <span class="hlFld-ContribAuthor ">Carl  Ng</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>, <span class="hlFld-ContribAuthor ">Josefa  dela Cruz-Chuh</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Jinhua  Chen</span>, <span class="hlFld-ContribAuthor ">Zijin  Xu</span>, <span class="hlFld-ContribAuthor ">John  Wai</span>, <span class="hlFld-ContribAuthor ">Pragya  Adhikari</span>, <span class="hlFld-ContribAuthor ">Hans K.  Erickson</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Andrew G.  Polson</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Pillow</span>. </span><span class="cited-content_cbyCitation_article-title">Calicheamicin Antibody–Drug Conjugates with Improved Properties. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (6)
                                     , 1112-1120. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0035" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0035%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DCalicheamicin%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Bwith%252BImproved%252BProperties%26aulast%3DVollmar%26aufirst%3DBreanna%2BS.%26date%3D2021%26date%3D2021%26volume%3D20%26issue%3D6%26spage%3D1112%26epage%3D1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Su</span>, <span class="hlFld-ContribAuthor ">Dian  Xiao</span>, <span class="hlFld-ContribAuthor ">Fei  Xie</span>, <span class="hlFld-ContribAuthor ">Lianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Yanming  Wang</span>, <span class="hlFld-ContribAuthor ">Shiyong  Fan</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>, <span class="hlFld-ContribAuthor ">Song  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugates: Recent advances in linker chemistry. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1016/j.apsb.2021.03.042" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.03.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.03.042%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugates%25253A%252BRecent%252Badvances%252Bin%252Blinker%252Bchemistry%26aulast%3DSu%26aufirst%3DZheng%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanhong  Zhang</span>, <span class="hlFld-ContribAuthor ">Nina  Yin</span>, <span class="hlFld-ContribAuthor ">Anbang  Sun</span>, <span class="hlFld-ContribAuthor ">Qifang  Wu</span>, <span class="hlFld-ContribAuthor ">Wenzhu  Hu</span>, <span class="hlFld-ContribAuthor ">Xin  Hou</span>, <span class="hlFld-ContribAuthor ">Xixi  Zeng</span>, <span class="hlFld-ContribAuthor ">Min  Zhu</span>, <span class="hlFld-ContribAuthor ">Yanhong  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Transient Receptor Potential Channel 6 Knockout Ameliorates Kidney Fibrosis by Inhibition of Epithelial–Mesenchymal Transition. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcell.2020.602703" title="DOI URL">https://doi.org/10.3389/fcell.2020.602703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2020.602703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2020.602703%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DTransient%252BReceptor%252BPotential%252BChannel%252B6%252BKnockout%252BAmeliorates%252BKidney%252BFibrosis%252Bby%252BInhibition%252Bof%252BEpithelial%2525E2%252580%252593Mesenchymal%252BTransition%26aulast%3DZhang%26aufirst%3DYanhong%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yutian  Feng</span>, <span class="hlFld-ContribAuthor ">Zhengyuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Darryl  McDougald</span>, <span class="hlFld-ContribAuthor ">Rebecca L.  Meshaw</span>, <span class="hlFld-ContribAuthor ">Ganesan  Vaidyanathan</span>, <span class="hlFld-ContribAuthor ">Michael R.  Zalutsky</span>. </span><span class="cited-content_cbyCitation_article-title">Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2021,</strong> <em>92 </em>, 171-183. <a href="https://doi.org/10.1016/j.nucmedbio.2020.05.002" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2020.05.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2020.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2020.05.002%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DSite-specific%252Bradioiodination%252Bof%252Ban%252Banti-HER2%252Bsingle%252Bdomain%252Bantibody%252Bfragment%252Bwith%252Ba%252Bresidualizing%252Bprosthetic%252Bagent%26aulast%3DFeng%26aufirst%3DYutian%26date%3D2021%26volume%3D92%26spage%3D171%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, <span class="hlFld-ContribAuthor ">Matthew  Sung</span>, <span class="hlFld-ContribAuthor ">Dangshe  Ma</span>, <span class="hlFld-ContribAuthor ">Bitha  Narayanan</span>, <span class="hlFld-ContribAuthor ">Kimberly  Marquette</span>, <span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Jack  Bikker</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Casavant</span>, <span class="hlFld-ContribAuthor ">Eric M.  Bennett</span>, <span class="hlFld-ContribAuthor ">Manoj B.  Charati</span>, <span class="hlFld-ContribAuthor ">Jonathon  Golas</span>, <span class="hlFld-ContribAuthor ">Christine  Hosselet</span>, <span class="hlFld-ContribAuthor ">Cynthia M.  Rohde</span>, <span class="hlFld-ContribAuthor ">George  Hu</span>, <span class="hlFld-ContribAuthor ">Magali  Guffroy</span>, <span class="hlFld-ContribAuthor ">Hadi  Falahatpisheh</span>, <span class="hlFld-ContribAuthor ">Martin  Finkelstein</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Lioudmila  Tchistiakova</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Edward  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O'Donnell</span>, <span class="hlFld-ContribAuthor ">Hans-Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>. </span><span class="cited-content_cbyCitation_article-title">PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 2068-2078. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0237" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0237%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DPF-06804103%25252C%252BA%252BSite-specific%252BAnti-HER2%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252Bfor%252Bthe%252BTreatment%252Bof%252BHER2-expressing%252BBreast%25252C%252BGastric%25252C%252Band%252BLung%252BCancers%26aulast%3DGraziani%26aufirst%3DEdmund%2BI.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D2068%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Kumar</span>, <span class="hlFld-ContribAuthor ">Shenlan  Mao</span>, <span class="hlFld-ContribAuthor ">Nazzareno  Dimasi</span>, <span class="hlFld-ContribAuthor ">Changshou  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Validation of Linkers for Site-Specific Preparation of Antibody–Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (18)
                                     , 6882. <a href="https://doi.org/10.3390/ijms21186882" title="DOI URL">https://doi.org/10.3390/ijms21186882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21186882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21186882%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDesign%252Band%252BValidation%252Bof%252BLinkers%252Bfor%252BSite-Specific%252BPreparation%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BCarrying%252BMultiple%252BDrug%252BCopies%252BPer%252BCysteine%252BConjugation%252BSite%26aulast%3DKumar%26aufirst%3DAmit%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D18%26spage%3D6882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Yao  Sheng</span>, <span class="hlFld-ContribAuthor ">Ding  Wei</span>, <span class="hlFld-ContribAuthor ">Jianghui  Yu</span>, <span class="hlFld-ContribAuthor ">Hongli  Chen</span>, <span class="hlFld-ContribAuthor ">Biao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112080. <a href="https://doi.org/10.1016/j.ejmech.2020.112080" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112080%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBis%252528vinylsulfonyl%252529piperazines%252Bas%252Befficient%252Blinkers%252Bfor%252Bhighly%252Bhomogeneous%252Bantibody-drug%252Bconjugates%26aulast%3DHuang%26aufirst%3DRong%26date%3D2020%26volume%3D190%26spage%3D112080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">An Overview of the Current ADC Discovery Landscape. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-22. <a href="https://doi.org/10.1007/978-1-4939-9929-3_1" title="DOI URL">https://doi.org/10.1007/978-1-4939-9929-3_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-9929-3_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-9929-3_1%26sid%3Dliteratum%253Aachs%26atitle%3DAn%252BOverview%252Bof%252Bthe%252BCurrent%252BADC%252BDiscovery%252BLandscape%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2020%26date%3D2019%26spage%3D1%26epage%3D22%26pub%3DSpringer%2520US%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2020%26volume%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sajad  Yaghoubi</span>, <span class="hlFld-ContribAuthor ">Mohammad Hossein  Karimi</span>, <span class="hlFld-ContribAuthor ">Majid  Lotfinia</span>, <span class="hlFld-ContribAuthor ">Tohid  Gharibi</span>, <span class="hlFld-ContribAuthor ">Motahare  Mahi‐Birjand</span>, <span class="hlFld-ContribAuthor ">Esmaeil  Kavi</span>, <span class="hlFld-ContribAuthor ">Fahimeh  Hosseini</span>, <span class="hlFld-ContribAuthor ">Koushan  Sineh Sepehr</span>, <span class="hlFld-ContribAuthor ">Mehrdad  Khatami</span>, <span class="hlFld-ContribAuthor ">Nader  Bagheri</span>, <span class="hlFld-ContribAuthor ">Meghdad  Abdollahpour‐Alitappeh</span>. </span><span class="cited-content_cbyCitation_article-title">Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2020,</strong> <em>235 </em>
                                    (1)
                                     , 31-64. <a href="https://doi.org/10.1002/jcp.28967" title="DOI URL">https://doi.org/10.1002/jcp.28967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.28967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.28967%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DPotential%252Bdrugs%252Bused%252Bin%252Bthe%252Bantibody%2525E2%252580%252593drug%252Bconjugate%252B%252528ADC%252529%252Barchitecture%252Bfor%252Bcancer%252Btherapy%26aulast%3DYaghoubi%26aufirst%3DSajad%26date%3D2020%26date%3D2019%26volume%3D235%26issue%3D1%26spage%3D31%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Yong  Ma</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Pillow</span>, <span class="hlFld-ContribAuthor ">Jack D.  Sadowsky</span>, <span class="hlFld-ContribAuthor ">Dian  Su</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Andrew  Polson</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Cornelis E.C.A.  Hop</span>. </span><span class="cited-content_cbyCitation_article-title">Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2019,</strong> <em>47 </em>
                                    (10)
                                     , 1146-1155. <a href="https://doi.org/10.1124/dmd.119.087023" title="DOI URL">https://doi.org/10.1124/dmd.119.087023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.087023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.087023%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DExposure-Efficacy%252BAnalysis%252Bof%252BAntibody-Drug%252BConjugates%252BDelivering%252Ban%252BExcessive%252BLevel%252Bof%252BPayload%252Bto%252BTissues%26aulast%3DZhang%26aufirst%3DDonglu%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D10%26spage%3D1146%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jason B.  White</span>, <span class="hlFld-ContribAuthor ">Ryan  Fleming</span>, <span class="hlFld-ContribAuthor ">Luke  Masterson</span>, <span class="hlFld-ContribAuthor ">Ben T.  Ruddle</span>, <span class="hlFld-ContribAuthor ">Haihong  Zhong</span>, <span class="hlFld-ContribAuthor ">Christine  Fazenbaker</span>, <span class="hlFld-ContribAuthor ">Patrick  Strout</span>, <span class="hlFld-ContribAuthor ">Kim  Rosenthal</span>, <span class="hlFld-ContribAuthor ">Molly  Reed</span>, <span class="hlFld-ContribAuthor ">Vanessa  Muniz-Medina</span>, <span class="hlFld-ContribAuthor ">Philip  Howard</span>, <span class="hlFld-ContribAuthor ">Rakesh  Dixit</span>, <span class="hlFld-ContribAuthor ">Herren  Wu</span>, <span class="hlFld-ContribAuthor ">Mary Jane  Hinrichs</span>, <span class="hlFld-ContribAuthor ">Changshou  Gao</span>, <span class="hlFld-ContribAuthor ">Nazzareno  Dimasi</span>. </span><span class="cited-content_cbyCitation_article-title">Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2019,</strong> <em>11 </em>
                                    (3)
                                     , 500-515. <a href="https://doi.org/10.1080/19420862.2019.1578611" title="DOI URL">https://doi.org/10.1080/19420862.2019.1578611</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/19420862.2019.1578611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F19420862.2019.1578611%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DDesign%252Band%252Bcharacterization%252Bof%252Bhomogenous%252Bantibody-drug%252Bconjugates%252Bwith%252Ba%252Bdrug-to-antibody%252Bratio%252Bof%252Bone%252Bprepared%252Busing%252Ban%252Bengineered%252Bantibody%252Band%252Ba%252Bdual-maleimide%252Bpyrrolobenzodiazepine%252Bdimer%26aulast%3DWhite%26aufirst%3DJason%2BB.%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D3%26spage%3D500%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannes  Merten</span>, <span class="hlFld-ContribAuthor ">Jonas V.  Schaefer</span>, <span class="hlFld-ContribAuthor ">Fabian  Brandl</span>, <span class="hlFld-ContribAuthor ">Uwe  Zangemeister-Wittke</span>, <span class="hlFld-ContribAuthor ">Andreas  Plückthun</span>. </span><span class="cited-content_cbyCitation_article-title">Facile Site-Specific Multiconjugation Strategies in Recombinant Proteins Produced in Bacteria. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 253-273. <a href="https://doi.org/10.1007/978-1-4939-9654-4_17" title="DOI URL">https://doi.org/10.1007/978-1-4939-9654-4_17</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-9654-4_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-9654-4_17%26sid%3Dliteratum%253Aachs%26atitle%3DFacile%252BSite-Specific%252BMulticonjugation%252BStrategies%252Bin%252BRecombinant%252BProteins%252BProduced%252Bin%252BBacteria%26aulast%3DMerten%26aufirst%3DHannes%26date%3D2019%26date%3D2019%26spage%3D253%26epage%3D273%26pub%3DSpringer%2520New%2520York%26atitle%3DBioconjugation%26aulast%3DMassa%26aufirst%3DSam%26date%3D2019%26volume%3D2033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel T.  Cohen</span>, <span class="hlFld-ContribAuthor ">Chi  Zhang</span>, <span class="hlFld-ContribAuthor ">Colin M.  Fadzen</span>, <span class="hlFld-ContribAuthor ">Alexander J.  Mijalis</span>, <span class="hlFld-ContribAuthor ">Liana  Hie</span>, <span class="hlFld-ContribAuthor ">Kenneth D.  Johnson</span>, <span class="hlFld-ContribAuthor ">Zachary  Shriver</span>, <span class="hlFld-ContribAuthor ">Obadiah  Plante</span>, <span class="hlFld-ContribAuthor ">Scott J.  Miller</span>, <span class="hlFld-ContribAuthor ">Stephen L.  Buchwald</span>, <span class="hlFld-ContribAuthor ">Bradley L.  Pentelute</span>. </span><span class="cited-content_cbyCitation_article-title">A chemoselective strategy for late-stage functionalization of complex small molecules with polypeptides and proteins. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (1)
                                     , 78-85. <a href="https://doi.org/10.1038/s41557-018-0154-0" title="DOI URL">https://doi.org/10.1038/s41557-018-0154-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41557-018-0154-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41557-018-0154-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemistry%26atitle%3DA%252Bchemoselective%252Bstrategy%252Bfor%252Blate-stage%252Bfunctionalization%252Bof%252Bcomplex%252Bsmall%252Bmolecules%252Bwith%252Bpolypeptides%252Band%252Bproteins%26aulast%3DCohen%26aufirst%3DDaniel%2BT.%26date%3D2019%26date%3D2018%26volume%3D11%26issue%3D1%26spage%3D78%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Richards</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2018,</strong> <em>30 </em>, 35-46. <a href="https://doi.org/10.1016/j.ddtec.2018.10.005" title="DOI URL">https://doi.org/10.1016/j.ddtec.2018.10.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2018.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2018.10.005%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DExploring%252Balternative%252Bantibody%252Bscaffolds%25253A%252BAntibody%252Bfragments%252Band%252Bantibody%252Bmimics%252Bfor%252Btargeted%252Bdrug%252Bdelivery%26aulast%3DRichards%26aufirst%3DDaniel%2BA.%26date%3D2018%26volume%3D30%26spage%3D35%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sebastian  Andris</span>, <span class="hlFld-ContribAuthor ">Michaela  Wendeler</span>, <span class="hlFld-ContribAuthor ">Xiangyang  Wang</span>, <span class="hlFld-ContribAuthor ">Jürgen  Hubbuch</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-step high-throughput conjugation platform for the development of antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biotechnology</span><span> <strong>2018,</strong> <em>278 </em>, 48-55. <a href="https://doi.org/10.1016/j.jbiotec.2018.05.004" title="DOI URL">https://doi.org/10.1016/j.jbiotec.2018.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jbiotec.2018.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jbiotec.2018.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biotechnology%26atitle%3DMulti-step%252Bhigh-throughput%252Bconjugation%252Bplatform%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bantibody-drug%252Bconjugates%26aulast%3DAndris%26aufirst%3DSebastian%26date%3D2018%26volume%3D278%26spage%3D48%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jintang  He</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Sharon  Yee</span>, <span class="hlFld-ContribAuthor ">Surinder  Kaur</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of
              in vivo
              biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2018,</strong> <em>51 </em>, 1-8. <a href="https://doi.org/10.1080/19420862.2018.1494487" title="DOI URL">https://doi.org/10.1080/19420862.2018.1494487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/19420862.2018.1494487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F19420862.2018.1494487%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DCharacterization%252Bof%252Bin%252Bvivo%252Bbiotransformations%252Bfor%252Btrastuzumab%252Bemtansine%252Bby%252Bhigh-resolution%252Baccurate-mass%252Bmass%252Bspectrometry%26aulast%3DHe%26aufirst%3DJintang%26date%3D2018%26date%3D2018%26volume%3D51%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Nittoli</span>, <span class="hlFld-ContribAuthor ">Marcus P.  Kelly</span>, <span class="hlFld-ContribAuthor ">Frank  Delfino</span>, <span class="hlFld-ContribAuthor ">John  Rudge</span>, <span class="hlFld-ContribAuthor ">Arthur  Kunz</span>, <span class="hlFld-ContribAuthor ">Thomas  Markotan</span>, <span class="hlFld-ContribAuthor ">Jan  Spink</span>, <span class="hlFld-ContribAuthor ">Zhaoyuan  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Shan</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Navarro</span>, <span class="hlFld-ContribAuthor ">Michele  Tait</span>, <span class="hlFld-ContribAuthor ">Kathleen  Provoncha</span>, <span class="hlFld-ContribAuthor ">Jason  Giurleo</span>, <span class="hlFld-ContribAuthor ">Feng  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Jiang</span>, <span class="hlFld-ContribAuthor ">Donna  Hylton</span>, <span class="hlFld-ContribAuthor ">Sosina  Makonnen</span>, <span class="hlFld-ContribAuthor ">Carlos  Hickey</span>, <span class="hlFld-ContribAuthor ">Jessica R.  Kirshner</span>, <span class="hlFld-ContribAuthor ">Gavin  Thurston</span>, <span class="hlFld-ContribAuthor ">Nicholas  Papadopoulos</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (9)
                                     , 2271-2279. <a href="https://doi.org/10.1016/j.bmc.2018.02.025" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.02.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.02.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAntibody%252Bdrug%252Bconjugates%252Bof%252Bcleavable%252Bamino-alkyl%252Band%252Baryl%252Bmaytansinoids%26aulast%3DNittoli%26aufirst%3DThomas%26date%3D2018%26volume%3D26%26issue%3D9%26spage%3D2271%26epage%3D2279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Shao</span>, <span class="hlFld-ContribAuthor ">Mei-Hsuan  Tsai</span>, <span class="hlFld-ContribAuthor ">Jiawei  Lu</span>, <span class="hlFld-ContribAuthor ">Tao  Yu</span>, <span class="hlFld-ContribAuthor ">Jin  Jin</span>, <span class="hlFld-ContribAuthor ">Di  Xiao</span>, <span class="hlFld-ContribAuthor ">Huanhuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Mo  Han</span>, <span class="hlFld-ContribAuthor ">Min  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (8)
                                     , 1363-1370. <a href="https://doi.org/10.1016/j.bmcl.2018.03.005" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSite-specific%252Band%252Bhydrophilic%252BADCs%252Bthrough%252Bdisulfide-bridged%252Blinker%252Band%252Bbranched%252BPEG%26aulast%3DShao%26aufirst%3DShuai%26date%3D2018%26volume%3D28%26issue%3D8%26spage%3D1363%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Yong  Ma</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Pillow</span>, <span class="hlFld-ContribAuthor ">Jack D.  Sadowsky</span>, <span class="hlFld-ContribAuthor ">Dian  Su</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>, <span class="hlFld-ContribAuthor ">Andrew G.  Polson</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Cornelis E.C.A.  Hop</span>. </span><span class="cited-content_cbyCitation_article-title">Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (3)
                                     , 677-685. <a href="https://doi.org/10.1158/1535-7163.MCT-17-0697" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-0697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-0697%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DIntratumoral%252BPayload%252BConcentration%252BCorrelates%252Bwith%252Bthe%252BActivity%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DZhang%26aufirst%3DDonglu%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D3%26spage%3D677%26epage%3D685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jorge  Verkade</span>, <span class="hlFld-ContribAuthor ">Marloes  Wijdeven</span>, , <span class="hlFld-ContribAuthor ">Brian  Janssen</span>, , . </span><span class="cited-content_cbyCitation_article-title">A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2018,</strong> <em>7 </em>
                                    (1)
                                     , 12. <a href="https://doi.org/10.3390/antib7010012" title="DOI URL">https://doi.org/10.3390/antib7010012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib7010012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib7010012%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DA%252BPolar%252BSulfamide%252BSpacer%252BSignificantly%252BEnhances%252Bthe%252BManufacturability%25252C%252BStability%25252C%252Band%252BTherapeutic%252BIndex%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DVerkade%26aufirst%3DJorge%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D1%26spage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georg  Falck</span>, <span class="hlFld-ContribAuthor ">Kristian  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2018,</strong> <em>7 </em>
                                    (1)
                                     , 4. <a href="https://doi.org/10.3390/antib7010004" title="DOI URL">https://doi.org/10.3390/antib7010004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib7010004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib7010004%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DEnzyme-Based%252BLabeling%252BStrategies%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Band%252BAntibody%252BMimetics%26aulast%3DFalck%26aufirst%3DGeorg%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D1%26spage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">Next Generation Payloads for ADCs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 187-214. <a href="https://doi.org/10.1007/978-3-319-78154-9_8" title="DOI URL">https://doi.org/10.1007/978-3-319-78154-9_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-78154-9_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-78154-9_8%26sid%3Dliteratum%253Aachs%26atitle%3DNext%252BGeneration%252BPayloads%252Bfor%252BADCs%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2018%26date%3D2018%26spage%3D187%26epage%3D214%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DInnovations%252Bfor%252BNext-Generation%252BAntibody-Drug%252BConjugates%26aulast%3DDamelin%26aufirst%3DMarc%26date%3D2018%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matt H.  Hutchinson</span>, <span class="hlFld-ContribAuthor ">Rachel S.  Hendricks</span>, <span class="hlFld-ContribAuthor ">Xin Xin  Lin</span>, <span class="hlFld-ContribAuthor ">Dana A.  Olson</span>. </span><span class="cited-content_cbyCitation_article-title">Process Development and Manufacturing of Antibody-Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 813-836. <a href="https://doi.org/10.1016/B978-0-08-100623-8.00041-4" title="DOI URL">https://doi.org/10.1016/B978-0-08-100623-8.00041-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-100623-8.00041-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-100623-8.00041-4%26sid%3Dliteratum%253Aachs%26atitle%3DProcess%252BDevelopment%252Band%252BManufacturing%252Bof%252BAntibody-Drug%252BConjugates%26aulast%3DHutchinson%26aufirst%3DMatt%2BH.%26date%3D2018%26spage%3D813%26epage%3D836%26pub%3DElsevier%26atitle%3DBiopharmaceutical%252BProcessing%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra  Aguiar</span>, <span class="hlFld-ContribAuthor ">Joana  Dias</span>, <span class="hlFld-ContribAuthor ">Ana M.  Manuel</span>, <span class="hlFld-ContribAuthor ">Roberto  Russo</span>, <span class="hlFld-ContribAuthor ">Pedro M.P.  Gois</span>, <span class="hlFld-ContribAuthor ">Frederico A.  da Silva</span>, <span class="hlFld-ContribAuthor ">Joao  Goncalves</span>. </span><span class="cited-content_cbyCitation_article-title">Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 143-182. <a href="https://doi.org/10.1016/bs.apcsb.2018.03.002" title="DOI URL">https://doi.org/10.1016/bs.apcsb.2018.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apcsb.2018.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apcsb.2018.03.002%26sid%3Dliteratum%253Aachs%26atitle%3DChimeric%252BSmall%252BAntibody%252BFragments%252Bas%252BStrategy%252Bto%252BDeliver%252BTherapeutic%252BPayloads%26aulast%3DAguiar%26aufirst%3DSandra%26date%3D2018%26spage%3D143%26epage%3D182%26pub%3DElsevier%26atitle%3DTherapeutic%252BProteins%252Band%252BPeptides%26date%3D2018%26volume%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eshita  Khera</span>, <span class="hlFld-ContribAuthor ">Cornelius  Cilliers</span>, <span class="hlFld-ContribAuthor ">Sumit  Bhatnagar</span>, <span class="hlFld-ContribAuthor ">Greg M.  Thurber</span>. </span><span class="cited-content_cbyCitation_article-title">Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecular Systems Design & Engineering</span><span> <strong>2018,</strong> <em>3 </em>
                                    (1)
                                     , 73-88. <a href="https://doi.org/10.1039/C7ME00093F" title="DOI URL">https://doi.org/10.1039/C7ME00093F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7ME00093F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7ME00093F%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Systems%2520Design%2520%2526%2520Engineering%26atitle%3DComputational%252Btransport%252Banalysis%252Bof%252Bantibody-drug%252Bconjugate%252Bbystander%252Beffects%252Band%252Bpayload%252Btumoral%252Bdistribution%25253A%252Bimplications%252Bfor%252Btherapy%26aulast%3DKhera%26aufirst%3DEshita%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D1%26spage%3D73%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Calise  Bahou</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Richards</span>, <span class="hlFld-ContribAuthor ">Antoine  Maruani</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Love</span>, <span class="hlFld-ContribAuthor ">Faiza  Javaid</span>, <span class="hlFld-ContribAuthor ">Stephen  Caddick</span>, <span class="hlFld-ContribAuthor ">James R.  Baker</span>, <span class="hlFld-ContribAuthor ">Vijay  Chudasama</span>. </span><span class="cited-content_cbyCitation_article-title">Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (8)
                                     , 1359-1366. <a href="https://doi.org/10.1039/C7OB03138F" title="DOI URL">https://doi.org/10.1039/C7OB03138F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB03138F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB03138F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DHighly%252Bhomogeneous%252Bantibody%252Bmodification%252Bthrough%252Boptimisation%252Bof%252Bthe%252Bsynthesis%252Band%252Bconjugation%252Bof%252Bfunctionalised%252Bdibromopyridazinediones%26aulast%3DBahou%26aufirst%3DCalise%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D8%26spage%3D1359%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleksandr  Koniev</span>, <span class="hlFld-ContribAuthor ">Igor  Dovgan</span>, <span class="hlFld-ContribAuthor ">Brigitte  Renoux</span>, <span class="hlFld-ContribAuthor ">Anthony  Ehkirch</span>, <span class="hlFld-ContribAuthor ">Jitka  Eberova</span>, <span class="hlFld-ContribAuthor ">Sarah  Cianférani</span>, <span class="hlFld-ContribAuthor ">Sergii  Kolodych</span>, <span class="hlFld-ContribAuthor ">Sébastien  Papot</span>, <span class="hlFld-ContribAuthor ">Alain  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Reduction–rebridging strategy for the preparation of ADPN-based antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (5)
                                     , 827-830. <a href="https://doi.org/10.1039/C8MD00141C" title="DOI URL">https://doi.org/10.1039/C8MD00141C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00141C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00141C%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DReduction%2525E2%252580%252593rebridging%252Bstrategy%252Bfor%252Bthe%252Bpreparation%252Bof%252BADPN-based%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DKoniev%26aufirst%3DOleksandr%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D5%26spage%3D827%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Malik</span>, <span class="hlFld-ContribAuthor ">Colin  Phipps</span>, <span class="hlFld-ContribAuthor ">Andrea  Edginton</span>, <span class="hlFld-ContribAuthor ">Jonathan  Blay</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2017,</strong> <em>34 </em>
                                    (12)
                                     , 2579-2595. <a href="https://doi.org/10.1007/s11095-017-2259-3" title="DOI URL">https://doi.org/10.1007/s11095-017-2259-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-017-2259-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-017-2259-3%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DPharmacokinetic%252BConsiderations%252Bfor%252BAntibody-Drug%252BConjugates%252Bagainst%252BCancer%26aulast%3DMalik%26aufirst%3DPaul%26date%3D2017%26date%3D2017%26volume%3D34%26issue%3D12%26spage%3D2579%26epage%3D2595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xian  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Xiaojin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Prodrug strategy for cancer cell-specific targeting: A recent overview. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>139 </em>, 542-563. <a href="https://doi.org/10.1016/j.ejmech.2017.08.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProdrug%252Bstrategy%252Bfor%252Bcancer%252Bcell-specific%252Btargeting%25253A%252BA%252Brecent%252Boverview%26aulast%3DZhang%26aufirst%3DXian%26date%3D2017%26volume%3D139%26spage%3D542%26epage%3D563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Botzanowski</span>, <span class="hlFld-ContribAuthor ">Stéphane  Erb</span>, <span class="hlFld-ContribAuthor ">Oscar  Hernandez-Alba</span>, <span class="hlFld-ContribAuthor ">Anthony  Ehkirch</span>, <span class="hlFld-ContribAuthor ">Olivier  Colas</span>, <span class="hlFld-ContribAuthor ">Elsa  Wagner-Rousset</span>, <span class="hlFld-ContribAuthor ">David  Rabuka</span>, <span class="hlFld-ContribAuthor ">Alain  Beck</span>, <span class="hlFld-ContribAuthor ">Penelope M.  Drake</span>, <span class="hlFld-ContribAuthor ">Sarah  Cianférani</span>. </span><span class="cited-content_cbyCitation_article-title">Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2017,</strong> <em>9 </em>
                                    (5)
                                     , 801-811. <a href="https://doi.org/10.1080/19420862.2017.1316914" title="DOI URL">https://doi.org/10.1080/19420862.2017.1316914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/19420862.2017.1316914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F19420862.2017.1316914%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DInsights%252Bfrom%252Bnative%252Bmass%252Bspectrometry%252Bapproaches%252Bfor%252Btop-%252Band%252Bmiddle-%252Blevel%252Bcharacterization%252Bof%252Bsite-specific%252Bantibody-drug%252Bconjugates%26aulast%3DBotzanowski%26aufirst%3DThomas%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D5%26spage%3D801%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">Haiyin  He</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, <span class="hlFld-ContribAuthor ">Jesse  Teske</span>, <span class="hlFld-ContribAuthor ">Michael  Green</span>, <span class="hlFld-ContribAuthor ">Xingzhi  Tan</span>, <span class="hlFld-ContribAuthor ">Christine  Hosselet</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>, <span class="hlFld-ContribAuthor ">Chakrapani  Subramanyam</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, <span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, . </span><span class="cited-content_cbyCitation_article-title">Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2017,</strong> <em>12 </em>
                                    (5)
                                     , e0178452. <a href="https://doi.org/10.1371/journal.pone.0178452" title="DOI URL">https://doi.org/10.1371/journal.pone.0178452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0178452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0178452%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DMultivalent%252Bpeptidic%252Blinker%252Benables%252Bidentification%252Bof%252Bpreferred%252Bsites%252Bof%252Bconjugation%252Bfor%252Ba%252Bpotent%252Bthialanstatin%252Bantibody%252Bdrug%252Bconjugate%26aulast%3DPuthenveetil%26aufirst%3DSujiet%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D5%26spage%3De0178452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorin  Toader</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 289-289. <a href="https://doi.org/10.1007/7355_2017_29" title="DOI URL">https://doi.org/10.1007/7355_2017_29</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_29%26sid%3Dliteratum%253Aachs%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DToader%26aufirst%3DDorin%26date%3D2017%26spage%3D289%26epage%3D289%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Hendriks</span>, <span class="hlFld-ContribAuthor ">G.  Choi</span>, <span class="hlFld-ContribAuthor ">M.  de Bruyn</span>, <span class="hlFld-ContribAuthor ">V.R.  Wiersma</span>, <span class="hlFld-ContribAuthor ">E.  Bremer</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-Based Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 289-383. <a href="https://doi.org/10.1016/bs.ircmb.2016.10.002" title="DOI URL">https://doi.org/10.1016/bs.ircmb.2016.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.ircmb.2016.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.ircmb.2016.10.002%26sid%3Dliteratum%253Aachs%26atitle%3DAntibody-Based%252BCancer%252BTherapy%26aulast%3DHendriks%26aufirst%3DD.%26date%3D2017%26spage%3D289%26epage%3D383%26pub%3DElsevier%26date%3D2017%26volume%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mira  Woitok</span>, <span class="hlFld-ContribAuthor ">Diana  Klose</span>, <span class="hlFld-ContribAuthor ">Judith  Niesen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Richter</span>, <span class="hlFld-ContribAuthor ">Muhammad  Abbas</span>, <span class="hlFld-ContribAuthor ">Christoph  Stein</span>, <span class="hlFld-ContribAuthor ">Rolf  Fendel</span>, <span class="hlFld-ContribAuthor ">Magdalena  Bialon</span>, <span class="hlFld-ContribAuthor ">Christiane  Püttmann</span>, <span class="hlFld-ContribAuthor ">Rainer  Fischer</span>, <span class="hlFld-ContribAuthor ">Stefan  Barth</span>, <span class="hlFld-ContribAuthor ">Katharina  Kolberg</span>. </span><span class="cited-content_cbyCitation_article-title">The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2016,</strong> <em>381 </em>
                                    (2)
                                     , 323-330. <a href="https://doi.org/10.1016/j.canlet.2016.08.003" title="DOI URL">https://doi.org/10.1016/j.canlet.2016.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2016.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2016.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DThe%252Befficient%252Belimination%252Bof%252Bsolid%252Btumor%252Bcells%252Bby%252BEGFR-specific%252Band%252BHER2-specific%252BscFv-SNAP%252Bfusion%252Bproteins%252Bconjugated%252Bto%252Bbenzylguanine-modified%252Bauristatin%252BF%26aulast%3DWoitok%26aufirst%3DMira%26date%3D2016%26volume%3D381%26issue%3D2%26spage%3D323%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sam  Massa</span>, <span class="hlFld-ContribAuthor ">Niravkumar  Vikani</span>, <span class="hlFld-ContribAuthor ">Cecilia  Betti</span>, <span class="hlFld-ContribAuthor ">Steven  Ballet</span>, <span class="hlFld-ContribAuthor ">Saskia  Vanderhaegen</span>, <span class="hlFld-ContribAuthor ">Jan  Steyaert</span>, <span class="hlFld-ContribAuthor ">Benedicte  Descamps</span>, <span class="hlFld-ContribAuthor ">Christian  Vanhove</span>, <span class="hlFld-ContribAuthor ">Anton  Bunschoten</span>, <span class="hlFld-ContribAuthor ">Fijs W. B.  van Leeuwen</span>, <span class="hlFld-ContribAuthor ">Sophie  Hernot</span>, <span class="hlFld-ContribAuthor ">Vicky  Caveliers</span>, <span class="hlFld-ContribAuthor ">Tony  Lahoutte</span>, <span class="hlFld-ContribAuthor ">Serge  Muyldermans</span>, <span class="hlFld-ContribAuthor ">Catarina  Xavier</span>, <span class="hlFld-ContribAuthor ">Nick  Devoogdt</span>. </span><span class="cited-content_cbyCitation_article-title">Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities. </span><span class="cited-content_cbyCitation_journal-name">Contrast Media & Molecular Imaging</span><span> <strong>2016,</strong> <em>11 </em>
                                    (5)
                                     , 328-339. <a href="https://doi.org/10.1002/cmmi.1696" title="DOI URL">https://doi.org/10.1002/cmmi.1696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmmi.1696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmmi.1696%26sid%3Dliteratum%253Aachs%26jtitle%3DContrast%2520Media%2520%2526%2520Molecular%2520Imaging%26atitle%3DSortase%252BA-mediated%252Bsite-specific%252Blabeling%252Bof%252Bcamelid%252Bsingle-domain%252Bantibody-fragments%25253A%252Ba%252Bversatile%252Bstrategy%252Bfor%252Bmultiple%252Bmolecular%252Bimaging%252Bmodalities%26aulast%3DMassa%26aufirst%3DSam%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D5%26spage%3D328%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cornelius  Cilliers</span>, <span class="hlFld-ContribAuthor ">Hans  Guo</span>, <span class="hlFld-ContribAuthor ">Jianshan  Liao</span>, <span class="hlFld-ContribAuthor ">Nikolas  Christodolu</span>, <span class="hlFld-ContribAuthor ">Greg M.  Thurber</span>. </span><span class="cited-content_cbyCitation_article-title">Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2016,</strong> <em>18 </em>
                                    (5)
                                     , 1117-1130. <a href="https://doi.org/10.1208/s12248-016-9940-z" title="DOI URL">https://doi.org/10.1208/s12248-016-9940-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-016-9940-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-016-9940-z%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DMultiscale%252BModeling%252Bof%252BAntibody-Drug%252BConjugates%25253A%252BConnecting%252BTissue%252Band%252BCellular%252BDistribution%252Bto%252BWhole%252BAnimal%252BPharmacokinetics%252Band%252BPotential%252BImplications%252Bfor%252BEfficacy%26aulast%3DCilliers%26aufirst%3DCornelius%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D5%26spage%3D1117%26epage%3D1130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katie F.  Maass</span>, <span class="hlFld-ContribAuthor ">Chethana  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Alison M.  Betts</span>, <span class="hlFld-ContribAuthor ">K. Dane  Wittrup</span>. </span><span class="cited-content_cbyCitation_article-title">Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2016,</strong> <em>18 </em>
                                    (3)
                                     , 635-646. <a href="https://doi.org/10.1208/s12248-016-9892-3" title="DOI URL">https://doi.org/10.1208/s12248-016-9892-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-016-9892-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-016-9892-3%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DDetermination%252Bof%252BCellular%252BProcessing%252BRates%252Bfor%252Ba%252BTrastuzumab-Maytansinoid%252BAntibody-Drug%252BConjugate%252B%252528ADC%252529%252BHighlights%252BKey%252BParameters%252Bfor%252BADC%252BDesign%26aulast%3DMaass%26aufirst%3DKatie%2BF.%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D3%26spage%3D635%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Adumeau</span>, <span class="hlFld-ContribAuthor ">Sai Kiran  Sharma</span>, <span class="hlFld-ContribAuthor ">Colleen  Brent</span>, <span class="hlFld-ContribAuthor ">Brian M.  Zeglis</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 2: Peptide Tags and Unnatural Amino Acids. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging and Biology</span><span> <strong>2016,</strong> <em>18 </em>
                                    (2)
                                     , 153-165. <a href="https://doi.org/10.1007/s11307-015-0920-y" title="DOI URL">https://doi.org/10.1007/s11307-015-0920-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11307-015-0920-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11307-015-0920-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%2520and%2520Biology%26atitle%3DSite-Specifically%252BLabeled%252BImmunoconjugates%252Bfor%252BMolecular%252BImaging%2525E2%252580%252594Part%252B2%25253A%252BPeptide%252BTags%252Band%252BUnnatural%252BAmino%252BAcids%26aulast%3DAdumeau%26aufirst%3DPierre%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D2%26spage%3D153%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Adumeau</span>, <span class="hlFld-ContribAuthor ">Sai Kiran  Sharma</span>, <span class="hlFld-ContribAuthor ">Colleen  Brent</span>, <span class="hlFld-ContribAuthor ">Brian M.  Zeglis</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 1: Cysteine Residues and Glycans. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging and Biology</span><span> <strong>2016,</strong> <em>18 </em>
                                    (1)
                                     , 1-17. <a href="https://doi.org/10.1007/s11307-015-0919-4" title="DOI URL">https://doi.org/10.1007/s11307-015-0919-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11307-015-0919-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11307-015-0919-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%2520and%2520Biology%26atitle%3DSite-Specifically%252BLabeled%252BImmunoconjugates%252Bfor%252BMolecular%252BImaging%2525E2%252580%252594Part%252B1%25253A%252BCysteine%252BResidues%252Band%252BGlycans%26aulast%3DAdumeau%26aufirst%3DPierre%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D1%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher D.  Thanos</span>, <span class="hlFld-ContribAuthor ">Paul D.  Rennert</span>. </span><span class="cited-content_cbyCitation_article-title">The New Frontier of Antibody Drug Conjugates: Targets, Biology, Chemistry, Payloads. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 181-201. <a href="https://doi.org/10.1007/978-3-319-29827-6_8" title="DOI URL">https://doi.org/10.1007/978-3-319-29827-6_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-29827-6_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-29827-6_8%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BNew%252BFrontier%252Bof%252BAntibody%252BDrug%252BConjugates%25253A%252BTargets%25252C%252BBiology%25252C%252BChemistry%25252C%252BPayloads%26aulast%3DThanos%26aufirst%3DChristopher%2BD.%26date%3D2016%26date%3D2016%26spage%3D181%26epage%3D201%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNovel%252BImmunotherapeutic%252BApproaches%252Bto%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DRennert%26aufirst%3DPaul%2BD.%26date%3D2016%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Padma  Akkapeddi</span>, <span class="hlFld-ContribAuthor ">Saara-Anne  Azizi</span>, <span class="hlFld-ContribAuthor ">Allyson M.  Freedy</span>, <span class="hlFld-ContribAuthor ">Pedro M. S. D.  Cal</span>, <span class="hlFld-ContribAuthor ">Pedro M. P.  Gois</span>, <span class="hlFld-ContribAuthor ">Gonçalo J. L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2016,</strong> <em>7 </em>
                                    (5)
                                     , 2954-2963. <a href="https://doi.org/10.1039/C6SC00170J" title="DOI URL">https://doi.org/10.1039/C6SC00170J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6SC00170J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6SC00170J%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DConstruction%252Bof%252Bhomogeneous%252Bantibody%2525E2%252580%252593drug%252Bconjugates%252Busing%252Bsite-selective%252Bprotein%252Bchemistry%26aulast%3DAkkapeddi%26aufirst%3DPadma%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D5%26spage%3D2954%26epage%3D2963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Polakis</span>, . </span><span class="cited-content_cbyCitation_article-title">Antibody Drug Conjugates for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2016,</strong> <em>68 </em>
                                    (1)
                                     , 3-19. <a href="https://doi.org/10.1124/pr.114.009373" title="DOI URL">https://doi.org/10.1124/pr.114.009373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.114.009373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.114.009373%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DAntibody%252BDrug%252BConjugates%252Bfor%252BCancer%252BTherapy%26aulast%3DPolakis%26aufirst%3DPaul%26date%3D2016%26date%3D2015%26volume%3D68%26issue%3D1%26spage%3D3%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Russell J  Sanderson</span>, <span class="hlFld-ContribAuthor ">Nicole D  Nicholas</span>, <span class="hlFld-ContribAuthor ">Cassandra  Baker Lee</span>, <span class="hlFld-ContribAuthor ">Shawna Mae  Hengel</span>, <span class="hlFld-ContribAuthor ">Robert P  Lyon</span>, <span class="hlFld-ContribAuthor ">Dennis R  Benjamin</span>, <span class="hlFld-ContribAuthor ">Stephen C  Alley</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-conjugated drug assay for protease-cleavable antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2016,</strong> <em>8 </em>
                                    (1)
                                     , 55-63. <a href="https://doi.org/10.4155/bio.15.230" title="DOI URL">https://doi.org/10.4155/bio.15.230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio.15.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio.15.230%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DAntibody-conjugated%252Bdrug%252Bassay%252Bfor%252Bprotease-cleavable%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DSanderson%26aufirst%3DRussell%2BJ%26date%3D2016%26volume%3D8%26issue%3D1%26spage%3D55%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jay  Tibbitts</span>. </span><span class="cited-content_cbyCitation_article-title">Investigating the Nonclinical ADME and PK/PD of an Antibody-Drug Conjugate: A Case Study of Ado-Trastuzumab Emtansine (T-DM1). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 1-11. <a href="https://doi.org/10.1002/9780470571224.pse561" title="DOI URL">https://doi.org/10.1002/9780470571224.pse561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9780470571224.pse561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9780470571224.pse561%26sid%3Dliteratum%253Aachs%26atitle%3DInvestigating%252Bthe%252BNonclinical%252BADME%252Band%252BPK%25252FPD%252Bof%252Ban%252BAntibody-Drug%252BConjugate%25253A%252BA%252BCase%252BStudy%252Bof%252BAdo-Trastuzumab%252BEmtansine%252B%252528T-DM1%252529%26aulast%3DTibbitts%26aufirst%3DJay%26date%3D2015%26date%3D2015%26spage%3D1%26epage%3D11%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPharmaceutical%252BSciences%252BEncyclopedia%26aulast%3DGad%26aufirst%3DShayne%2BCox%26date%3D2010%26date%3D2010%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Jiang</span>, <span class="hlFld-ContribAuthor ">Biao  Liu</span>, <span class="hlFld-ContribAuthor ">Jun  Lu</span>, <span class="hlFld-ContribAuthor ">Fangfei  Li</span>, <span class="hlFld-ContribAuthor ">Defang  Li</span>, <span class="hlFld-ContribAuthor ">Chao  Liang</span>, <span class="hlFld-ContribAuthor ">Lei  Dang</span>, <span class="hlFld-ContribAuthor ">Jin  Liu</span>, <span class="hlFld-ContribAuthor ">Bing  He</span>, <span class="hlFld-ContribAuthor ">Shaikh  Badshah</span>, <span class="hlFld-ContribAuthor ">Cheng  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaojuan  He</span>, <span class="hlFld-ContribAuthor ">Baosheng  Guo</span>, <span class="hlFld-ContribAuthor ">Xiao-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Weihong  Tan</span>, <span class="hlFld-ContribAuthor ">Aiping  Lu</span>, <span class="hlFld-ContribAuthor ">Ge  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Progress and Challenges in Developing  Aptamer-Functionalized Targeted Drug Delivery Systems. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2015,</strong> <em>16 </em>
                                    (10)
                                     , 23784-23822. <a href="https://doi.org/10.3390/ijms161023784" title="DOI URL">https://doi.org/10.3390/ijms161023784</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms161023784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms161023784%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DProgress%252Band%252BChallenges%252Bin%252BDeveloping%252BAptamer-Functionalized%252BTargeted%252BDrug%252BDelivery%252BSystems%26aulast%3DJiang%26aufirst%3DFeng%26date%3D2015%26date%3D2015%26volume%3D16%26issue%3D10%26spage%3D23784%26epage%3D23822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magdalena  Dorywalska</span>, <span class="hlFld-ContribAuthor ">Pavel  Strop</span>, <span class="hlFld-ContribAuthor ">Jody A.  Melton-Witt</span>, <span class="hlFld-ContribAuthor ">Adela  Hasa-Moreno</span>, <span class="hlFld-ContribAuthor ">Santiago E.  Farias</span>, <span class="hlFld-ContribAuthor ">Meritxell  Galindo Casas</span>, <span class="hlFld-ContribAuthor ">Kathy  Delaria</span>, <span class="hlFld-ContribAuthor ">Victor  Lui</span>, <span class="hlFld-ContribAuthor ">Kris  Poulsen</span>, <span class="hlFld-ContribAuthor ">Janette  Sutton</span>, <span class="hlFld-ContribAuthor ">Gary  Bolton</span>, <span class="hlFld-ContribAuthor ">Dahui  Zhou</span>, <span class="hlFld-ContribAuthor ">Ludivine  Moine</span>, <span class="hlFld-ContribAuthor ">Russell  Dushin</span>, <span class="hlFld-ContribAuthor ">Thomas-Toan  Tran</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Mathias  Rickert</span>, <span class="hlFld-ContribAuthor ">Davide  Foletti</span>, <span class="hlFld-ContribAuthor ">David L.  Shelton</span>, <span class="hlFld-ContribAuthor ">Jaume  Pons</span>, <span class="hlFld-ContribAuthor ">Arvind  Rajpal</span>, . </span><span class="cited-content_cbyCitation_article-title">Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2015,</strong> <em>10 </em>
                                    (7)
                                     , e0132282. <a href="https://doi.org/10.1371/journal.pone.0132282" title="DOI URL">https://doi.org/10.1371/journal.pone.0132282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0132282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0132282%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DSite-Dependent%252BDegradation%252Bof%252Ba%252BNon-Cleavable%252BAuristatin-Based%252BLinker-Payload%252Bin%252BRodent%252BPlasma%252Band%252BIts%252BEffect%252Bon%252BADC%252BEfficacy%26aulast%3DDorywalska%26aufirst%3DMagdalena%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D7%26spage%3De0132282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hitesh  Kulhari</span>, <span class="hlFld-ContribAuthor ">Deep  Pooja</span>, <span class="hlFld-ContribAuthor ">Sri V. K.  Rompicharla</span>, <span class="hlFld-ContribAuthor ">Ramakrishna  Sistla</span>, <span class="hlFld-ContribAuthor ">David J.  Adams</span>. </span><span class="cited-content_cbyCitation_article-title">Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2015,</strong> <em>35 </em>
                                    (4)
                                     , 849-876. <a href="https://doi.org/10.1002/med.21345" title="DOI URL">https://doi.org/10.1002/med.21345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21345%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DBiomedical%252BApplications%252Bof%252BTrastuzumab%25253A%252BAs%252Ba%252BTherapeutic%252BAgent%252Band%252Ba%252BTargeting%252BLigand%26aulast%3DKulhari%26aufirst%3DHitesh%26date%3D2015%26date%3D2015%26volume%3D35%26issue%3D4%26spage%3D849%26epage%3D876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo
              biotransformations of antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2015,</strong> <em>7 </em>
                                    (13)
                                     , 1649-1664. <a href="https://doi.org/10.4155/bio.15.84" title="DOI URL">https://doi.org/10.4155/bio.15.84</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio.15.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio.15.84%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DIn%252Bvivo%252Bbiotransformations%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DTumey%26aufirst%3DL%2BNathan%26date%3D2015%26volume%3D7%26issue%3D13%26spage%3D1649%26epage%3D1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin D  Witte</span>, <span class="hlFld-ContribAuthor ">Tongfei  Wu</span>, <span class="hlFld-ContribAuthor ">Carla P  Guimaraes</span>, <span class="hlFld-ContribAuthor ">Christopher S  Theile</span>, <span class="hlFld-ContribAuthor ">Annet E M  Blom</span>, <span class="hlFld-ContribAuthor ">Jessica R  Ingram</span>, <span class="hlFld-ContribAuthor ">Zeyang  Li</span>, <span class="hlFld-ContribAuthor ">Lenka  Kundrat</span>, <span class="hlFld-ContribAuthor ">Shalom D  Goldberg</span>, <span class="hlFld-ContribAuthor ">Hidde L  Ploegh</span>. </span><span class="cited-content_cbyCitation_article-title">Site-specific protein modification using immobilized sortase in batch and continuous-flow systems. </span><span class="cited-content_cbyCitation_journal-name">Nature Protocols</span><span> <strong>2015,</strong> <em>10 </em>
                                    (3)
                                     , 508-516. <a href="https://doi.org/10.1038/nprot.2015.026" title="DOI URL">https://doi.org/10.1038/nprot.2015.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nprot.2015.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnprot.2015.026%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Protocols%26atitle%3DSite-specific%252Bprotein%252Bmodification%252Busing%252Bimmobilized%252Bsortase%252Bin%252Bbatch%252Band%252Bcontinuous-flow%252Bsystems%26aulast%3DWitte%26aufirst%3DMartin%2BD%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D3%26spage%3D508%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) In vitro plasma stability analysis of Tmab-MCC-DM1 showed an appreciable level of deconjugation and overall instability of the ADC in mouse plasma as compared to the buffer control up to 96 h. Concentrations of total and conjugated antibodies were determined using ELISA and the average of three replicates plotted. (B) Formation of unconjugated (or free) DM1, a product of deconjugation of Tmab-MCC-DM1, was seen increasing with time up to 168 h and in mouse plasma vs buffer control measured by LC–MS/MS for the in vitro plasma stability study. (C) Reversibility of the connection between a thiol-containing antibody or drug and a maleimide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of new maytansinoid linker–drugs and their connection to an antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for Stable Maytansinoid Linker–Drugs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. 2-DAR site-specific Tmab ADCs with stable linker–drugs (ThioTmab-MPA-May and ThioTmab-MC-May) showed (A) similar HER2 binding to and (B) reduced in vitro cell killing compared to Tmab-MCC-DM1 (3.5 DAR) in the HER2-amplified SK-BR-3 breast cancer cell line, with the cell proliferation activity correlating with drug load.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vitro stability of (A) thioTmab-MPA-May and (B) thioTmab-MC-May in mouse plasma and in (C, D) human plasma. In vitro plasma stability analysis of (A) thioTmab-MPA-May and (B) thioTmab-MC-May ADCs showed low levels of deconjugation and overall stability of the ADC in mouse plasma as compared to the buffer control. Concentrations of total and conjugated antibodies were determined using ELISA, and the average of three replicates was plotted. Similar in vitro plasma stability studies were conducted for thioTmab-MPA-May (C) and thioTmab-MC-May (D) in human plasma, and the samples were analyzed using an LC–MS method.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Concentrations of unconjugated (or free) DM1 released upon incubation of thioTmab-LC-MPEO-DM1 and thioTmab-MPA-May in mouse plasma and PBS buffer (control) up to 168 h and measured by LC–MS/MS. Please note that no detectable DM1 was observed in plasma or buffer control for thioTmab-MPA-May.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo efficacy of 2-DAR site-specific Tmab ADCs vs Tmab-MCC-DM1 in a HER2+ Fo5 mammary tumor transplant mouse model. The MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the number 2/3 mammary fat pads of nu/nu mice in sections that measured approximately 2 mm × 2 mm. The tumor-bearing animals were randomized to a mean tumor volume range of 126–152 mm<sup>3</sup> (A) and 149–162 mm<sup>3</sup> (B) of 10 mice/group and then dosed iv once (day 0) with vehicle, thio gD-MPA-May or thio gD-MC-May controls, thioTmab-LC-MPEO-DM1(10 mg/kg, 284 μg drug/m<sup>2</sup>), thioTmab-MPA-May (10 mg/kg, 300 μg drug/m<sup>2</sup>), or Tmab-MCC-DM1 (10 mg/kg, 578 μg drug/m<sup>2</sup>). Fitted tumor volumes are plotted over time (days post dose). (A) At the same antibody dose, thioTmab-MPA-May showed improved efficacy over thioTmab-LC-MPEO-DM1. (A, B) thioTmab-MPA-May and Tmab-MCC-DM1 had similar efficacy at 10 mg/kg despite the former having a lower drug load.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/medium/jm-2014-00552c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. 4-DAR site specific Tmab ADCs with stable linker–drugs (thioTmab-MPA-May and thioTmab-MC-May) showed (A) similar HER2 binding to and (B) equivalent in vitro cell killing compared to Tmab-MCC-DM1 (3.5 DAR) in the HER2-amplified SK-BR-3 breast cancer cell line. (C) In vivo efficacy in a HER2+ Fo5 mammary tumor transplant mouse model. The MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the number 2/3 mammary fat pads of nu/nu mice in sections that measured approximately 2 mm × 2 mm. The tumor-bearing animals were randomized to a mean tumor volume range of 149–162 mm<sup>3</sup> of 10 mice/group and then dosed iv once (day 0) with vehicle or thio gD-MC-May controls, thioTmab-MC-May, thioTmab-MPA-May, or Tmab-MCC-DM1 at the doses indicated. Fitted tumor volumes are plotted over time (days post dose). 4-DAR site-specific ADCs at 5 mg/kg (326 μg drug/m<sup>2</sup>) resulted in less efficacy than Tmab-MCC-DM1 at 10 mg/kg (578 μg drug/m<sup>2</sup>). However, as expected, 10 mg/kg (652 μg drug/m<sup>2</sup>) of site-specific 4-DAR ADCs demonstrated superior efficacy over Tmab-MCC-DM1 at the same antibody dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500552c/20141006/images/large/jm-2014-00552c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500552c&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Mann, J.</span><span> </span><span class="NLM_article-title">Natural Products in Cancer Chemotherapy: Past, Present and Future</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnrc723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=12635177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVehtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=143-148&author=J.+Mann&title=Natural+Products+in+Cancer+Chemotherapy%3A+Past%2C+Present+and+Future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products in cancer chemotherapy: past, present and future</span></div><div class="casAuthors">Mann, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-148</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products have been the mainstay of cancer chemotherapy for the past 30 yr.  However, the quickening pace of (aberrant) gene identification, and the new technologies of combinatorial chem. and high-throughput screening, should provide access to a wide range of new, totally synthetic drugs.  Will these new approaches sound the death knell for therapies based on natural products.  In reality, natural products are likely to provide many of the lead structures, and these will be used as templates for the construction of novel compds. with enhanced biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXHpZOuqpKvLVg90H21EOLACvtfcHk0lhDRO3KbQaxHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVehtL8%253D&md5=e58dae200970644fcc8f43883fdcb428</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc723%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DJ.%26atitle%3DNatural%2520Products%2520in%2520Cancer%2520Chemotherapy%253A%2520Past%252C%2520Present%2520and%2520Future%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D143%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Cragg, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, D. J.</span><span> </span><span class="NLM_article-title">Impact of Natural Products on Developing New Anti-Cancer Agents</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3012</span><span class="NLM_x">–</span> <span class="NLM_lpage">3043</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr900019j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=3012-3043&author=G.+M.+Craggauthor=P.+G.+Grothausauthor=D.+J.+Newman&title=Impact+of+Natural+Products+on+Developing+New+Anti-Cancer+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Natural Products on Developing New Anti-Cancer Agents</span></div><div class="casAuthors">Cragg, Gordon M.; Grothaus, Paul G.; Newman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3012-3043</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Throughout the ages, Nature has catered to the basic needs of humans, not the least of which is the provision of medicines for the treatment of a wide spectrum of diseases.  Plants, in particular, have played a dominant role in the development of sophisticated traditional medicine systems.  The continuing and essential role played by plant-based systems in the healthcare of many different cultures has been extensively documented, and the World Health Organization (WHO) has estd. that approx. 65 % of the world's population rely mainly on plant-derived traditional medicines for their primary health care.  Plant products, however, also play an important role in the health care systems of the remaining population, mainly residing in developed countries.  In a survey of plant-derived pure compds. used as drugs in countries hosting WHO-Traditional Medicine Centers, 80 % of 122 such compds. identified were found to be used for the same or related ethnomedical purposes and were derived from only 94 plant species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMIOcfoMKc7Vg90H21EOLACvtfcHk0ljATL88KM6AGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCns7Y%253D&md5=4d74768e702c8978c15c4802864b6deb</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fcr900019j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900019j%26sid%3Dliteratum%253Aachs%26aulast%3DCragg%26aufirst%3DG.%2BM.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26atitle%3DImpact%2520of%2520Natural%2520Products%2520on%2520Developing%2520New%2520Anti-Cancer%2520Agents%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D3012%26epage%3D3043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Scott, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Old, L. J.</span><span> </span><span class="NLM_article-title">Antibody Therapy of Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnrc3236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22437872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=278-287&author=A.+M.+Scottauthor=J.+D.+Wolchokauthor=L.+J.+Old&title=Antibody+Therapy+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody therapy of cancer</span></div><div class="casAuthors">Scott, Andrew M.; Wolchok, Jedd D.; Old, Lloyd J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-287</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years.  Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumors, and immunomodulatory antibodies have also recently achieved remarkable clin. success.  The development of therapeutic antibodies requires a deep understanding of cancer serol., protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells.  This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclin. studies to human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-oFh7ngWZT7Vg90H21EOLACvtfcHk0ljATL88KM6AGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegsbs%253D&md5=568d4e9d2385eeba9d0bd211b31492f9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3236%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DA.%2BM.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26atitle%3DAntibody%2520Therapy%2520of%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D278%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Flygare, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aristoff, P.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates for the Treatment of Cancer</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1111%2Fcbdd.12085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=23253133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=113-121&author=J.+A.+Flygareauthor=T.+H.+Pillowauthor=P.+Aristoff&title=Antibody-Drug+Conjugates+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for the treatment of cancer</span></div><div class="casAuthors">Flygare, John A.; Pillow, Thomas H.; Aristoff, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-121</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  With over 20 antibody-drug conjugates in clin. trials as well as a recently FDA-approved drug, it is clear that this is becoming an important and viable approach for selectively delivering highly cytotoxic agents to tumor cells while sparing normal tissue.  This review discusses the crit. aspects for this approach with an emphasis on the properties of the linker between the antibody and the cytotoxic payload that are required for an effective antibody-drug conjugate.  Different linkers are illustrated with attention focused on (i) the specifics of attachment to the antibody, (ii) the polarity of the linker, (iii) the trigger on the linker that initiates cleavage from the drug, and (iv) the self-immolative spacer that liberates the active payload.  Future directions in the field are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVlj709scT7Vg90H21EOLACvtfcHk0ljATL88KM6AGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D&md5=236ee3d312781e0b2ad27ad1f6c9365d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12085%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DAristoff%26aufirst%3DP.%26atitle%3DAntibody-Drug%2520Conjugates%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Adair, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, K. A.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates—A Perfect Synergy</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1191</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1517%2F14712598.2012.693473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22650648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Wls73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1191-1206&author=J.+R.+Adairauthor=P.+W.+Howardauthor=J.+A.+Hartleyauthor=D.+G.+Williamsauthor=K.+A.+Chester&title=Antibody-Drug+Conjugates%E2%80%94A+Perfect+Synergy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates - a perfect synergy</span></div><div class="casAuthors">Adair, John R.; Howard, Philip W.; Hartley, John A.; Williams, David G.; Chester, Kerry A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1191-1206</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: There is a great unmet need for effective new treatments in cancer, which continues to be a major cause of death.  Antibody-drug conjugates (ADCs) are emerging, after a long gestation, as a class of biopharmaceuticals with the potential to address this need by directing highly potent cytotoxic drugs to their point of action.  There is increasing interest in ADCs by major pharmaceutical companies and a growing pipeline of candidates for clin. use.  This review summarises progress with development of this new class of drugs.Areas covered: The authors describe sep. the antibody and drug elements of ADCs and then examine the technol. and consequences of linkage.  The work is presented in the light of recent developments in the design, using clin. examples where possible.Expert opinion: Since their emergence as independent drugs, antibodies and chemotherapy are being brought together in effective synergy.  The conjunction is timely: many of the tech. challenges in prepg. antibodies have been addressed; potent new drugs are available and linker technol. is advancing apace.  ADCs however are not just a sum of their individual parts.  The current challenge is in understanding the holistic nature of this exciting class of drugs that promise a new avenue for cancer treatment.  Target selection, the interaction of ADC with tumor and off-tumor targets and the internalisation of ADCs, are crit. to the effective maturation of ADC technol.  Ongoing recent developments in attachment sites and linker chem. can provide fine-tuning of drug loading, elements of ADC PK and off-target ADC toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY30NZYFPh-rVg90H21EOLACvtfcHk0lhU6QijukpoCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Wls73P&md5=e3604ba9b52c917335b4c5568e54057c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F14712598.2012.693473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2012.693473%26sid%3Dliteratum%253Aachs%26aulast%3DAdair%26aufirst%3DJ.%2BR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DChester%26aufirst%3DK.%2BA.%26atitle%3DAntibody-Drug%2520Conjugates%25E2%2580%2594A%2520Perfect%2520Synergy%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2012%26volume%3D12%26spage%3D1191%26epage%3D1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Teicher, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Antibody Conjugate Therapeutics: Challenges and Potential</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6389</span><span class="NLM_x">–</span> <span class="NLM_lpage">6397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1078-0432.CCR-11-1417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22003066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6389-6397&author=B.+A.+Teicherauthor=R.+V.+J.+Chari&title=Antibody+Conjugate+Therapeutics%3A+Challenges+and+Potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Conjugate Therapeutics: Challenges and Potential</span></div><div class="casAuthors">Teicher, Beverly A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6389-6397</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells.  The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.  The history of antibody conjugates is marked by hurdles that have been identified and overcome.  Early conjugates used mouse antibodies; cytotoxic agents that were immunogenic (proteins), too toxic, or not sufficiently potent; and linkers that were not sufficiently stable in circulation.  Investigators have explored 4 main avenues using antibodies to target cytotoxic agents to malignant cells: antibody-protein toxin (or antibody fragment-protein toxin fusion) conjugates, antibody-chelated radionuclide conjugates, antibody-small-mol. drug conjugates, and antibody-enzyme conjugates administered along with small-mol. prodrugs that require metab. by the conjugated enzyme to release the activated species.  Only antibody-radionuclide conjugates and antibody-drug conjugates have reached the regulatory approval stage, and nearly 20 antibody conjugates are currently in clin. trials.  The time may have come for this technol. to become a major contributor to improving treatment for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhe-7pzpGkZbVg90H21EOLACvtfcHk0lhU6QijukpoCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzK&md5=860b08fb5e2dfda813cb411cf124e664</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1417%26sid%3Dliteratum%253Aachs%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DAntibody%2520Conjugate%2520Therapeutics%253A%2520Challenges%2520and%2520Potential%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6389%26epage%3D6397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Sapra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, H.-P.</span><span> </span><span class="NLM_article-title">Investigational Antibody Drug Conjugates for Solid Tumors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1131</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1131-1149&author=P.+Sapraauthor=A.+T.+Hooperauthor=C.+J.+O%E2%80%99Donnellauthor=H.-P.+Gerber&title=Investigational+Antibody+Drug+Conjugates+for+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSapra%26aufirst%3DP.%26aulast%3DHooper%26aufirst%3DA.%2BT.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DGerber%26aufirst%3DH.-P.%26atitle%3DInvestigational%2520Antibody%2520Drug%2520Conjugates%2520for%2520Solid%2520Tumors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1131%26epage%3D1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Polson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span> </span><span class="NLM_article-title">Investigational Antibody-Drug Conjugates for Hematological Malignancies</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=75-85&author=A.+G.+Polsonauthor=W.+Y.+Hoauthor=V.+Ramakrishnan&title=Investigational+Antibody-Drug+Conjugates+for+Hematological+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DHo%26aufirst%3DW.%2BY.%26aulast%3DRamakrishnan%26aufirst%3DV.%26atitle%3DInvestigational%2520Antibody-Drug%2520Conjugates%2520for%2520Hematological%2520Malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D75%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Antibody–Drug Conjugates: Targeted Drug Delivery for Cancer</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1016%2Fj.cbpa.2010.06.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=20643572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=529-537&author=S.+C.+Alleyauthor=N.+M.+Okeleyauthor=P.+D.+Senter&title=Antibody%E2%80%93Drug+Conjugates%3A+Targeted+Drug+Delivery+for+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: Targeted drug delivery for cancer</span></div><div class="casAuthors">Alley, Stephen C.; Okeley, Nicole M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technol., and the stoichiometry and placement of conjugated drugs.  The underlying reason for this was obtained in pre-clin. biodistribution and pharmacokinetics studies showing that targeted delivery leads to high intratumoral free drug concns., while non-target tissues are largely spared from chemotherapeutic exposure.  Recent developments in the field have led to an increase in the no. of ADCs being tested clin., with 3 in late stage clin. trials: Brentuximab vedotin (also referred to as SGN-35) for Hodgkin lymphoma; Trastuzumab-DM1 for breast cancer; and Inotuzumab ozogamicin for non-Hodgkin lymphoma.  This review highlights the recent pre-clin. and clin. advances that have been made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-9ugy8pi8C7Vg90H21EOLACvtfcHk0lhU6QijukpoCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D&md5=ace266066ea07d49d0e0b4338b48eeb3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.170%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugates%253A%2520Targeted%2520Drug%2520Delivery%2520for%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D529%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Potent Antibody Drug Conjugates for Cancer Therapy</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1016%2Fj.cbpa.2009.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=19414278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=235-244&author=P.+D.+Senter&title=Potent+Antibody+Drug+Conjugates+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in the past few years in the area of antibody drug conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors.  Early work in this field incorporated clin. approved drugs and mouse monoclonal antibodies (mAbs), which had modest activities, and were generally immunogenic.  The results of these studies prompted investigation that led to the identity of several key parameters that influenced activity and tolerability.  These included the antigen target, the use of non-immunogenic mAb carriers, the incorporation of highly potent drugs and novel conditionally stable linker technologies, and the specific methods used to attach drugs to mAbs.  As a result of these investigations, new agents with pronounced clin. activities have been developed.  These include SGN-35, an ADC directed against the CD30-pos. malignancies such as Hodgkin's disease and anaplastic large cell lymphoma, and trastuzumab-DM1 which has shown activity in metastatic breast carcinoma.  This review details many of the technol. advancements, and provides examples of promising ADCs that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomJSUUPIrcbVg90H21EOLACvtfcHk0lgqP1Talg38ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D&md5=3cf72b412351bae075fab1159c49d8c5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DPotent%2520Antibody%2520Drug%2520Conjugates%2520for%2520Cancer%2520Therapy%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700108g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=98-107&author=R.+V.+J.+Chari&title=Targeted+Cancer+Therapy%3A+Conferring+Specificity+to+Cytotoxic+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs</span></div><div class="casAuthors">Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Most anticancer drugs in clin. use today display poor tumor specificity, resulting in high systemic toxicity.  Monoclonal antibodies that recognize specific markers on the surface of tumor cells offer an alternative therapy that is tumor-specific and, thus, less toxic.  Although highly selective, very few monoclonal antibodies are therapeutically useful because they only display modest cell-killing activity.  The tumor selectivity of monoclonal antibodies can be exploited for the targeted delivery of highly cytotoxic drugs that are otherwise too toxic to be used on their own.  This Account provides a brief history of the development of antibody-drug conjugates, followed by a review of recent advances, wherein highly cytotoxic drugs have been linked to tumor-reactive antibodies.  Linkers have been designed such that these monoclonal antibody-drug conjugates are stable in circulation and are virtually nontoxic until they bind to the tumor cell through the antibody component.  Upon binding to the tumor cell and internalization, lysosomal processing releases the potent cytotoxic agents inside the cell.  These conjugates display high target-specific cytotoxicity in vitro and antitumor activity that is superior to that of the antibodies alone or the std. anticancer drugs in human tumor xenograft models.  Several conjugates from this new class of tumor-targeted anticancer agents are currently undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHel9bmmcerVg90H21EOLACvtfcHk0lgqP1Talg38ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D&md5=83bb7694ba47151534d9fd5c626edfc2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Far700108g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700108g%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DTargeted%2520Cancer%2520Therapy%253A%2520Conferring%2520Specificity%2520to%2520Cytotoxic%2520Drugs%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D98%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bross, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1490</span><span class="NLM_x">–</span> <span class="NLM_lpage">1496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=11410481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1490-1496&author=P.+F.+Brossauthor=J.+Beitzauthor=G.+Chenauthor=X.+H.+Chenauthor=E.+Duffyauthor=L.+Kiefferauthor=S.+Royauthor=R.+Sridharaauthor=A.+Rahmanauthor=G.+Williamsauthor=R.+Pazdur&title=Approval+Summary%3A+Gemtuzumab+Ozogamicin+in+Relapsed+Acute+Myeloid+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia</span></div><div class="casAuthors">Bross, Peter F.; Beitz, Julie; Chen, Gang; Chen, Xiao Hong; Duffy, Eric; Kieffer, Lydia; Roy, Sandip; Sridhara, Rajeshwari; Rahman, Atiqur; Williams, Grant; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1490-1496</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review with refs.  Gemtuzumab ozogamicin (Mylotarg; Wyeth Labs., Philadelphia, PA) consists of a semisynthetic deriv. of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).  In this study, we review the preclin. and clin. profiles of this immuno-conjugate and the regulatory review that led to marketing approval by the United States Food and Drug Administration.  From the literature and manufacturer's data, we review the activity, tolerability, and pharmacokinetics of gemtuzumab ozogamicin in preclin. and Phase I studies and its activity, efficacy, and side effects in three Phase 2 trials of 142 patients with relapsed AML.  In Phase I studies, the major toxicity was myelosuppression, esp. neutropenia and thrombocytopenia, resulting from the expression of CD33 on myeloid progenitor cells.  The Phase 2 dose was 9 mg/m2 infused i.v. over 4 h, repeated on day 14.  A minority of patients experienced acute infusion-related symptoms, usually transient and occasionally requiring hospitalization.  The complete response (CR) rate with full recovery of hematopoiesis was 16%.  A subset of patients [CRs with incomplete platelet recovery (CRps)] was identified with blast clearance and neutrophil recovery but incomplete platelet recovery.  The duration of responses of CRps appeared to be similar to those of the CRs, although the nos. were small.  The question of the equivalence of these response groups was a central issue in the review of this new drug application (NDA).  After considerable discussion, the Oncol. Drugs Advisory Committee recommended allowing inclusion of CRps resulting in an overall response rate in the Phase 2 studies of 30%.  In the subgroup of patients over 60 yr of age, the overall response rate was 26%.  Response duration was difficult to establish because of the high prevalence of postremission therapies.  Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes.  One patient died of liver failure in the Phase 2 trials.  Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by the United States Food and Drug Administration under the Accelerated Approval regulations.  Gemtuzumab ozogamicin is indicated for the treatment of patients with CD33 pos. AML in first relapse who are 60 yr of age or older and who are not considered candidates for cytotoxic chemotherapy.  The approved dose was 9 mg/m2 i.v. over 4 h and repeated in 14 days.  Completion of the ongoing studies of gemtuzumab ozogamicin in relapsed AML and initiation of randomized clin. trials comparing the effects of gemtuzumab ozogamicin in combination with conventional induction chemotherapy to conventional chemotherapy alone on survival are mandated to confirm clin. benefit under the accelerated approval Subpart H regulations.  Postmarketing reports of fatal anaphylaxis, adult respiratory distress syndrome (ARDS), and hepatotoxicity, esp. venoocclusive disease (VOD) in patients treated with gemtuzumab ozogamicin, with and without assocd. hematopoietic stem cell transplantation (HSCT), have required labeling revisions and the initiation of a registration surveillance program.  Tumor lysis and ARDS have been reported in patients with leukocytes above 30,000/mL treated with gemtuzumab ozogamicin; therefore, the redn. of leukocyte counts to below 30,000/mL is recommended prior to treatment.  Patients should be carefully monitored for acute hypersensitivity, hypoxia, and delayed hepatotoxicity following treatment with gemtuzumab ozogamicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxE3VNYYST67Vg90H21EOLACvtfcHk0lgqP1Talg38ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D&md5=8a85e32e3113034e98f05dfbd119110b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DBeitz%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DDuffy%26aufirst%3DE.%26aulast%3DKieffer%26aufirst%3DL.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520Summary%253A%2520Gemtuzumab%2520Ozogamicin%2520in%2520Relapsed%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D1490%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Katz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, A.</span><span> </span><span class="NLM_article-title">Brentuximab Vedotin (SGN-35)</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6428</span><span class="NLM_x">–</span> <span class="NLM_lpage">6436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1078-0432.CCR-11-0488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22003070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSksr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6428-6436&author=J.+Katzauthor=J.+E.+Janikauthor=A.+Younes&title=Brentuximab+Vedotin+%28SGN-35%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Brentuximab Vedotin (SGN-35)</span></div><div class="casAuthors">Katz, Jessica; Janik, John E.; Younes, Anas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6428-6436</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma.  SGN-35 consists of the cAC10 chimerized IgG1 monoclonal antibody SGN30, modified by the addn. of a valine-citrulline dipeptide linker to permit attachment of the potent inhibitor of microtubule polymn. monomethylauristatin E (MMAE).  In phase II trials, SGN-35 produced response rates of 75% in patients with Hodgkin lymphoma (n = 102) and 87% in patients with anaplastic large cell lymphoma (n = 30).  Responses to SGN-35 might be related not only to the cytotoxic effect due to release of MMAE within the malignant cell but also to other effects.  First, SGN-35 may signal malignant cells through CD30 ligation to deliver an apoptotic or proliferative response.  The former would amplify the cytotoxicity of MMAE.  A proliferative signal delivered in the context of MMAE intoxication could enhance cell death.  Second, the efficacy of SGN-35, particularly in Hodgkin lymphoma, might be attributed to its effect on the tumor microenvironment.  Diffusion of free MMAE from the targeted tumor cells could result in a bystander effect that kills the normal supporting cells in close proximity to the malignant cells.  The elimination of T regulatory cells that inhibit cytotoxic effector cells and elimination of cells that provide growth factor support for Hodgkin/Reed-Sternberg cells could further enhance the cytotoxic activity of SGN-35.  Here we review the biol. of SGN-35 and the clin. effects of SGN-35 administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr3UOlpwo1_LVg90H21EOLACvtfcHk0lgqP1Talg38ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSksr3M&md5=69707687c7cde6b47d7297c7524cc7fa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0488%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DJanik%26aufirst%3DJ.%2BE.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DBrentuximab%2520Vedotin%2520%2528SGN-35%2529%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6428%26epage%3D6436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welslau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diéras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">EMILIA Study Group.</span><span> </span><span class="NLM_article-title">Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1056%2FNEJMoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.-Y.+Ohauthor=V.+Di%C3%A9rasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwellauthor=EMILIA+Study+Group.&title=Trastuzumab+Emtansine+for+HER2-Positive+Advanced+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0lh8uIT7wCXR3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26aulast%3D%26atitle%3DTrastuzumab%2520Emtansine%2520for%2520HER2-Positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blättler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Bl%C3%A4ttlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-Positive+Breast+Cancer+with+Trastuzumab-DM1%2C+an+Antibody-Cytotoxic+Drug+Conjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lh8uIT7wCXR3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-Positive%2520Breast%2520Cancer%2520with%2520Trastuzumab-DM1%252C%2520an%2520Antibody-Cytotoxic%2520Drug%2520Conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wakankar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span> </span><span class="NLM_article-title">Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes Due to Modification and Conjugation Processes</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1588</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc900434c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1588-1595&author=A.+A.+Wakankarauthor=M.+B.+Feeneyauthor=J.+Riveraauthor=Y.+Chenauthor=M.+Kimauthor=V.+K.+Sharmaauthor=Y.+J.+Wang&title=Physicochemical+Stability+of+the+Antibody-Drug+Conjugate+Trastuzumab-DM1%3A+Changes+Due+to+Modification+and+Conjugation+Processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes</span></div><div class="casAuthors">Wakankar, Aditya A.; Feeney, Maria B.; Rivera, Javier; Chen, Yan; Kim, Michael; Sharma, Vikas K.; Wang, Y. John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1588-1595</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the manuf. of the antibody-drug conjugate Trastuzumab-DM1 (T-DM1), the lysine residues on the antibody trastuzumab (Tmab) are modified to form the intermediate Tmab-MCC (T-MCC) and then conjugated with the drug DM1.  Our goal is to understand the effects of modification and conjugation steps on the physicochem. stability of the antibody.  The structural stability of Tmab relative to its modified and conjugated forms was assessed, employing thermally induced stress conditions to formulations contg. Tmab, T-MCC, and T-DM1.  DSC, SEC, CE-SDS, and LC-MS were used to study the stability of Tmab, T-MCC, and T-DM1 to thermal stress.  The DSC thermograms show a decrease in melting temp. for the CH2 transition, in the order Tmab > T-MCC > T-DM1.  As per SEC anal., a significant increase in level of aggregation was detected in T-MCC (∼32%) and T-DM1 (∼5%) after 14 days at 40°.  Tmab did not show significant aggregate formation.  CE-SDS and LC-MS data demonstrate that the aggregation in the case of T-MCC is largely covalent and involves mechanisms other than formation of intermol. disulfide crosslinks.  The aggregation obsd. for T-MCC was significantly inhibited upon addn. of amino acids with nucleophilic side chains contg. thiol (Cys) and hydroxyl moieties (Ser, Tyr).  The covalent aggregation obsd. for T-MCC and the ability of nucleophilic amino acids, particularly Cys, to inhibit it indicate that the maleimide moiety in the MCC linker may react to form intermol. covalent crosslinks between T-MCC mols., possibly through a Michael addn. mechanism.  In addn., DSC results demonstrate that the conjugation of the drug moiety DM1 to Tmab results in destabilization of the CH2 domain of the antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoTooyTYRrPLVg90H21EOLACvtfcHk0lh8uIT7wCXR3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D&md5=6c67fb904a35f97adfeb62ec69b7d4be</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fbc900434c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc900434c%26sid%3Dliteratum%253Aachs%26aulast%3DWakankar%26aufirst%3DA.%2BA.%26aulast%3DFeeney%26aufirst%3DM.%2BB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DPhysicochemical%2520Stability%2520of%2520the%2520Antibody-Drug%2520Conjugate%2520Trastuzumab-DM1%253A%2520Changes%2520Due%2520to%2520Modification%2520and%2520Conjugation%2520Processes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D1588%26epage%3D1595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraragi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4769</span><span class="NLM_x">–</span> <span class="NLM_lpage">4778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1078-0432.CCR-10-0987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=20805300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4769-4778&author=J.+R.+Junutulaauthor=K.+M.+Flagellaauthor=R.+A.+Grahamauthor=K.+L.+Parsonsauthor=E.+Haauthor=H.+Raabauthor=S.+Bhaktaauthor=T.+Nguyenauthor=D.+L.+Duggerauthor=G.+Liauthor=E.+Maiauthor=G.+D.+Lewis+Phillipsauthor=H.+Hiraragiauthor=R.+N.+Fujiauthor=J.+Tibbittsauthor=R.+Vandlenauthor=S.+D.+Spencerauthor=R.+H.+Schellerauthor=P.+Polakisauthor=M.+X.+Sliwkowski&title=Engineered+Thio-Trastuzumab-DM1+Conjugate+with+an+Improved+Therapeutic+Index+to+Target+Human+Epidermal+Growth+Factor+Receptor+2-Positive+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer</span></div><div class="casAuthors">Junutula, Jagath R.; Flagella, Kelly M.; Graham, Richard A.; Parsons, Kathryn L.; Ha, Edward; Raab, Helga; Bhakta, Sunil; Nguyen, Trung; Dugger, Debra L.; Li, Guangmin; Mai, Elaine; Lewis Phillips, Gail D.; Hiraragi, Hajime; Fuji, Reina N.; Tibbitts, Jay; Vandlen, Richard; Spencer, Susan D.; Scheller, Richard H.; Polakis, Paul; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4769-4778</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) combine the ideal properties of both antibodies and cytotoxic drugs by targeting potent drugs to the antigen-expressing tumor cells, thereby enhancing their antitumor activity.  Successful ADC development for a given target antigen depends on optimization of antibody selection, linker stability, cytotoxic drug potency, and mode of linker-drug conjugation to the antibody.  Here, we systematically examd. the in vitro potency as well as in vivo preclin. efficacy and safety profiles of a heterogeneous prepn. of conventional trastuzumab-mcc-DM1 (TMAb-mcc-DM1) ADC with that of a homogeneous engineered thio-trastuzumab-mpeo-DM1 (thioTMAb-mpeo-DM1) conjugate.  To generate thioTMAb-mpeo-DM1, one drug maytansinoid 1 (DM1) mol. was conjugated to an engineered cysteine residue at Ala114 (Kabat numbering) on each trastuzumab-heavy chain, resulting in two DM1 mols. per antibody.  ThioTMAb-mpeo-DM1 retained similar in vitro anti-cell proliferation activity and human epidermal growth factor receptor 2 (HER2) binding properties to that of the conventional ADC.  Furthermore, it showed improved efficacy over the conventional ADC at DM1-equiv doses (μg/m2) and retained efficacy at equiv. antibody doses (mg/kg).  An improved safety profile of >2-fold was obsd. in a short-term target-independent rat safety study.  In cynomolgus monkey safety studies, thioTMAb-mpeo-DM1 was tolerated at higher antibody doses (up to 48 mg/kg or 6000 μg DM1/m2) compared with the conventional ADC that had dose-limiting toxicity at 30 mg/kg (6000 μg DM1/m2).  The engineered thioTMAb-mpeo-DM1 with broadened therapeutic index represents a promising antibody drug conjugate for future clin. development of HER2-pos. targeted breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowkqzAMGHmA7Vg90H21EOLACvtfcHk0lj6oIzftdH2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK&md5=888bda7f06d1ed864111b607dae5f969</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0987%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DGraham%26aufirst%3DR.%2BA.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DHiraragi%26aufirst%3DH.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DEngineered%2520Thio-Trastuzumab-DM1%2520Conjugate%2520with%2520an%2520Improved%2520Therapeutic%2520Index%2520to%2520Target%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor%25202-Positive%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4769%26epage%3D4778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venook, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee Wong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallet, W.</span><span> </span><span class="NLM_article-title">Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&author=J.+R.+Junutulaauthor=H.+Raabauthor=S.+Clarkauthor=S.+Bhaktaauthor=D.+D.+Leipoldauthor=S.+Weirauthor=Y.+Chenauthor=M.+Simpsonauthor=S.+P.+Tsaiauthor=M.+S.+Dennisauthor=Y.+Luauthor=Y.+G.+Mengauthor=C.+Ngauthor=J.+Yangauthor=C.+C.+Leeauthor=E.+Duenasauthor=J.+Gorrellauthor=V.+Kattaauthor=A.+Kimauthor=K.+McDormanauthor=K.+Flagellaauthor=R.+Venookauthor=S.+Rossauthor=S.+D.+Spencerauthor=W.+Lee+Wongauthor=H.+B.+Lowmanauthor=R.+Vandlenauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=W.+Mallet&title=Site-Specific+Conjugation+of+a+Cytotoxic+Drug+to+an+Antibody+Improves+the+Therapeutic+Index"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0lj6oIzftdH2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DWeir%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSimpson%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DY.%2BG.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DDuenas%26aufirst%3DE.%26aulast%3DGorrell%26aufirst%3DJ.%26aulast%3DKatta%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DVenook%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DLee%2BWong%26aufirst%3DW.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DMallet%26aufirst%3DW.%26atitle%3DSite-Specific%2520Conjugation%2520of%2520a%2520Cytotoxic%2520Drug%2520to%2520an%2520Antibody%2520Improves%2520the%2520Therapeutic%2520Index%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ducry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stump, B.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc9002019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=5-13&author=L.+Ducryauthor=B.+Stump&title=Antibody-Drug+Conjugates%3A+Linking+Cytotoxic+Payloads+to+Monoclonal+Antibodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span></div><div class="casAuthors">Ducry, Laurent; Stump, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-13</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic mols., thereby taking advantage of the best characteristics of both components.  Along with the development of the mAbs and cytotoxins, the design of chem. linkers to covalently bind these building blocks is making rapid progress but remains challenging.  Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlMw1v5iWdG7Vg90H21EOLACvtfcHk0lhsA7Trs7uQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I&md5=bf79ac611e08674604d6b8cc29636abb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbc9002019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9002019%26sid%3Dliteratum%253Aachs%26aulast%3DDucry%26aufirst%3DL.%26aulast%3DStump%26aufirst%3DB.%26atitle%3DAntibody-Drug%2520Conjugates%253A%2520Linking%2520Cytotoxic%2520Payloads%2520to%2520Monoclonal%2520Antibodies%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D5%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc7004329" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=759-765&author=S.+C.+Alleyauthor=D.+R.+Benjaminauthor=S.+C.+Jeffreyauthor=N.+M.+Okeleyauthor=D.+L.+Meyerauthor=R.+J.+Sandersonauthor=P.+D.+Senter&title=Contribution+of+Linker+Stability+to+the+Activities+of+Anticancer+Immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates</span></div><div class="casAuthors">Alley, Stephen C.; Benjamin, Dennis R.; Jeffrey, Scott C.; Okeley, Nicole M.; Meyer, Damon L.; Sanderson, Russell J.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">759-765</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are highly active at well tolerated doses.  For maximal intratumoral drug delivery, linkers are required that are highly stable in the systemic circulation, yet allow for efficient drug release at the target site.  In this respect, amide bond-based technologies constitute a technol. advancement, since the linker half-lives in circulation (t1/2 ∼ 7 days) are much longer than earlier generation linkers that break down within 1-2 days.  The amide linkers, some of which contain peptides, are appended to the mAb carriers through thioether/maleimide adducts.  Here, we describe that use of a bromoacetamidecaproyl (bac) in place of the maleimidocaproyl (mc) increases the plasma stability of resulting thioether ADCs.  One such ADC, 1F6-C4v2-bac-MMAF, which is directed against the CD70 antigen on lymphomas and renal cell carcinoma, was prepd. contg. a bac thioether spacer between the drug (MMAF) and the mAb carrier (1F6-C4v2).  There was no measurable systemic drug release from this ADC for 2 wk postadministration in mice.  In order to assess the impact of improving linker stability beyond mc contg. ADCs, a series of mc and bac-linked 1F6-MMAF conjugates were compared for tolerability, intratumoral drug delivery, and therapeutic efficacy in nude mice with renal cell carcinoma xenografts.  There were no statistically significant efficacy differences between sets of mc and bac contg. ADCs, although the bac linker technol. led to 25% higher intratumoral drug exposure over a 7 day period compared to the corresponding mc linker.  The mechanism of drug release from maleimide-adducts likely involves a retro-Michael reaction that takes place in plasma, based on in vitro studies demonstrating that some of the released drug-maleimide deriv. became covalently bound to cysteine-34 of serum albumin.  In summary, the data indicate that new linkers can be obtained with improved in vivo stability by replacing the maleimide with an acetamide, but the resulting ADCs had similar tolerability and activity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAEuKHrhYzvrVg90H21EOLACvtfcHk0lhsA7Trs7uQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D&md5=62abdec871dda99c160a9b989c12f6f0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbc7004329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc7004329%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DContribution%2520of%2520Linker%2520Stability%2520to%2520the%2520Activities%2520of%2520Anticancer%2520Immunoconjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D759%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Shen, B.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Reponte, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hass, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solis, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span> </span><span class="NLM_article-title">Conjugation Site Modulates the in Vivo Stability and Therapeutic Activity of Antibody-Drug Conjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&author=B.-Q.+Shenauthor=K.+Xuauthor=L.+Liuauthor=H.+Raabauthor=S.+Bhaktaauthor=M.+Kenrickauthor=K.+L.+Parsons-Reponteauthor=J.+Tienauthor=S.-F.+Yuauthor=E.+Maiauthor=D.+Liauthor=J.+Tibbittsauthor=J.+Baudysauthor=O.+M.+Saadauthor=S.+J.+Scalesauthor=P.+J.+McDonaldauthor=P.+E.+Hassauthor=C.+Eigenbrotauthor=T.+Nguyenauthor=W.+A.+Solisauthor=R.+N.+Fujiauthor=K.+M.+Flagellaauthor=D.+Patelauthor=S.+D.+Spencerauthor=L.+A.+Khawliauthor=A.+Ebensauthor=W.+L.+Wongauthor=R.+Vandlenauthor=S.+Kaurauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=J.+R.+Junutula&title=Conjugation+Site+Modulates+the+in+Vivo+Stability+and+Therapeutic+Activity+of+Antibody-Drug+Conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0lhsA7Trs7uQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DKenrick%26aufirst%3DM.%26aulast%3DParsons-Reponte%26aufirst%3DK.%2BL.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DMcDonald%26aufirst%3DP.%2BJ.%26aulast%3DHass%26aufirst%3DP.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSolis%26aufirst%3DW.%2BA.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DConjugation%2520Site%2520Modulates%2520the%2520in%2520Vivo%2520Stability%2520and%2520Therapeutic%2520Activity%2520of%2520Antibody-Drug%2520Conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provenzano, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span> </span><span class="NLM_article-title">The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F1535-7163.MCT-11-0727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22408268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1133-1142&author=H.+K.+Ericksonauthor=G.+D.+Lewis+Phillipsauthor=D.+D.+Leipoldauthor=C.+A.+Provenzanoauthor=E.+Maiauthor=H.+A.+Johnsonauthor=B.+Gunterauthor=C.+A.+Audetteauthor=M.+Guptaauthor=J.+Pinkasauthor=J.+Tibbitts&title=The+Effect+of+Different+Linkers+on+Target+Cell+Catabolism+and+Pharmacokinetics%2FPharmacodynamics+of+Trastuzumab+Maytansinoid+Conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates</span></div><div class="casAuthors">Erickson, Hans K.; Lewis Phillips, Gail D.; Leipold, Douglas D.; Provenzano, Carmela A.; Mai, Elaine; Johnson, Holly A.; Gunter, Bert; Audette, Charlene A.; Gupta, Manish; Pinkas, Jan; Tibbitts, Jay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1133-1142</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of the anti-HER2 antibody trastuzumab linked via a nonreducible thioether linker to the maytansinoid antitubulin agent DM1.  T-DM1 has shown favorable safety and efficacy in patients with HER2-pos. metastatic breast cancer.  In previous animal studies, T-DM1 exhibited better pharmacokinetics (PK) and slightly more efficacy than several disulfide-linked versions.  The efficacy findings are unique, as other disulfide-linked antibody-drug conjugates (ADC) have shown greater efficacy than thioether-linked designs.  To explore this further, the in vitro and in vivo activity, PK, and target cell activation of T-DM1 and the disulfide-linked T-SPP-DM1 were examd.  Both ADCs showed high in vitro potency, with T-DM1 displaying greater potency in two of four breast cancer cell lines.  In vitro target cell processing of T-DM1 and T-SPP-DM1 produced lysine-N.vepsiln.-MCC-DM1, and lysine-N.vepsiln.-SPP-DM1 and DM1, resp.; in vivo studies confirmed these results.  The in vitro processing rates for the two conjugate to their resp. catabolites were similar.  In vivo, the potencies of the conjugates were similar, and T-SPP-DM1 had a faster plasma clearance than T-DM1.  Slower T-DM1 clearance translated to higher overall tumor concns. (conjugate plus catabolites), but unexpectedly, similar levels of tumor catabolite.  These results indicate that, although the ADC linker can have clear impact on the PK and the chem. nature of the catabolites formed, both linkers seem to offer the same payload delivery to the tumor.  Mol Cancer Ther; 11(5); 1133-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynXKVoEvq_7Vg90H21EOLACvtfcHk0lh9DYn0gJC_Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D&md5=e7485e8164a5bf3210f6c68f174df112</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0727%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DProvenzano%26aufirst%3DC.%2BA.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DH.%2BA.%26aulast%3DGunter%26aufirst%3DB.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26atitle%3DThe%2520Effect%2520of%2520Different%2520Linkers%2520on%2520Target%2520Cell%2520Catabolism%2520and%2520Pharmacokinetics%252FPharmacodynamics%2520of%2520Trastuzumab%2520Maytansinoid%2520Conjugates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1133%26epage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Poon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, T.</span><span> </span><span class="NLM_article-title">Preclinical Safety Profile of Trastuzumab Emtansine (T-DM1): Mechanism of Action of Its Cytotoxic Component Retained with Improved Tolerability</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1016%2Fj.taap.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=24035823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2013&pages=298-313&author=K.+A.+Poonauthor=K.+Flagellaauthor=J.+Beyerauthor=J.+Tibbittsauthor=S.+Kaurauthor=O.+Saadauthor=J.-H.+Yiauthor=S.+Girishauthor=N.+Dybdalauthor=T.+Reynolds&title=Preclinical+Safety+Profile+of+Trastuzumab+Emtansine+%28T-DM1%29%3A+Mechanism+of+Action+of+Its+Cytotoxic+Component+Retained+with+Improved+Tolerability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability</span></div><div class="casAuthors">Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  The therapeutic premise of ADCs is based on the hypothesis that targeted delivery of potent cytotoxic drugs to tumors will provide better tolerability and efficacy compared with non-targeted delivery, where poor tolerability can limit efficacious doses.  Here, we present results from preclin. studies characterizing the toxicity profile of T-DM1, including limited assessment of unconjugated DM1.  T-DM1 binds primate ErbB2 and human HER2 but not the rodent homolog c-neu.  Therefore, antigen-dependent and non-antigen-dependent toxicity was evaluated in monkeys and rats, resp., in both single- and repeat-dose studies; toxicity of DM1 was assessed in rats only.  T-DM1 was well tolerated at doses up to 40 mg/kg (~ 4400 μg DM1/m2) and 30 mg/kg (~ 6000 μg DM1/m2) in rats and monkeys, resp.  In contrast, DM1 was only tolerated up to 0.2 mg/kg (1600 μg DM1/m2).  This suggests that at least two-fold higher doses of the cytotoxic agent are tolerated in T-DM1, supporting the premise of ADCs to improve the therapeutic index.  In addn., T-DM1 and DM1 safety profiles were similar and consistent with the mechanism of action of DM1 (i.e., microtubule disruption).  Findings included hepatic, bone marrow/hematol. (primarily platelet), lymphoid organ, and neuronal toxicities, and increased nos. of cells of epithelial and phagocytic origin in metaphase arrest.  These adverse effects did not worsen with chronic dosing in monkeys and are consistent with those reported in T-DM1-treated patients to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp36u8JDO92mbVg90H21EOLACvtfcHk0lh9DYn0gJC_Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO&md5=f2ae6f6fc865d8ad027752e1301be3cc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DDybdal%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DT.%26atitle%3DPreclinical%2520Safety%2520Profile%2520of%2520Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520Mechanism%2520of%2520Action%2520of%2520Its%2520Cytotoxic%2520Component%2520Retained%2520with%2520Improved%2520Tolerability%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2013%26volume%3D273%26spage%3D298%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzker, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span> </span><span class="NLM_article-title">Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients with HER2-Positive Metastatic Breast Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2698</span><span class="NLM_x">–</span> <span class="NLM_lpage">2704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1200%2FJCO.2009.26.2071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=20421541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2698-2704&author=I.+E.+Kropauthor=M.+Beeramauthor=S.+Modiauthor=S.+F.+Jonesauthor=S.+N.+Holdenauthor=W.+Yuauthor=S.+Girishauthor=J.+Tibbittsauthor=J.-H.+Yiauthor=M.+X.+Sliwkowskiauthor=F.+Jacobsonauthor=S.+G.+Lutzkerauthor=H.+A.+Burris&title=Phase+I+Study+of+Trastuzumab-DM1%2C+an+HER2+Antibody-Drug+Conjugate%2C+Given+Every+3+Weeks+to+Patients+with+HER2-Positive+Metastatic+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Krop, Ian E.; Beeram, Muralidhar; Modi, Shanu; Jones, Suzanne F.; Holden, Scott N.; Yu, Wei; Girish, Sandhy; Tibbitts, Jay; Yi, Joo-Hee; Sliwkowski, Mark X.; Jacobson, Fred; Lutzker, Stuart G.; Burris, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2698-2704</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-pos. cells.  This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-pos. breast cancer.  Patients and Methods: Successive cohorts of patients who had progressed on trastuzumab-based therapy received escalating doses of T-DM1.  Outcomes were assessed by std. solid-tumor phase I methods.  Results: Twenty-four patients who had received a median of four prior chemotherapeutic agents for metastatic disease received T-DM1 at 0.3 mg/kg to 4.8 mg/kg on an every-3-wk schedule.  Transient thrombocytopenia was dose-limiting at 4.8 mg/kg; the max.-tolerated dose (MTD) was 3.6 mg/kg.  The half-life of T-DM1 at the MTD was 3.5 days, with peak DM1 levels < 10 ng/mL.  Clearance at doses < 1.2 mg/kg was faster than at higher doses.  Common drug-related adverse events (AEs) included grade ≤ 2 thrombocytopenia, elevated transaminases, fatigue, nausea, and anemia.  No grade > 1 nausea, vomiting, alopecia, or neuropathy events and no cardiac effects requiring dose modification were reported.  The clin. benefit rate (objective response plus stable disease at 6 mo) among 15 patients treated at the MTD was 73%, including five objective responses.  The confirmed response rate in patients with measurable disease at the MTD (n = 9) was 44%.  Conclusion: At the MTD of 3.6 mg/kg every 3 wk, T-DM1 was assocd. with mild, reversible toxicity and substantial clin. activity in a heavily pretreated population.  Phase II and III trials in patients with advanced HER2-pos. breast cancer are under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65WWeQ3_JV7Vg90H21EOLACvtfcHk0lgwMiPx_ljWmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D&md5=98ba29a289f4ac0ea38c37a9b6bd0c5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.2071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.2071%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DJacobson%26aufirst%3DF.%26aulast%3DLutzker%26aufirst%3DS.%2BG.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DPhase%2520I%2520Study%2520of%2520Trastuzumab-DM1%252C%2520an%2520HER2%2520Antibody-Drug%2520Conjugate%252C%2520Given%2520Every%25203%2520Weeks%2520to%2520Patients%2520with%2520HER2-Positive%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2698%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris Iii, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span> </span><span class="NLM_article-title">Clinical Pharmacology of Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate in Development for the Treatment of HER2-Positive Cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1007%2Fs00280-011-1817-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=22271209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1229-1240&author=S.+Girishauthor=M.+Guptaauthor=B.+Wangauthor=D.+Luauthor=I.+E.+Kropauthor=C.+L.+Vogelauthor=H.+A.+Burris+Iiiauthor=P.+M.+LoRussoauthor=J.-H.+Yiauthor=O.+Saadauthor=B.+Tongauthor=Y.-W.+Chuauthor=S.+Holdenauthor=A.+Joshi&title=Clinical+Pharmacology+of+Trastuzumab+Emtansine+%28T-DM1%29%3A+An+Antibody-Drug+Conjugate+in+Development+for+the+Treatment+of+HER2-Positive+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer</span></div><div class="casAuthors">Girish, Sandhya; Gupta, Manish; Wang, Bei; Lu, Dan; Krop, Ian E.; Vogel, Charles L.; Burris, Howard A., III; LoRusso, Patricia M.; Yi, Joo-Hee; Saad, Ola; Tong, Barbara; Chu, Yu-Waye; Holden, Scott; Joshi, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1240</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab and DM1, a microtubule polymn. inhibitor, covalently bound via a stable thioether linker.  To characterize the pharmacokinetics (PK) of T-DM1 in patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer, data from four studies (TDM3569g, TDM4258g, TDM4374g, and TDM4688g) of single-agent T-DM1 administered at 3.6 mg/kg every 3 wk (q3w) were assessed in aggregate.  Methods: Multiple analytes-T-DM1, total trastuzumab (TT), DM1, and key metabolites-were quantified using enzyme-linked immunosorbent assays or liq. chromatog. tandem mass spectrometry.  PK parameters of T-DM1, TT, and DM1 exposure were calcd. using std. noncompartmental approaches and correlated to efficacy (objective response rate) and safety (platelet counts, hepatic transaminase concns.).  Immunogenicity was evaluated by measuring anti-therapeutic antibodies (ATA) to T-DM1 after repeated dosing using validated bridging antibody electrochemiluminescence or enzyme-linked immunosorbent assays.  Results: PK parameters for T-DM1, TT, and DM1 were consistent across studies at cycle 1 and steady state.  T-DM1 PK was not affected by residual trastuzumab from prior therapy or circulating extracellular domain of HER2.  No significant correlations were obsd. between T-DM1 exposure and efficacy, thrombocytopenia, or increased concns. of transaminases.  Across the studies, ATA formation was detected in 4.5% (13/286) of evaluable patients receiving T-DM1 q3w.  Conclusions The PK profile of single-agent T-DM1 (3.6 mg/kg q3w) is predictable, well characterized, and unaffected by circulating levels of HER2 extracellular domain or residual trastuzumab.  T-DM1 exposure does not correlate with clin. responses or key adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA6MaBSuH37Vg90H21EOLACvtfcHk0lgHfTppCprpQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D&md5=f4b2a4ef4aaa79a96adbb1810a0c44d9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1817-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1817-3%26sid%3Dliteratum%253Aachs%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DBurris%2BIii%26aufirst%3DH.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DTong%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.-W.%26aulast%3DHolden%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%26atitle%3DClinical%2520Pharmacology%2520of%2520Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520An%2520Antibody-Drug%2520Conjugate%2520in%2520Development%2520for%2520the%2520Treatment%2520of%2520HER2-Positive%2520Cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1229%26epage%3D1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dere, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendricks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span> </span><span class="NLM_article-title">Characterization of the Drug-to-Antibody Ratio Distribution for Antibody-Drug Conjugates in Plasma/Serum</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.4155%2Fbio.13.66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=23641696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFOks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1057-1071&author=K.+Xuauthor=L.+Liuauthor=R.+Dereauthor=E.+Maiauthor=R.+Ericksonauthor=A.+Hendricksauthor=K.+Linauthor=J.+R.+Junutulaauthor=S.+Kaur&title=Characterization+of+the+Drug-to-Antibody+Ratio+Distribution+for+Antibody-Drug+Conjugates+in+Plasma%2FSerum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum</span></div><div class="casAuthors">Xu, Keyang; Liu, Luna; Dere, Randall; Mai, Elaine; Erickson, Rebecca; Hendricks, Angela; Lin, Kedan; Junutula, Jagath R.; Kaur, Surinder</div><div class="citationInfo"><span class="NLM_cas:title">Bioanalysis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1057-1071</span>CODEN:
                <span class="NLM_cas:coden">BIOAB4</span>;
        ISSN:<span class="NLM_cas:issn">1757-6180</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Antibody-drug conjugates (ADCs) are a new class of cancer therapeutics that deliver potent cytotoxins specifically to tumors to minimize systemic toxicity.  However, undesirable release of covalently linked drugs in circulation can affect safety and efficacy.  The objective of this manuscript was to propose and assess the assays that allow for the characterization of the drug deconjugation in plasma/serum.  Results: ADCs of three main drug conjugation platforms, linked via lysine, site-specific engineered cysteine or reduced interchain disulfide cysteine residues, were analyzed using affinity capture for sample enrichment coupled with LC-MS or hydrophobic interaction chromatog.-UV for detection.  These novel approaches enabled measurement of the relative abundance of individual ADC species with different drug-to-antibody ratios, while maintaining their structural integrity.  Conclusion: The characterization data generated by affinity capture LC-MS or hydrophobic interaction chromatog.-UV provided crit. mechanistic insights into understanding the stability and bioactivity of ADCs in vivo, and also helped the development of appropriate quant. ELISAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5VhU6IzYMjbVg90H21EOLACvtfcHk0lgHfTppCprpQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFOks7g%253D&md5=ad6754407f7da2b0c0addf4e6b16bc88</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4155%2Fbio.13.66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.13.66%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDere%26aufirst%3DR.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DHendricks%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKaur%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520the%2520Drug-to-Antibody%2520Ratio%2520Distribution%2520for%2520Antibody-Drug%2520Conjugates%2520in%2520Plasma%252FSerum%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D1057%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanagh, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blättler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Bl%C3%A4ttlerauthor=R.+V.+J.+Chari&title=Semisynthetic+Maytansine+Analogues+for+the+Targeted+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0lgHfTppCprpQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DSemisynthetic%2520Maytansine%2520Analogues%2520for%2520the%2520Targeted%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Cassady, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floss, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leistner, E.</span><span> </span><span class="NLM_article-title">Recent Developments in the Maytansinoid Antitumor Agents</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1248%2Fcpb.52.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=14709862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVCitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=1-26&author=J.+M.+Cassadyauthor=K.+K.+Chanauthor=H.+G.+Flossauthor=E.+Leistner&title=Recent+Developments+in+the+Maytansinoid+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the maytansinoid antitumor agents</span></div><div class="casAuthors">Cassady, John M.; Chan, Kenneth K.; Floss, Heinz G.; Leistner, Eckhard</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-26</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  Maytansine and its congeners have been isolated from higher plants, mosses and from an Actinomycete, Actinosynnema pretiosum.  Many of these compds. are antitumor agents of extraordinary potency, yet phase II clin. trials with maytansine proved disappointing.  The chem. and biol. of maytansinoids has been reviewed repeatedly in the late 1970s and early 1980s; the present review covers new developments in this field during the last two decades.  These include the use of maytansinoids as "warheads" in tumor-specific antibodies, preliminary metab. studies, investigations of their biosynthesis at the biochem. and genetic level, and ecol. issues related to the occurrence of such typical microbial metabolites in higher plants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbS-UKXv38LVg90H21EOLACvtfcHk0ljTTmjKHd8BJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVCitLw%253D&md5=6073feaee668e24d08e5e93a5b588c4f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1248%2Fcpb.52.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.52.1%26sid%3Dliteratum%253Aachs%26aulast%3DCassady%26aufirst%3DJ.%2BM.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DFloss%26aufirst%3DH.%2BG.%26aulast%3DLeistner%26aufirst%3DE.%26atitle%3DRecent%2520Developments%2520in%2520the%2520Maytansinoid%2520Antitumor%2520Agents%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span> </span><span class="NLM_article-title">Characterization of Intact Antibody-Drug Conjugates from Plasma/Serum in Vivo by Affinity Capture Capillary Liquid Chromatography–Mass Spectrometry</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2011&pages=56-66&author=K.+Xuauthor=L.+Liuauthor=O.+M.+Saadauthor=J.+Baudysauthor=L.+Williamsauthor=D.+Leipoldauthor=B.+Shenauthor=H.+Raabauthor=J.+R.+Junutulaauthor=A.+Kimauthor=S.+Kaur&title=Characterization+of+Intact+Antibody-Drug+Conjugates+from+Plasma%2FSerum+in+Vivo+by+Affinity+Capture+Capillary+Liquid+Chromatography%E2%80%93Mass+Spectrometry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DKaur%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520Intact%2520Antibody-Drug%2520Conjugates%2520from%2520Plasma%252FSerum%2520in%2520Vivo%2520by%2520Affinity%2520Capture%2520Capillary%2520Liquid%2520Chromatography%25E2%2580%2593Mass%2520Spectrometry%26jtitle%3DAnal.%2520Biochem.%26date%3D2011%26volume%3D412%26spage%3D56%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Dijkgraaf, G. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Januario, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Sauvage, F. J.</span><span> </span><span class="NLM_article-title">Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm500552c&amp;key=10.1158%2F0008-5472.CAN-10-2876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm500552c&amp;key=21123452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm500552c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=435-444&author=G.+J.+P.+Dijkgraafauthor=B.+Alickeauthor=L.+Weinmannauthor=T.+Januarioauthor=K.+Westauthor=Z.+Modrusanauthor=D.+Burdickauthor=R.+Goldsmithauthor=K.+Robargeauthor=D.+Sutherlinauthor=S.+J.+Scalesauthor=S.+E.+Gouldauthor=R.+L.+Yauchauthor=F.+J.+de+Sauvage&title=Small+Molecule+Inhibition+of+GDC-0449+Refractory+Smoothened+Mutants+and+Downstream+Mechanisms+of+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance</span></div><div class="casAuthors">Dijkgraaf, Gerrit J. P.; Alicke, Bruno; Weinmann, Lasse; Januario, Thomas; West, Kristina; Modrusan, Zora; Burdick, Dan; Goldsmith, Richard; Robarge, Kirk; Sutherlin, Dan; Scales, Suzie J.; Gould, Stephen E.; Yauch, Robert L.; de Sauvage, Frederic J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-444</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inappropriate Hedgehog (Hh) signaling has been directly linked to medulloblastoma (MB), a common malignant brain tumor in children.  GDC-0449 is an Hh pathway inhibitor (HPI) currently under clin. investigation as an anticancer agent.  Treatment of a MB patient with GDC-0449 initially regressed tumors, but this individual ultimately relapsed with a D473H resistance mutation in Smoothened (SMO), the mol. target of GDC-0449.  To explore the role of the mutated aspartic acid residue in SMO function, we substituted D473 with every amino acid and found that all functional mutants were resistant to GDC-0449, with pos. charged residues conferring potential oncogenic properties.  Alanine scan mutagenesis of SMO further identified E518 as a novel prospective mutation site for GDC-0449 resistance.  To overcome this form of acquired resistance, we screened a panel of chem. diverse HPIs and identified several antagonists with potent in vitro activity against these GDC-0449-resistant SMO mutants.  The bis-amide compd. 5 was of particular interest, as it was able to inhibit tumor growth mediated by drug resistant SMO in a murine allograft model of MB.  However, focal amplifications of the Hh pathway transcription factor Gli2 and the Hh target gene cyclin D1 (Ccnd1) were obsd. in two addnl. resistant models, indicating that resistance may also occur downstream of SMO.  Importantly, these HPI resistant MB allografts retained their sensitivity to PI3K inhibition, presenting addnl. opportunities for the treatment of such tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJl8oB7usSbVg90H21EOLACvtfcHk0ljTTmjKHd8BJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFKmtA%253D%253D&md5=d0b110e7c8c22ba9bde5635503565b72</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2876%26sid%3Dliteratum%253Aachs%26aulast%3DDijkgraaf%26aufirst%3DG.%2BJ.%2BP.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DWeinmann%26aufirst%3DL.%26aulast%3DJanuario%26aufirst%3DT.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DSutherlin%26aufirst%3DD.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3Dde%2BSauvage%26aufirst%3DF.%2BJ.%26atitle%3DSmall%2520Molecule%2520Inhibition%2520of%2520GDC-0449%2520Refractory%2520Smoothened%2520Mutants%2520and%2520Downstream%2520Mechanisms%2520of%2520Drug%2520Resistance%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D435%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Pinheiro, P.; Bates, D.; DebRoy, S.; Sarkar, D.; R Development Core Team 2013.</span><span> </span><span class="NLM_article-title">Nlme: Linear and Nonlinear Mixed Effects Models</span>.  <span class="citation_source-book">R Package</span>, version <span class="NLM_edition">3.1-108</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pinheiro%2C+P.%3B+Bates%2C+D.%3B+DebRoy%2C+S.%3B+Sarkar%2C+D.%3B+R+Development+Core+Team+2013.+Nlme%3A+Linear+and+Nonlinear+Mixed+Effects+Models.+R+Package%2C+version+3.1-108."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPinheiro%26aufirst%3DP.%26atitle%3DNlme%253A%2520Linear%2520and%2520Nonlinear%2520Mixed%2520Effects%2520Models%26btitle%3DR%2520Package" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">R Development Core Team 2012</span><span class="NLM_x">. </span>R Package, version <span class="NLM_edition">3.1-110</span>; <span class="NLM_publisher-name">R Foundation for Statistical Computing</span>: <span class="NLM_publisher-loc">Vienna, Austria</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R+Development+Core+Team+2012&title=R+Package"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DR%2520Package%26pub%3DR%2520Foundation%2520for%2520Statistical%2520Computing%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500552c&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm500552c%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500552c" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798fe3e5ca11975","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
